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ABSTRACT 
HUALI WU: Clinical Pharmacology of Anticancer Agents Delivered via 
PEGylated Liposomes 
(Under the direction of William C. Zamboni, Pharm.D., Ph.D.) 
 
PEGylated liposome is one of the most useful nanocarriers for cancer therapy. Studies 
described in this dissertation provide new knowledge about (1) the nature of nonlinear PK of 
PEGylated liposomal anticancer agents, (2) the role of the bi-directional interaction between 
PEGylated liposomes and the monocytes/macrophages in the PK/PD of these agents, and (3) 
patient factors that significantly influence the PK/PD of PEGylated liposomal anticancer 
agents. 
The PK disposition of encapsulated CPT-11, released CPT-11, and SN-38 after IHL-
305 (PEGylated liposomal CPT-11) in cancer patients was evaluated using 
noncompartmental, individual-based compartmental and population PK analysis. The PK of 
IHL-305 was characterized by a prolonged circulation time, a reduced volume of distribution 
and saturable clearance. The high inter-patient variability in the PK and PD of IHL-305 was 
associated with age, body composition, gender, and monocyte function.  
The PK disposition of S-CKD602 (PEGylated liposomal CKD-602) was evaluated 
using population PK analysis. PK of encapsulated CKD-602 was described by 1-
compartment model with nonlinear clearance and PK of released CKD-602 was described by 
a 2-compartment model with linear clearance for all patients.  The release rate of CKD-602 
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from S-CKD602 was influenced by age and clearance of encapsulated CKD-602 was 
influenced by presence of tumors in liver.  
A mechanism-based PK-PD model was also developed that described the relationship 
between PEGylated liposomal anticancer drug and monocyte in cancer patients treated with 
S-CKD602 and IHL-305. In this model, an irreversible uptake of liposomal drug to monocyte 
was used account for the bi-directional interaction between PEGylated liposomal anticancer 
drug and monocyte. The degradation of liposomes through routes other than uptake by 
monocytes was included. The estimated half-life and baseline value of monocytes were close 
to the published data. The mechanism-based PK-PD model was compared with a published 
PK-PD model used for neutropenia and leukocytopenia. Both of these two models adequately 
described the PK and PD of S-CKD602 and IHL-305.   
Overall, this work helped to explain the nonlinear PK and high interpatient variability 
in PK of PEGylated liposomal anticancer agents and defined the role of the bi-directional 
interaction between PEGylated liposomes and the monocytes in the PK/PD of these agents. 
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INTRODUCTION 
 2 
A. INTRODUCTION 
Liposomal drug delivery systems have been studied extensively to increase the 
solubility and therapeutic index of chemotherapeutic agents (1). A variety of agents such as 
conventional drugs, proteins, genes and oligonucleotides can be delivered via liposomes 
because of their attractive biological properties including biocompatibility, improved 
solubility of hydrophobic compounds, increased stability of large molecules, improved 
efficacy and reduced toxicity. Current applications of the liposomes are in the immunology, 
dermatology, vaccine adjuvant, eye disorders, brain targeting, infective disease and in tumour 
therapy (2) (Table 1.1).  
A liposome is an artificial microscopic vesicle consisting of an aqueous core 
surrounded by one or more phospholipid layers. Drugs with widely varying lipophilicities 
can be encapsulated in liposomes, either in the phospholipid bilayer, in the entrapped 
aqueous volume or at the bilayer interface (3). As drugs are encapsulated in liposome, the 
pharmacokinetic (PK) disposition of the liposomal drugs is dependent upon the liposome and 
not the parent-drug until the drug is released from the carrier (4).  The drug that remains 
encapsulated in liposomes is an inactive-prodrug and thus the drug must be released from the 
carrier to be active (5, 6). The PK disposition of liposome and the encapsulated drug are 
often different. Therefore, it is very important to understand the PK of liposomes to predict 
the efficacy and toxicity of liposomal drugs.  
In this introduction, we will briefly describe the characteristics of liposome 
formulations and discuss the effect of various factors including liposome associated factors, 
host associated factors and dose schedules on the PK and pharmacodynamics (PD) of 
liposomal agents.  
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B.  Classification of Liposome formulations 
Liposomes are micro-particulates or colloidal carriers, usually 0.05 to 5.0 μm in 
diameter which form spontaneously when certain lipids are hydrated in aqueous media (3). 
Vesicle formulations are usually based on natural and synthetic phospholipids and 
cholesterol. There are a number of different types of liposomes. Liposomes can be classified 
according to different aspects, such as physiocochemical properties, surface modification, 
method of preparation and application. From the point of PK, liposomes can be classified as 
mononuclear phagocytic system (MPS) or reticuloendothelial system (RES) targeting 
liposomes and MPS or RES avoiding liposomes, which have significantly different PK 
properties.  The physicochemical properties of liposomes such as lipid composition, structure 
(lamellarity), size, stability and surface characteristics, membrane fluidity can affect 
liposome behavior in biological systems and influence the biodistribution, efficacy and safety 
of liposome loaded with therapeutic agents (3).  
 
C.  PK Characteristics of Liposomal Drugs 
Depending on the specific application, liposomal drugs can be administered in a 
number of different routes including intravenous, intraperitoneal, subcutaneous, 
intramuscular, oral, inhalational and topical (ocular). Intravenous injection is the most 
commonly-used administration route for liposomal drugs.  
 
C.1 Distribution.  
Following administration, unlike small molecule drugs, the distribution of liposomes 
is greatly limited because they are larger than the holes or gaps of the endothelial walls of 
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most normal tissues. Tissues surrounded by endothelial wall with larger holes or gaps such as 
liver, spleen, and bone marrow usually are the major deposition sites of liposomes (7, 8). The 
enhanced uptake in the liver, spleen, and bone marrow is largely attributed to the 
macrophages residing in the tissues, which are responsible for clearing particulates and 
macromolecules circulating in the blood (9). The abnormal and leaky vasculature of tumor 
results in enhanced permeability of liposomal drugs in tumors. Moreover, tumor tissues 
usually lack effective lymphatic drainage. Therefore, liposomes, other nanoparticles, or 
macromolecules can be drained through the leaky blood vessels and be retained which results 
in an increased accumulation of liposomal anticancer agents in tumors. This phenomenon 
was called the enhanced permeation and retention (EPR) effect (10, 11).   
 
C.2 Elimination.  
Unlike small molecular drugs which are cleared by enzymes and secretion in the liver 
and filtration and secretion in the kidneys, the clearance of liposomes is via the MPS or RES 
which includes monocytes, macrophages and dendritic cells located primarily in the liver and 
spleen (12) (Figure 1.1). Uptake by the MPS usually results in irreversible sequestering of 
the encapsulated drug in the MPS, where it can be degraded. Moreover, the capture of the 
liposomes by the MPS can result in acute impairment of the mononuclear phagocyte system 
and toxicity. There are two sides to the interaction between liposomes and macrophages in 
MPS. This is beneficial for the treatment of macrophage-associated diseases such as 
infectious disease, autoimmune disease, transplantation, neurological disorders, gene therapy 
and cancer. However, this is an unfavorable for the treatment of disease not involving the 
MPS and the target site is outside of liver, spleen, and bone marrow such as cancer. MPS 
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avoiding liposomes were developed to treat the diseases not involving the MPS. These 
liposomes can evade the immune system and prolong the duration of exposure (Figure 1.1) 
 
C.3 Release of Drug from Liposomes.  
There are two potential mechanisms of release of drug from liposomes. The 
encapsulated drug can diffuse out of the liposome. The encapsulated drug can also be 
released from the carrier as the liposome carrier is cleared. The rate of in vivo drug release is 
an extremely important parameter since it can influence the rate of clearance of the drug from 
the general circulation, the bioavailability and thus the activity of the drug at its site of action, 
the targetability of the drug, and the observed toxicities (13-15). After the drug is released 
from the carrier, the PK disposition of the drug will be the same as after administration of the 
non-carrier form of the drug. Delivery of drugs to their target site is an important step for 
desired therapeutic effect. Release of drug at the target site is an equally important step since 
only released drug is active and the accumulation of active drug at the target site depends on 
the rate of drug release. The term 'drug release' refers to the desired process of the release of 
drugs from liposomes, which is necessary to enable drug-target interaction. The term 'drug 
leakage' implies the unwanted loss of the drug caused by instability or destruction of the 
liposomal carrier (16). The uptake of liposome by MPS is a desired process of the release of 
liposomal drugs for the treatment of macrophage-associated diseases such as infectious 
disease, autoimmune disease, transplantation, neurological disorders, gene therapy and 
cancer. While for the treatment of disease not involving MPS and the target site is outside of 
liver, spleen, and bone marrow, such as cancer, the uptake of liposome by MPS is an 
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unwanted loss of drug. Decreasing the uptake of liposome by MPS while increasing drug 
release at the target site is the goal. 
 
C.4 PK Nomenclature 
The nomenclature used to describe the PK disposition of carrier-mediated drugs are 
termed encapsulated or conjugated (drug within or bound to the carrier), released (the active-
drug released from the carrier), and sum total (encapsulated or conjugated drug plus released 
drug) (5).  The released drug has also been called the legacy drug, regular drug, or warhead 
(5, 17).  Released drug consists of drug that is protein bound and unbound or free drug.  The 
ability to evaluate the various forms (encapsulated, released, unbound) of the drug after 
administration of liposome or nanoparticle formulation is dependent upon specific sample 
processing methods (18).   
 
D.  Factors Affecting PK of Liposomal Agents 
There are two major sources of factors that influence the PK and PD of liposomal 
drugs. One is liposome associated factors including the physiochemical properties of 
liposomes, such as size, surface charge and membrane composition. The other is host 
associated factors. In addition, dose schedule and drug-drug interaction also play a role in the 
PK disposition of liposomal agents. 
 
D.1 Liposome Associated Factors 
D.1.1 Particle Size.  
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When a liposomal drug is introduced into the body, where it can go mainly depends 
on its particle size. Unlike conventional small molecule drugs which can diffuse freely 
through the endothelial wall, the diffusion of intact liposomes is dependent on both particle 
size and the anatomical structure of the tissue. The tissues can be classified as non-endocrine 
organs (heart, lung, kidney, muscle and fat tissue), endocrine tissues (liver and 
adrenocortical), and spleen and lymphatics according to their capillaries and extracellular 
matrices.  The accessibility of liposome to these tissues is in this order: spleen and 
lymphatics > endocrine tissues (liver and adrenocortical) > non-endocrine organs (heart, 
lung, kidney, muscle and fat tissue) (7).  
The effect of particle size on the tumor uptake of liposomes has been demonstrated by 
different groups. In one study, liposomes with a size between 100 nm and 200 nm showed a 
4-fold higher rate of uptake in the tumor compared to the liposomes with a size less than 50 
nm or greater than 300 nm (19). In another study, liposomes with a size ranged between 80 
and 160 nm resulted in a significantly greater accumulation in tumor compared to liposomes 
with a size of 241 nm (20). The lower uptake of larger liposome in tumor may be explained 
by the sized limited permeability of tumor vascular. The lower accumulation of very small 
liposomes (< 20-30 nm in diameter) may be explained by their high permeability but low 
retention because they can easily pass through the leaky capillary wall in the tumor but can 
also be returned to circulating blood by diffusion (21).  
Particle size also affects the uptake of liposomes by monocytes. The effect of 
liposome size on inactivation or depletion of monocytes was investigated by Golomb group 
(22). In this study, larger liposomes were internalized faster by monocytes compared to 
smaller liposomes. Following 30-min incubation of human monocytes with empty liposomes 
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and the liposomes containing alendronate, human monocytes internalized 49 ± 5, 61 ± 4, 72 
± 3 and 80 ± 5% of empty liposomes, and liposomes containing alendronate with a size of 85 
± 20, 190 ± 24, 400 ± 64 and 654 ± 124 nm, respectively (22). In addition, the increased 
cellular internalization capacity of larger liposomes resulted in an increased effect of 
monocyte/macrophage inhibition. The in vivo depletion of monocytes following iv 
administration of liposomal bisphosphonates was examined using rabbits. Depletion of rabbit 
monocytes after treatments with small liposomes with a size of 55 nm (40±5%) was 
significantly less than that after treatments with larger liposomes (>67%) (22). 
 
D.1.2 Surface Charge 
In general, uncharged liposomes were cleared from the circulation slower than either 
positively or negatively charged liposomes (15). The reduced clearance of uncharged 
liposomes is thought to be the result of reduced opsonisation followed by the decreased MPS 
uptake. Surface charge can also affect the biodistribution of liposomes. For example, high 
concentrations of anionic lipids increase accumulation of liposomes in the liver and spleen 
(13, 23, 24).  Cationic liposomes often exhibit a rapid blood clearance phase with a large 
dose accumulating primarily in the liver, spleen, and lung (24, 25) In addition, cationic 
liposomes were found to be selectively delivered to tumor vascular endothelial cell because 
of the natural affinity of cationic carrier molecules for the tumor microvasculature (25, 26). 
Although utilization of cationic liposome for gene delivery and cancer therapy gains 
increasing interests, the toxic effect of positively charged compounds in cationic liposomes 
should be taken into consideration (27, 28). Large amounts of cationic liposomes may cause 
a tissue inflammatory response (29). However, even cationic liposomes can be made stable 
 9 
and long circulating by reducing the content of cationic lipid and inclusion of PEG-lipid 
stabilizers (27). 
 
D.1.3 Lipid Composition 
The effect of lipid composition on the PK of liposomal drug lies in two aspects. 
Firstly, it can affect the drug release rate as the permeability of drug against lipid bilayer is 
controlled by lipid composition. Secondly, it is important in determining the PK fate of 
liposomal drug since the property of lipid bilayer is also controlled by lipid composition.  
The permeability of solute against lipid bilayer is dependent on the species of 
phospholipids and lipid composition. For instance, if the acyl chains and unsaturated 
phospholipid is included in the lipid bilayer, the permeability is relatively higher because of 
lower phase transition temperature and high membrane fluidity (30).  Thus, permeability and 
phase transition temperature is determined from the lipid molecule structure. In general, the 
lipid with a higher phase transition temperature than body temperature (35 to 37ºC) is 
preferably used for the main membrane component since it can prevent the unwanted leakage 
of drug from the liposome during the storage.     
pH sensitive liposomes, which are made of pH-sensitive phospholipids such as 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine with cholesteryl hemisuccinate, can fuse with 
the endosomal membrane as a result of the lower pH inside the endosome, and release their 
content into the cytoplasm following endocytotic uptake (16). pH-sensitive liposomes are 
used to deliver highly polar drugs, such as DNA, RNA or siRNA molecules to the cytosol or 
nucleus of cells and thus the degradation of the drug by lysosome is avoided.  
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The synthesis of novel lipids with desired properties made a major progress in 
liposomal drug delivery. PEGylated lipids are an example of such lipids. PEGylated 
liposomes have a lipid bilayer membrane like conventional liposomes, but the surface 
contains surface-grafted linear segments of PEG extending 5 nm from the surface (31, 32). 
The presence of PEG on the surface of the liposome can prevent protein adsorption on outer 
leaflet of liposomes and reduce MPS uptake of liposome (Figure 1.1). As a result, 
PEGylated liposomes can remain in the circulation for prolonged periods after IV injection. 
In addition to prolonged plasma exposure, the PEGylated liposomes help to achieve better 
passive targeting effect because longer circulation time will allow more drugs reach the 
target site before they are removed out of the body. 
Currently, there are two types of PEGylated liposome as shown in Figure 1.2.  One 
has PEG tether projected on both the inside and outside of liposome.  This is the PEGylated 
liposome used for like Doxil and S-CKD602. Doxil is a PEGylated liposomal formulation of 
doxorubicin which is approved for the treatment of refractory ovarian cancer, Kaposi 
sarcoma, and multiple myeloma (33, 34).  S-CKD602 is a PEGylated liposomal formulation 
of CKD-602, a camptothecin analogue which inhibits topoisomerase I (5). The other type has 
PEG tether only localized on the outer leaflet.  This PEGylated liposome has been used for 
IHL-305. IHL-305 is a PEGylated liposomal formulation of irinotecan (CPT-11), also a 
camptothecin analogue. 
Thus, there are several aspects of the liposomal formulation to consider that are major 
factors that influence the PK and PD of liposomal agents. The coverage amount and 
consistency of PEG lipid on the surface might be the most important of these factors.  As 
described above PEGylated liposomes have significant advantages compared with non-
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PEGylated or non-stabilized liposomes. PEGylated lipids are widely used to improve PK 
properties of other liposomal delivery systems, such as cationic liposomes and pH-sensitive 
liposomes. 
 
D.1.4 Ligand Conjugation 
The conjugation of a targeting ligand to the surface of a liposome can affect its PK 
and biodistribution (15). The targeting ligands for liposomes include peptides, growth 
factors, proteins, antibodies or antibody fragments, and small molecules such as folate that 
can recognize cancer cells (35-37). A summary of some of the targeting ligands that have 
been used in liposomal carriers to achieve active targeting is listed in Table 1.2. In theory, 
the presence of targeting ligands promotes the accumulation of liposomes or other 
nanoparticles within certain tissues or cells in the body as a result of highly specific 
interactions between the ligands and the target (38). Estrone conjugated PEGylated liposome 
doxorubicin (ES-SL-DOX) was reported to have an increased accumulation in the tumor 
tissue compared to non-conjugated PEGylated liposome doxorubicin (39). Additionally, the 
half-life of estrone conjugated liposomes was also increased compared to non-conjugated 
liposomes (39).  
 
D.1.5 Environment Factors 
Environment factors can affect the release of drug from liposomes. There are two 
types of environment factors. The first type of environment factors is the factors inside the 
body such as the presence of particular chemicals and enzymes. These internal environment 
factors trigger release of drug from specially designed liposomes. For example, glucose-
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triggered release from pH-sensitive liposomes with surface-bound glucose oxidase has been 
reported (40). Novel liposomes modified with surface-bound substrate (GPOn) of matrix 
metalloproteases (MMP) rapidly released their content in the presence of cell-secreted 
MMP9 (41). The second type of environment factors is the factors outside the body (external 
stimuli) such as heat or ultrasound (42-45).  Use of external stimuli has attracted much 
attentions for targeted drug delivery in the clinic (16). Release from thermosensitive 
liposomes (TSL) occurs at temperatures close to the Tm (solid gel to liquid disordered phase 
transition temperature) of the membrane lipids because of the increased the membrane 
permeability at Tm. The Tm of the TSLs can be adjusted to the clinical attainable 
temperatures (Tm = 40 to 42°C) by altering the lipid composition (43, 46). ThermoDox (TSL 
doxorubicin; Celsion Corp Yakult Honsha KK) was the first TSL formulation to enter 
clinical trials, and is in phase III clinical trials for the treatment of patients with 
hepatocellular carcinoma (ClinicalTrials.gov Identifier: NCT00617981) (16). Ultrasound was 
also demonstrated to trigger drug release from TSL in vivo (44).  
 
D.2 Host associated factors 
As discussed above, PK properties of different formulations of liposomal drugs are 
affected by the formulation-related factors. Inter-individual variabilities in PK of a liposomal 
drug are affected by host associated factors. There is significant interpatient variability in the 
PK disposition of liposomal encapsulated agents (5, 47, 48).  It appears that the PK 
variability of the carrier formulation of a drug is several-fold higher compared with the non-
liposomal formulation of the drug (5, 48, 49).  For example, the inter-patient PK variability 
of PEGylated liposomal CKD-602 (S-CKD602) was approximately 100-fold at lower doses 
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and 10- to 25-fold at higher doses (47).  However, certain PEGylated liposomal agents, such 
as PEGylated liposomal irinotecan (IHL-305) appear to have less PK variability (47, 50, 51).  
Thus, there is a need to identify factors associated with the significant PK variability.  A few 
factors have been reported to be associated with the significant PK variability of liposomal 
drugs.   
 
D.2.1 Age 
Age was reported to be associated with PK of S-CKD602 and Doxil. In a phase I and 
PK study of S-CKD602, patients ≥ 60 years of age have a 2.7-fold higher exposure of S-
CKD602 compared with patients < 60 years of age (P = 0.02) (Figure 1.3a and 1.3b) (48, 
52).   In phase I and II studies of Doxil in patients with solid tumors (n = 23) and in patients 
with AIDS-related Kaposi’s sarcoma (KS) (n = 37) , mean ± SD Doxil clearance in patients 
with solid tumors that were < 60 yo and ≥ 60 yo were 48.2 ±19.9 and 27.2 ± 10.4 L/h/m2, 
respectively (P = 0.001) (53). Gender and age effect were reported in PK studies of 
PEGylated liposomal drugs including Doxil, S-CKD602, and IHL-305. Male patients < 60 
years of age have a 2.2-fold higher clearance of Doxil compared with male patients ≥ 60 
years of age (54). Male patients < 60 years of age have a 2.1-fold higher clearance of S-
CKD602 compared with male patients ≥ 60 years of age (54). Age appeared to affect the 
clearance of Doxil and S-CKD602 in male patients but not female patients (54).  
 
D.2.2 Gender 
Gender was found to be a factor affecting the PK of a PEGylated liposomal drug. The 
effect of gender on clearance with and without stratification by age was evaluated. Female 
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patients had lower clearance of Doxil (P <0.001), IHL-305 (P = 0.068), and SCKD-602 (P = 
0.67) as compared with male patients overall and also when stratified by age (54). The 
gender effect on PK of TLI (Optisomal Topotecan) and S-CKD602 in rats was also reported 
(55). In this study, clearance of TLI and S-CKD602 was 1.2-fold (P = 0.14) and 1.4-fold (P = 
0.009) lower in female rats compared with male rats, respectively. The difference in PK of 
PEGylated liposomal agents in male and female subjects may be related to age, body 
composition, and reticuloendothalial system activity (54). 
 
D.2.3 Body composition 
Body composition was a factor associated with PK of S-CKD602.  Patients with a 
lean body composition have an increased plasma exposure of S-CKD602 (P = 0.02) (Figure 
1.4) (48, 52).  However, there was no relationship between Doxil clearance and body 
composition as measure by TBW/IBW or BMI. In a PK study of liposomal daunorubicin in 
pediatric patients, body weight was found to be an significant covariate on clearance and 
volume of distribution of liposomal daunorubicin through population PK analysis (56). The 
effect of body weight on clearance of volume of distribution was also demonstrated in a PK 
study of liposomal amphotericin B in pediatric patients (57). 
 
D.2.4 Estrous Cycle Stage 
The estrous cycle comprises the recurring physiologic changes that are induced by 
reproductive hormones in most mammalian placental females. The dynamic balance among 
reproductive hormones modulates cellular proliferation in many organs, such as ovary, 
uterus, and breast. The rhythmic fluctuation of sex hormones during the estrous cycle also 
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controls breast cancer angiogenesis and/or tumor vascular permeability. There are four 
estrous stages – diestrus, proestrus, estrus, and medestrus.  The estrous cycle stage of 4T1 
tumor-bearing mice altered the retention of Doxil in transplanted murine mammary tumors 
(58). In this study, Doxil was administered at certain time point during the mouse estrous 
cycle. A significant higher (5.6 fold) drug concentration were detected in the tumor tissues 
when Doxil was injected during the diestrus stage compared to when drug was administered 
at all other estrous stages. The effect of estrous cycle on the plasma PK of Doxil was not 
evaluated in this study. The altered retention of drug may be explained by the changes in 
breast cancer capillary permeability resulting from the changing sex hormone milieus during 
the estrous cycle.   
 
D.2.5 Prior treatment 
Prior treatment can also affect the PK of liposomal drugs. In a phase I and PK study 
of S-CKD602, patients receiving prior PEGylated liposomal doxorubicin (PLD) had a 2.2-
fold higher exposure of S-CKD602 compared with patients not receiving PLD (P = 0.045).   
Gabizon and colleagues reported that the clearance of sum total (encapsulated + 
released doxorubicin) decreased by approximately 25 to 50% from cycle 1 to 3 in patients 
with ovarian cancer (Figure 1.5) (59).  In addition, La and colleagues reported that this 
reduction in clearance of Doxil from cycle 1 to cycle 3 was associated with a reduction in 
pre-cycle monocyte count (60).  These studies suggest that there is a reduction in the 
clearance of liposomes over time that is associated with a reduction in MPS function. Thus, 
dose reductions may be needed in subsequent cycles to minimize the risk of toxicity (59). 
Interestingly, repeat dose studies of PEGylated liposomal doxorubicin in mice and rats did 
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not report accumulation of drug in plasma suggesting that these preclinical models may not 
accurately reflect the disposition of PEGylated liposomal agents after repeated dosing (61, 
62).  Thus, there is a need to develop better preclinical animal models for pharmacology and 
toxicology studies of liposomal and nanoparticle agents.   
 
D.3 Effect of Dose Schedules 
Conventional liposome formulations show a dose-dependent clearance (12, 13). 
Circulation time of conventional liposomes increase proportionately with increasing lipid 
dose. The decreased clearance of conventional liposomes may due to a combination of 
saturation of MPS (63) and due to depletion of serum opsonins at high lipid doses (64, 65). 
PK of drug-free pegylated liposomes has been reported to be independent of dose within a 
certain range. However, inhibition of MPS-mediated liposome clearance by PEGylated 
liposomal doxorubicine (PLD) but not drug-free liposomes or non-liposomal doxorubicin 
was reported in murine model. In this study, treatment with PLD followed one day later by 
injection of drug-free radio-labeled liposomes or repeated treatment with PLD every 4 days 
for a total of four injections have been shown to cause a delay in liposome and liposomal 
drug clearance. In addition, clinical PK analysis of Doxil suggests a dose-dependent 
clearance and saturation of clearance phenomenon when a broad range of doses are examined 
(66). Dose-dependent clearance was also observed in a phase I PK study of S-CKD602 (47, 
48). 
The dose-dependent PK not only is reflected in saturation of clearance but also 
changed the biodistribution of Doxil. In murine model, dose escalation results in a 
disproportional increase of the amount of liposomal drug accumulating in tumor (66). The 
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enhancement of tumor drug levels with liposomal delivery is much more prominent at higher 
doses than at lower doses. In addition, decreased amounts of liposomes in liver and increased 
amounts of liposomes in spleen and blood were observed with increasing liposome dose (67, 
68). 
 
D.4 Drug-Drug Interaction 
Drug-drug interactions were also reported for the PK of liposomal drugs. Pazopanib 
is a small-molecue inhibitor of vascular endothelial growth factor (VEGF) and platelet-
derived growth factor (PDGF) receptors. Coadministration of Pazopanib and Doxil resulted 
in a significantly reduced penetration of Doxil from microvessels of tumor. No significant 
difference in doxorubicin concentration normalized by tumor weight between Pazopanib 
treated and control tumor was observed (69). The effect of Pazopanib on distribution of 
Doxil may be explained by the altered vessel permeability and oncotic pressure gradients 
which play an important role in the liposomal drug delivery to tumor. In addition, cisplatin 
has been shown to increase the clearance of Doxil; however, the mechanism of this 
interaction is unclear (70).  
 
E.  Factors Affecting PD of Liposomal Agents 
Liposome drug delivery systems have been widely used to reduce the drug toxicity 
while at the same time improve or maintain the drug efficacy. Like conventional drugs, 
efficacy and toxicity of liposomal drugs can be accounted for to a great extent by its PK 
disposition. The factors that affect PK of liposomal drugs may also have an effect on the PD 
of liposomal drugs. 
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E.1 Efficacy 
Liposomal delivery system improved efficacy of drugs by changing the PK 
disposition and biodistribution of encapsulated drugs. The improved efficacy of liposomal 
drugs has been repeatedly demonstrated. In addition to the improved biodistribution, the 
interaction between liposome and blood cells including platelets provided a PK-independent 
enhancement in efficacy of hemophilia treatment. Recombinant FVIII formulated in PEG-
ylated liposomes (rFVIII-PEG-Lip) was reported to increase the bleed-free days from 7 to 13 
days (at 35 IU/kg rFVIII) in severe hemophilia A patients (71).  The efficacy of rFVIII-PEG-
Lip represents an approximately 2.5-fold higher "apparent" FVIII activity, which is not 
accounted for by its modestly increased (13%) half-life (72).  PEG-Lip associates with the 
majority of platelets and monocytes in vivo, and results in increased P-selectin surface 
expression on platelets in response to collagen (72). 
Family history of ovarian cancer was reported to be a factor on the efficacy of 
PEGylated liposomal doxorubicin (PLD). The median time to progression was 11.5 months 
for high-risk patients versus 6.5 months for patients with sporadic cancer (P = 0.0188) and 
the median overall survival for high-risk patients was 48.7 months (95% CI, 21.2-) compared 
with 16.2 months (95% CI, 11.8 - 24.0) for the patients with sporadic cancer (P = 0.0032) 
(73). Patients with hereditary ovarian cancer were more sensitive to PLD.  This observation 
may be related to a high incidence of a BRCA1 or BRCA2 germ-line mutation in these 
patients. 
 
E.2 Toxicity 
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Liposomal formulations can also modify the toxicity profile of a drug (e.g., 
Ambisome) (74).  Amphotericin B is a polyene antibiotic used in the treatment of systemic 
fungal infection. The use of non-liposomal amphotericin B is associated with extensive renal 
toxicity (75). The toxicity of this compound is due to non specific binding to the mammalian 
cell cholesterol (75). The liposome formulation of amphotericin B (AmBisome) reduces the 
renal and general toxicity of amphotericin B by passively targeting the liver and spleen (6, 
12, 76).  The cardiotoxicity of Doxil is significantly less than non-liposomal doxorubicin, 
whereas, the efficacy of Doxil is comparable to non-liposomal doxorubicin. Histologic 
examination of cardiac biopsies from patients who received cumulative doses of Doxil  from 
440 mg/m
2 
to 840 mg/m
2
, and had no prior exposure to anthracyclines, revealed significantly 
less cardiac toxicity than in matched doxorubicin controls (P < 0.001) (77).  These results 
suggest that the decreased cardiotoxicity of Doxil may be due to reduced accumulation of 
doxorubicin in heart. However, a new adverse event called hand-foot syndrome (HFS) also 
known as palmar-plantar erythrodysesthesia (PPE) and stomatitis commonly occurs after 
Doxil treatment (78). PPE/HFS can be dose limiting in some patients. This has not been 
reported with non-liposomal doxorubicin at standard doses (79). The exact mechanisms 
associated with these toxicities are unknown, but these toxicities are schedule and dose 
dependent.  The relationship between PK of Doxil and HFS incidence was studied by Lyass 
et al.  It was found that HFS incidence correlated with elimination half-life, but not with drug 
dose, maximum plasma concentration, or area under the concentration curve (AUC) (70, 80, 
81).  These findings suggested that prolonged exposure and that longer dosing interval may 
decrease the risk of HFS.  Doxil is generally well tolerated and its side-effect profile 
compares favorably with other chemotherapy used in the treatment of refractory ovarian 
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cancer.  Proper dosing and monitoring may further enhance tolerability while preserving 
efficacy; however, these is still a need to identify factors associated with PPE (79). 
In general, drug toxicity is reduced using liposomal delivery system due to their 
limited distribution to normal tissue and organs. Although liposome toxicity appears to be 
minimal, potential toxicity should be considered for tissues such as the liver, spleen, and 
lungs because of macrophage ingestion of liposomes. The interaction between liposome and 
MPS may cause toxicity to MPS after administration of liposomal agents. Our group 
performed the first study evaluating the PK and PD relationships between a liposomal 
anticancer agent and monocytes, a primary cell of the MPS, in patients (52).  In this study, 
the relationship between monocyte count and absolute neutrophil count (ANC) in the blood 
and PK disposition of S-CKD602 and non-liposomal CKD-602 (NL-CKD602) in patients 
were evaluated.  For S-CKD602 in patients <60 years, the percent decrease in ANC and 
monocytes were 43 ± 31 and 58 ± 26%, respectively (P = 0.001). For S-CKD602 in patients 
>= 60, the percent decrease in ANC and monocytes were 41 ± 31 and 45 ± 36%, respectively 
(P = 0.50). For NL-CKD602 (n = 42), the percent decrease in ANC and monocytes were 
similar (P > 0.05). The results of our study suggest that monocytes are more sensitive to S-
CKD602 as compared with neutrophils and that the increased sensitivity is related to the 
liposomal formulation and not the encapsulated CKD-602.  The relationship between 
changes in monocytes and the PK disposition of S-CKD602 suggest that monocytes engulf 
liposomal anticancer agents which cause the release of CKD-602 from the liposome and 
toxicity to the monocytes (82).  Our study also suggests that there are age-related factors 
associated with the PD interaction between S-CKD602 and monocytes with a decrease in the 
function of monocytes in older patients.  
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Interestingly, the interaction between liposomes and small molecule drugs may be 
used to reduce toxicity of the drugs. Pretreatment with empty liposomes reduced acute 
toxicity of non-liposomal amphotericin B in mice (83). The protective effect of liposomes 
from the erythrocyte membrane damage induced by non-liposomal amphotericin B may be 
due to an altered structure of amphotericin B after interacting with the liposomes (84).  
Positively charged liposomes are associated with pulmonary toxicity. The pulmonary 
toxicity of liposome depends on dose and charge (85). The toxicities of differently charged 
liposomes were evaluated after pulmonary administration in mice. It was found that 
multivalent cationic liposome LipofectAMINE was much more toxic than the monovalent 
cationic liposome DOTAP, and that neutral and negative liposomes were not toxic at similar 
concentrations (85).  
 
F.  CONCLUSION 
Liposomes have been used to increase the therapeutic index of a wide range of drugs 
because of their unique PK properties.  Liposomal properties such as particle size, charge and 
lipid composition have been extensively investigated for their influence on the PK of 
liposomal drugs in preclinical studies.  Based on the understanding of the role of these factors 
along with the advanced liposomal technology, it is now possible to engineer a wide range of 
liposomes of different physicochemical properties suitable for a wide range of applications. 
However, the clinical use of liposomal drugs is complicated by large intra- and inter-
individual variabilities in their PK and PD. Although several physiological factors such as 
age, body composition, and gender have been reported to affect the fate of liposomal drugs, 
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much work is still needed to identify factors and validate the identified factors in clinical 
studies of liposomal drugs.   
Liposomal drugs generally have comparable or greater activity than conventional 
drugs while at the same time reducing toxicity of conventional drugs. Factors associated with 
PK of liposomal drugs are of great importance in driving the PD of liposomal drugs. In 
addition, understanding of the interaction between liposome and organ systems, such as 
MPS, provides stronger basis to predict efficacy and safety of liposomal drugs. 
Future studies need to evaluate the mechanism of clearance of liposomal agents and 
identify the factors associated with PK and PD variability of liposomes and nanoparticle 
anticancer agents in patients and specifically in tumors (86, 87).  Future studies also need to 
develop phenotypic probes that can be used to predict this variability and individualize 
therapy with liposomal agents.  In addition, to advance the science and the translational 
development of liposomal agents it is of the utmost importance to determine the most 
appropriate animal model for the pharmacology, toxicology and efficacy studies of liposomal 
agents and all carrier-mediated agents. 
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G. RATIONALE AND OVERVIEW OF PROPOSED RESEARCH 
The PK disposition of carrier-mediated agents, such as, nanoparticles, liposomes, and 
conjugated agents, is dependent upon the carrier until the drug is released from the carrier. 
Thus, the pharmacology of a particular liposomal drug is significantly affected by the PK, 
biodistribution, and drug release rates of the liposomal carrier. Physiochemical properties of 
liposomal formulations and environment factors affecting the PK of liposomal drugs have 
been extensively evaluated in preclinical studies.  However, nonlinear and highly variable PK 
property of the PEGylated liposomal anticancer agents has been observed in the clinical 
studies. The nonlinear PK of Doxil may be explained by the saturation of MPS. The factors 
associated with the PK/PD variability of these agents remain unclear, but most likely include 
the MPS.  
 PEGylated liposomes are mainly cleared by the MPS which includes monocytes in 
the blood circulation and macrophages in the tissue. The clearance of PEGylated liposomal 
anticancer agents by monocytes causes the release of anticancer agents and acute cytotoxicity 
to the monocytes. This toxicity to the monocytes in turn decreases clearance of the 
PEGylated liposomal anticancer agents and affects the PD of PEGylated liposomal 
anticancer agents. PK of PEGylated liposomal anticancer agents has been evaluated by 
empirical modeling approach. However, mechanistic models based on physiology and 
pharmacology have not been developed for PEGylated liposomal anticancer agents to date. 
The goals of this dissertation work is to understand the role of bi-directional interaction 
between the PEGylated liposomal anticancer agents and monocytes in determining the PK 
and PD of PEGylated liposomal anticancer agents,  and identify patient factors associated 
with the significant PK/PD variability of PEGylated liposomal anticancer agents. A 
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population PK/PD modeling approach will be used to characterize the PK/PD of PEGylated 
liposomal anticancer agents.  
The central hypothesis of this project is that the bi-directional interaction between the 
PEGylated liposomal anticancer agents and cells of the MPS, such as monocytes, 
macrophages, and dendritic cells, drives the PK/PD of PEGylated liposomal anticancer 
agents. Therefore, this interaction can be monitored and utilized to optimize the treatment 
with PEGylated liposomal anticancer agents. S-CKD602 and IHL-305 were selected as 
representative PEGylated liposomal anticancer agents for this work. 
S-CKD602 is a PEGylated liposomal formulation of CKD-602, a camptothecin 
analogue which inhibits topoisomerase I (5). The PEGylated liposomal formulation consists 
of phospholipids covalently bound to methoxypolyethylene glycol (mPEG) on the outside of 
the lipid bilayer.  Non-liposomal CKD-602 administered IV at 0.5 mg/m
2
/day for 5 
consecutive days repeated every 21 days is approved in Korea for the treatment of newly 
diagnosed small cell lung cancer and relapsed ovarian cancer (88-91). The results of a phase I 
study of S-CKD602 administered IV x1 over 1 hour every 21 days reported that S-CKD602 
was associated with high interpatient variability in the PK disposition of encapsulated and 
released CKD-602 (48).  There was a 100-fold range at lower dose and a 10-fold to 20-fold 
range at higher dose in encapsulated CKD-602 AUC (47). We were the first to report a 
reduced clearance of the liposomal encapsulated forms of Doxil and S-CKD602 in patients ≥ 
60 years of age (92, 93).  We have also reported that patients with a lean body composition 
may have a reduced tissue distribution and an increased plasma exposure of S-CKD602 (92, 
93). In addition, we have reported an age related decrease in the function of monocytes 
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which may be associated with a reduced clearance of liposomes and reduced cytotoxicity to 
the monocytes (52, 94, 95). 
IHL-305 is a PEGylated liposomal formulation of irinotecan (CPT-11), also a 
camptothecin analogue. CPT-11 has been approved for the treatment of metastatic colorectal 
cancer (5, 96-98). Unlike S-CKD602, CPT-11, the encapsulated drug in IHL-305, is a 
prodrug that requires activation to the active metabolite, 7-ethyl-10-hydroxy-camptothecin 
(SN-38). SN-38 is approximately 100- to 1000-fold more active than the parent CPT-11. 
IHL-305 is currently in phase I clinical studies (99). The PEGylated liposomes of S-CKD602 
and IHL-305 were made using two different methods. The PEGylated liposome of S-
CKD602 was made by adding the PEG lipid before the process of liposomal formation which 
results PEG tether being projected on both the inside and outside of liposome. The 
PEGylated liposome of IHL-305 is made by adding the PEG lipids after the process of 
liposomal formation which results in PEG tether only being localized on the outer leaflet 
(100). 
The major goals of this research plan are: 
Aim 1. To identify important patient factors affecting the PK of PEGylated liposomal 
anticancer agents. 
1a) Evaluate the influence of patient characteristics on PK parameters using 
noncompartmenal PK analysis. 
1b) Evaluate the influence of patient characteristics on PK parameters using 
individual-based PK analysis. 
1c) Evaluate the influence of patient characteristics on PK parameters using 
population-based PK analysis.   
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Aim 2. To develop a mechanism-based population PK/PD model for the 
representative PEGylated liposomal anticancer agents by incorporating the bi-directional 
interaction between the PEGylated liposomal anticancer agents and the monocytes as a 
component.   
2a) Investigate the nature of nonlinear PK of these agents 
2b) Evaluate the role of the bi-directional interaction between these agents and the 
monocytes in the PK and PD of these agents. 
In this dissertation, various PK analyses were performed for S-CKD602 and IHL-305 
to define role of bi-directional interaction between the PEGylated liposomal anticancer 
agents and monocytes in determining the PK and PD of PEGylated liposomal anticancer 
agents. In addition, this work identified patient factors affecting the PK/PD of these agents. 
Non-compartmental analysis was performed as part of a phase I study of IHL-305 in patients 
with advanced solid tumors to evaluate the PK disposition of sum total (encapsulated + 
released) and released CPT-11, and its metabolites, and the PD of IHL-305. Conventional PK 
analysis based on individual patient data was performed to evaluate the factors associated 
with the inter-patient variability in the PK and PD of IHL-305 in patients with advanced solid 
tumors. A population PK analysis of IHL-305 based on a conventional (empirical) PK model 
was performed to describe the population PK of the encapsulated CPT-11, released CPT-11 
and the active metabolite SN-38 after administration of the PEGylated liposomal form of the 
drug. This model was also used to characterize clinical covariates that influence IHL-305 PK. 
A mechanism-based population PK-PD model was developed to investigate the nature of 
nonlinear PK of IHL-305 and to increase our understanding of the bi-directional interaction 
between PEGylated liposomal anticancer agents and monocytes in cancer patients.  
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Results of non-compartmental PK analysis and conventional PK analysis based on 
individual patient data of a phase I study of S-CKD602 have been published (47, 48). A 
population PK analysis of S-CKD602 based on conventional (empirical) PK model was 
performed to describe the population PK of the encapsulated CKD-602 and released CKD-
602 after administration of the PEGylated liposomal form of the drug and to characterize 
clinical covariates that influence S-CKD602 PK. A mechanism-based population PK-PD 
model was developed to investigate the nature of nonlinear PK of S-CKD602 and to increase 
our understanding of the bi-directional interaction between PEGylated liposomal anticancer 
agents and monocytes in cancer patients.  
Finally, we developed a mechanism-based population PK-PD model for PEGylated 
liposome membrane lipids to evaluate the bi-directional interaction between PEGylated 
liposome membrane lipids and monocytes. This model was used to test if PEGylated 
liposome membrane lipids alone can explain the toxicity associated with monocytes after 
administration of PEGylated liposomal anticancer agents. 
This project will generate new knowledge about: (1) the nature of the nonlinear PK of 
PEGylated liposomal anticancer agents; (2) the role of the bi-directional interaction between 
PEGylated liposomes and the monocytes in the PK/PD of these agents; and (3) patient factors 
that significantly affect the PK/PD of PEGylated liposomal anticancer agents.   
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Table 1.1 
 
Selected Liposomal Drugs Approved for Clinical Application or Undergoing Clinical 
Evaluation 
 
Active  
drug 
Product  
name 
PEGylated 
liposome 
Indication Trial 
Phase 
Reference 
Doxorubicin Doxil/ 
Caelyx 
yes Refractory 
ovarian cancer 
Approved (101) 
Doxorubicin Myocet no Metastatic 
breast cancer 
Approved (102) 
Daunorubicin DaunoXome no Advanced 
HIV-associated 
Kaposi’s 
sarcoma 
Approved (103) 
Amphotericin B AmBisome no Fungal 
infections 
Approved (104) 
Cytarabine Depocyt no Lymphomatou
s meningitis 
Approved (105) 
Annamycin L-AN no Doxorubicin-
resistant 
tumours 
Phase II (106) 
Lurtotecan NX211 
OSI-211 
no Hematologic 
malignancies 
Phase II (107) 
Cisplatin Lipoplatin no Advanced non-
small cell lung 
cancer 
Phase III (108, 109) 
Cisplatin SPI-77 yes Ovarian cancer Phase II (110, 111) 
CKD-602 S-CKD602 yes Solid tumors Phase I (47) 
CPT-11 IHL-305 yes Solid tumors Phase I (112) 
c-raf-1 antisense 
oligonucleotide 
LErafAON NA
a
 cancer Phase I (113) 
Oxaliplatin Lipoxal NA
a
 cancer Phase I (114) 
Vaccine BLP25 L-BLP25 no Non-small cell 
lung cancer 
Phase II (115) 
Busulphan LBu no Myeloablative 
agent for stem 
cell 
transplantation 
Phase II (116) 
MTP-PE L-MTP-PE no Osteosarcoma Phase III (117, 118) 
E1A gene E1A gene 
liposome 
no Recurrent 
Breast and 
Head and Neck 
Cancer 
Phase I (119) 
a
 Not reported. 
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Table 1.2 
 
Selected Liposomal Drugs with Conjugated Ligands to Achieve Active Targeting 
 
Active drug Targeting ligand Ligand class PEGylated 
liposome 
Reference 
Doxorubicin Folic acid Organic compound Yes (120) 
Doxorubicin 
Topotecan 
Anti-Her2 (ErbB2) 
mAb, and ScFv 
fragment 
Antibody Yes (121) 
Doxorubicin Tryptophan, 
threonine, and 
tyrosine (WTY) 
Peptide Yes (122) 
Doxorubicin Transferrin Glycoprotein Yes (123) 
Doxorubicin Anti-CEA mAb and 
Fab fragment 
Antibody Yes (124) 
Topotecan Anti-EGFR mAb 
ScFv, and Fab 
Antibody Yes (125) 
Doxorubicin RGD Peptide Yes (126) 
Doxorubicin PRβ Peptide Yes (127) 
Doxorubicin Estrone Hormone Yes (39) 
5-FU Transferrin Protein no (128) 
Doxorubicin Transferrin Protein no (129) 
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Figure 1.1. Clearance of stabilized and non-stabilized liposomes. 
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Figure 1.2. Structure of PEGylated liposomes. PEG tether are projected on both the inside 
and outside of liposome for Doxil and S-CKD602. PEG tether are only localized on the 
outside of liposome for IHL-305. 
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Figure 1.3a and 1.3b. The relationship between age and encapsulated CKD-602 AUC/dose 
after S-CKD602.  Figure 1.3a represents the continuous relationship between age and the 
encapsulated CKD-602 AUC/dose.  Individual patients AUC/Dose are represented by the ○.  
The best fit line of the data is represented by the curved-solid line (R
2
 = 0.2). There was a 
statistically significant (P = 0.01) relationship between age and CKD-602 encapsulated 
AUC/dose where a high age was associated with high AUC/dose.  Figure 1.3b represents the 
encapsulated CKD-602 AUC/Dose for patients < 60 and  60 years of age.  Individual 
patients AUC/Dose are represented by the ○.  The mean and median AUC/Dose for each 
group is represented by the ▲ and ■, respectively.  Mean ± SD sum total CKD-602 
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AUC/dose for patients < 60 and  60 years of age were 3,941 ± 5,283 and 9,644 ± 10,876 
(ng/mL)/(mg/m
2
), respectively (P = 0.02; CI = 9.7, 89.4).   
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Figure 1.4. Relationship between the ratio of total body weight to ideal body weight 
(TBW/IBW) and S-CKD602 encapsulated AUC/dose. Encapsulated AUC/dose in patients < 
60 and  60 years of age are represented by  and ○, respectively. The best fit line of the data 
is represented by the curved-solid line (R
2
 = 0.2). Controlling for age, there was a statistically 
significant (P = 0.02) inverse relationship between TBW/IBW and AUC/dose where low 
TBW/IBW was associated with high AUC/dose in both age groups.   
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Figure 1.5. The clearance of sum total (encapsulated + released) PEGylated liposomal 
doxorubicin (Doxil) within patients on cycles 1, 2 and 3.  There was a statistically significant 
reduction in the clearance of Doxil from cycle 1 to 3 (P < 0.0003). 
  
 
CHAPTER 2 
 
 
PHARMACOKINETIC (PK) STUDY OF PEGYLATED 
LIPOSOMAL IRINOTECAN (IHL-305) IN PATIENTS WITH 
ADVANCED SOLID TUMORS 
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A. INTRODUCTION 
IHL-305 is a PEGylated liposomal formulation of irinotecan (CPT-11), a 
camptothecin analogue which inhibits topoisomerase I and has been approved worldwide for 
the treatment of metastatic colorectal cancer (1-4). The PEGylated liposomal formulation 
consists of phospholipids covalently bound to polyethylene glycol (PEG) on the outside of 
the lipid bilayer.  CPT-11 is a prodrug that requires activation to the active metabolite, 7-
ethyl-10-hydroxy-camptothecin (SN-38), which is approximately 100- to 1000-fold more 
active than the parent drug. SN-38 is further conjugated to an inactive glucuronide (SN-38G) 
by uridine diphosphate glucuronosyltransferases (UGTs), primarily the UGT1A1 isoform. 
Other identified CPT-11 metabolites are 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-
piperidino]-carbonyloxycamptothecin (APC) and 7-ethyl-10-[4-amino-1-piperidino]-
carbonyloxycamptothecin (NPC) (3, 5).  
The development of PEGylated liposomes was based on the discovery that 
incorporation of methoxyPEG-lipids into liposomes yields preparations with prolonged 
plasma exposure and superior tumor delivery compared to conventional liposomes composed 
of natural phospholipids (4, 6, 7).  PEGylated liposomal doxorubicin (Doxil®) is approved 
for the treatment of refractory ovarian cancer, Kaposi sarcoma, and multiple myeloma (8, 9).  
The PEGylated liposomes of Doxil and IHL-305 were made using two different methods. 
The PEGylated liposome of Doxil was made by adding the PEG lipid before the process of 
liposomal formation which results PEG tether being projected on both the inside and outside 
of liposome.  The PEGylated liposome of IHL-305 is made by adding the PEG lipids after 
the process of liposomal formation which results in PEG tether only being localized on the 
outer leaflet (10).  Encapsulation of the CPT-11 in the acidic core of a PEGylated
 
liposome 
should also protect the active-lactone form of the drug from being converted to the inactive-
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hydroxy acid form in the blood and allow for release of the active-lactone form into the 
tumor over a protracted period of time, which is ideal for a cell cycle-specific drug (1-4, 11, 
12).  The clearance of non-PEGylated and PEGylated liposomes is via the mononuclear 
phagocytotic system (MPS), which has also been called the reticuloendothelial system (RES) 
(4, 6, 7, 13, 14).  Once the drug is released from the liposome the pharmacokinetic (PK) 
disposition will be the same as after administration of the non-liposomal formulation of the 
drug (4, 6, 7, 13, 14).   
The nomenclature used to describe the PK disposition of carrier-mediated drugs 
includes encapsulated or conjugated (drug within or bound to the carrier), released (the active 
drug released from the carrier), and sum total (encapsulated or conjugated drug plus released 
drug).  The ability to evaluate the various forms (encapsulated and released) of the drug after 
administration of nanosome or nanoparticle formulations is dependent upon specific sample 
processing methods (15).  The factors affecting the PK and pharmacodynamic variability of 
these agents remain unclear, but most likely include the MPS. S-CKD602 is a PEGylated 
liposomal formulation of CKD-602, a semi-synthetic camptothecin analogue. The PK 
disposition of liposomal encapsulated and released CKD-602 in plasma was evaluated as part 
of a phase I study in patients (16).  The interpatient variability in the disposition of 
encapsulated CKD-602 was 10-fold greater than for non-nanoparticle CKD-602. We also 
have reported that the PK variability of S-CKD602 was related to the age, body composition 
and monocyte function of patients (13, 17, 18). 
 Studies of the PK of IHL-305 compared to CPT-11 in mice, rats, and dogs showed a 
marked increase in the concentrations of CPT-11 and its metabolites in the 
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plasma, liver, kidney, spleen, and tumor tissue after administration of IHL-305 as compared 
with 
non-liposomal CPT-11 administration. The plasma exposure of IHL-305 at 16.7 mg/kg IV x 
1 was approximately 302-fold greater than non-liposomal CPT-11 at the same dose in tumor-
bearing mice (19). In mice bearing human tumor xenografts, the exposures of CPT-11 and 
SN-38 in tumor were 9.0 and 3.9-fold higher and the mean residence time of CPT-11 and 
SN-38 in plasma was 4.4 and 4.7-fold longer for IHL-305 compared with non-liposomal 
CPT-11 (20). In addition, the antitumor response was greater for IHL-305 compared with 
non-liposomal CPT-11 (20).  These results are consistent with reports that the antitumor 
response to camptothecin analogues is enhanced by prolonged duration of exposures in 
tumors  (11, 12, 14, 21, 22).   
 We performed the first study evaluating the PK disposition of IHL-305 as part of a 
phase I study in patients with advanced solid tumors.  The objectives of this study were to 
evaluate the PK disposition of sum total (encapsulated + released) and released CPT-11, and 
its metabolites, and evaluate the pharmacodynamics of IHL-305.  
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B. PATIENTS AND METHODS 
Patients 
 Written informed consent, approved by the Institutional Review board of the Sarah 
Cannon Research Institute and Vanderbilt University Medical Center, was obtained from all 
patients prior to study entry. Patients ≥ 18 years of age with a histologically confirmed 
malignant solid tumor for which no effective therapy was available or a conventional therapy 
have failed to treat or a conventional therapy does not exist were eligible for this study.  
Patients must have recovered from all acute adverse effects of prior therapies, excluding 
alopecia.  Pertinent  eligibility criteria included a Eastern Cooperative Oncology Group 
(ECOG) performance status of 0, 1, or 2, adequate bone marrow, hepatic, and renal function 
as evidenced by the following: absolute neutrophil count (ANC)  1500/L, platelets  
100,000/L, total bilirubin within normal institutional limits, aspartate aminotransferase 
(AST)  2.5 x institutional upper limit of normal (ULN) if liver metastases were not present 
and  5.0 x ULN if liver metastases were present, plasma creatinine  1.5 x the institutional 
ULN or creatinine clearance  60 ml/min/1.73 m2 for patients with creatinine levels above 
institutional normal.  Patients must have the ability to understand and the willingness to sign 
a written informed consent document.  Patient were excluded from the study for any of the 
following: prior treatment with CPT-11; chemotherapy or radiotherapy within 4 weeks (6 
weeks for nitrosoureas or mitomycin C); treatment with any other investigational agent 
during study; brain metastases; a history of allergic reactions to compounds of similar 
chemical composition to IHL-305; concurrent serious infections; pregnancy or breastfeeding; 
uncontrolled intercurrent illness including ongoing or active infection, unstable angina 
pectoris or psychiatric illness/social situations; significant cardiac disease including heart 
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failure that meets New York Heart Association (NYHA) class III and IV definitions, history 
of myocardial infarction within one year of study entry, uncontrolled dysrhythmias or poorly 
controlled angina; a history of serious ventricular arrhythmia, QTc ≥ 450 msec for men and 
470 msec for women, or LVEF ≤ 40% by MUGA.  Prior treatment with camptothecin 
analogues other than IHL-305 or CPT-11 was permitted.   
  
Dosage and Administration 
IHL-305 is a formulation of CPT-11 encapsulated in long-circulating PEGylated 
liposome.  In IHL-305, the PEGylated liposome bilayer is composed of cholesterol and 
hydrogenated soybean phosphatidylcholine (HSPC), and the surface of liposomes is modified 
with PEG. The mean particle diameter is approximately 100 nm and the ratio of CPT-11 to 
lipid is 1:4. The PEGylated liposomal formulation was generated by Terumo Corporation 
(Tokyo, Japan). IHL-305 was supplied by Yakult Honsha Corporation in sterile 10 mL light-
resistant, single-use glass vials as a translucent white to pale yellow liquid with a nominal 
total CPT-11 concentration of 5 mg/mL.  IHL-305 was diluted 25-fold in 5% dextrose or 
normal saline prior to administration.  Prior to administration of the study drug, patients were 
premedicated with ondansetron (or other 5-HT3 inhibitor should circumstances require) and 
dexamethasone, according to each institution’s standard of care.  
IHL-305 was administered IVx1 over 60 minutes every 4 weeks.  Doses 
administrated (expressed in mg of CPT-11) were 3.5, 7, 10.5, 14, 28, 33.5, 37, 50, 67, 80, 88, 
120, 160, and 210 mg/m
2
. This phase I study followed a standard dose escalation design with 
patients enrolled in cohorts of 3, with the possibility of extending the cohort up to 6 patients 
depending on the number of dose-limiting toxicities (DLT) (18). No intra-patient dose 
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escalation was permitted. The maximum tolerated dose (MTD) was defined based on 
standard criteria. 
 
Patient Assessment 
 Response and progression was measured by the Response Evaluation Criteria in Solid 
Tumors (RECIST) after receiving at least two cycles of study therapy (23). Toxicity was 
assessed according to the National Cancer Institute Common Terminology Criteria for 
Adverse Events version 3.0 (CTCAE version 3.0) and by relationship to study drug.  Dose 
limiting toxicities (DLT) on this study were defined as treatment-related events experienced 
during cycle 1 for patients with UGT1A1*28 genotype (wt/wt and wt/*28).  Hematologic 
DLT’s were defined as: grade 4 hematologic toxicity which lasts at least 5 days; grade 3 or 4 
febrile neutropenia or grade 4 thrombocytopenia of any duration; grade 3 or greater non-
hematologic toxicities (except alopecia and nausea/vomiting well-controlled with anti-
emetics) irrespective of clinical significance attributed by the investigator or baseline lab 
values; ≥ grade 3 prolonged QTc (QTc > 500 msec) as defined in CTCAEv.3.0; any toxicity 
resulting in a treatment delay beyond 1 week.  Complete blood counts were obtained weekly 
and as medically indicated.  The nadir and percentage decrease at nadir for the absolute 
neutrophil count (ANC), platelets, red blood cells (RBC), and monocytes were estimated 
using standard methods (24, 25). 
 
Sample Collection, Processing, Analytical Studies, and Pharmacokinetic Analysis 
 Plasma samples for PK assessment were obtained from all patients.  On cycle 1, 
blood (5 mL) was collected in tubes containing sodium heparin at prior to administration, at 
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end of the infusion (approximately 1 h), and at 1.5 h, 2 h, 3 h, 5 h, 9 h, 13 h, and 25 h after 
the start of the infusion for patients treated at < 67 mg/m
2
 and the first three patients treated 
at 67 mg/m
2
. Additional samples at 49 h, 73 h, 97 h, 169 h (day 7), 192 h (day 8), and 216 h 
(day 9) after the start of the infusion were also collected for patients treated at > 67 mg/m
2
 
and the last three patients treated at 67 mg/m
2
.   
 The blood samples were centrifuged at 3,000 x g for 15 min at 4ºC to separate plasma 
samples. Plasma samples were processed to measure sum total (encapsulated + released) 
CPT-11 and released CPT-11, SN-38, SN-38G, APC, and NPC as previously described (26). 
The sum total CPT-11, released CPT-11, SN-38, SN-38G, APC, and NPC concentrations 
were measured by a high-performance liquid chromatography (HPLC) as previously 
described (26). The total (lactone + hydroxy acid) form of camptothecin was measured for 
sum total CPT-11, released CPT-11, SN-38, SN-38G, and APC samples.  The lower limit of 
quantitation (LLQ) of the total form sum total CPT-11, released CPT-11, SN-38, SN-38G, 
APC, and NPC were 100, 2, 2, 2, 2, and 2 ng/mL, respectively. 
  The area under the sum total CPT-11, released CPT-11, SN-38, SN-38G, APC, and 
NPC plasma concentration versus time curve from 0 to last measurable sample (AUC0-t) and 
0 to infinity (AUC0-∞) were calculated using the log trapezoidal method (27).  The ratio of 
released CPT-11 AUC to sum total CPT-11 AUC for each patient was calculated. 
  
Statistical Analysis 
 Comparisons between the nadir and percent decrease at nadir for ANC, platelets, 
RBC, and monocytes on cycles 1 and 2 were performed using analysis of variance (28).  The 
statistical analysis was performed using SAS software (Cary, NC). 
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RESULTS 
 42 patients were enrolled on this study from December 14, 2006 to December 15, 
2008 at Sarah Cannon Research Institute and Vanderbilt University Medical Center.  All 
patients received at least one dose of drug and were evaluable for toxicity. A total of 112 
cycles were administered.  The mean (range) number of cycles administered was 2.9 (1 to 4).  
PK sampling was initiated in 39 patients enrolled on the study.   
 
Pharmacokinetics  
 The plasma concentrations versus time profiles of sum total CPT-11, released CPT-11 
and SN-38 in all patients treated with IHL-305 at the maximum tolerated dose (160 mg/m2) 
are presented in Figure 2.1. There was significant variability in the plasma concentrations of 
sum total CPT-11, released CPT-11 and SN-38.  The sum total CPT-11 plasma 
concentrations declined monoexponentially.  The maximum levels of released CPT-11 and 
SN-38 were observed 0 h to 72 h and 2 to 48 h after the end of infusion, respectively. The 
mean plasma concentrations of sum total CPT-11 was 30-fold to 600-fold higher than that of 
released CPT-11, whereas the mean plasma concentrations of released CPT-11 was 14-fold 
to 237-fold higher than that of SN-38. 
             The relationship between IHL-305 dose and sum total CPT-11 AUC is presented in 
Figures 2.2A .  There was significant variability in the sum total CPT-11 AUC at higher dose 
of IHL-305 and a roughly linear relationship between dose and sum total CPT-11 AUC.  At 
the MTD of 160 mg/m
2
, there was a 2.7-fold range in sum total CPT-11 AUC.  
 The relationship between IHL-305 dose and released CPT-11 AUC is presented in 
Figures 2.2B.  There was significant variability in the released CPT-11 AUC at each dose of 
 56 
IHL-305 and a poor linear relationship between dose and released CPT-11 AUC.  At the 
MTD of 160 mg/m
2
, there was a 4.0-fold range in released CPT-11 AUC.  The released CPT-
11 AUCs were similar from 3.5 to 14 mg/m
2
, from 37 to 50 mg/m
2
, and from 120 to 160 
mg/m
2
. However, the mean released CPT-11 AUC increased 8.6-fold from 14 to 28 mg/m
2
 
and 2.0-fold from 50 to 67 mg/m
2
, and 3.0-fold from 88 to 120 mg/m
2
.  
 The relationship between IHL-305 dose and SN-38 AUC is presented in Figures 
2.2C.  There was significant variability in the SN-38 AUC at each dose of IHL-305 and a 
poor linear relationship between dose and SN-38 AUC.  At the MTD of 160 mg/m
2
, there 
was a 12.5-fold range in SN-38 AUC.  The SN-38 AUCs were similar from 37 to 50 mg/m
2
 
and from 120 to 210 mg/m
2
. However, the mean SN-38 AUC increased 1.5-fold from 50 to 
67 mg/m
2
, and 2.5-fold from from 88 to 160 mg/m
2
, whereas it decreased 2.0-fold from 67 to 
88 mg/m
2
.    
 The relationship between IHL-305 dose and SN-38G AUC is presented in Figures 
2.2D.  The relationship between IHL-305 dose and APC AUC is presented in Figures 2.2E.  
There were significant variability in the SN-38G and APC AUCs at each dose of IHL-305 
and a poor linear relationship between dose and SN-38G and APC AUCs.  Plasma samples 
were also evaluated for NPC but were not detectable in most patients. 
 The sum total CPT-11, released CPT-11, SN-38, SN-38G, and APC AUCs at each 
IHL-305 dose are presented in Table 2.1. The sum total CPT-11 AUC was significantly 
greater than the released CPT-11, SN-38, SN-38G, and APC AUCs at all doses. In addition, 
released CPT-11 AUC was higher than SN-38G and APC AUCs; whereas, SN-38 AUC was 
lower than SN-38G and APC AUCs at all doses. The ratio of released CPT-11 AUC to sum 
 57 
total CPT-11 AUC, SN-38 AUC to released CPT-11 AUC, SN-38G AUC to SN-38 AUC, 
and APC AUC to released CPT-11 AUC at each IHL-305 dose are presented in Table 2.2.  
 
Pharmacodynamics 
 The cumulative toxicity of IHL-305 as related to ANC, platelets, red blood cells 
(RBC), and monocytes was evaluated. The nadir and % decrease at nadir for ANC, platelets, 
RBC, and monocytes are presented in Table 2.3.  The nadir and % decrease at nadir for 
ANC, platelets, RBC, and monocytes were similar on cycles 1, 2, 3, and 4 (P > 0.05).  The 
mean ± SD for intrapatient ratio of % decrease at nadir for ANC, platelets, RBC, and 
monocytes from cycle 1 to cycle 4 was 3.53 ± 4.9, 0.98 ± 2.1, 2.94 ± 6.0, and 1.04 ± 0.37, 
respectively. 
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C. DISCUSSION 
 Major advances in the use of liposomes, conjugates, and nanoparticles as vehicles to 
deliver drugs have occurred the past 10 years (4, 6, 7).  PEGylated liposomal doxorubicin 
(Doxil®) and albumin stabilized nanoparticle formulation of paclitaxel (Abraxane®) are now 
FDA approved (8, 9, 29).  In addition, there are greater than 100 liposomal and nanoparticle 
formulations of anticancer agents currently in development (4).  This is the first PK study of 
a PEGylated-liposomal formulation of CPT-11 that evaluates the PK disposition of the 
released drug from a liposomal carrier.  Evaluation of the PK disposition of the liposomal 
encapsulated verses released drug is of the utmost importance because the liposomal 
encapsulated drug is an inactive prodrug and thus only the released drug is active (1, 4).   
 The prolonged plasma exposure of released CPT-11 over 1 week after administration 
of IHL-305 is consistent with PEGylated liposomes and provides extended exposure 
compared with non-liposomal CPT-11  (1-4). The PK disposition of IHL-305 is consistent 
with the PEGylated concept (4, 6, 7, 13, 14).  After a single dose of IHL-305 at the MTD of 
160 mg/m
2
, the plasma exposure of sum total CPT-11 was 252-fold higher compared with a 
single dose of non-liposomal CPT-11 at the MTD of 150 mg/m
2
 (30).  Patients treated at 
doses of IHL-305 ≥ 67 mg/m2 had quantifiable plasma concentrations of released CPT-11 
from 4 to 8 days after administration of a single dose of IHL-305.  The sum total CPT-11 
AUC was significantly greater than the released CPT-11 AUC at all doses.  At the MTD of 
160 mg/m
2
, the mean ± SD ratio of released CPT-11 AUC to sum total CPT-11 AUC was 
0.0065 ± 0.0036.  This data suggests that most of the CPT-11 remains encapsulated in the 
plasma after administration of IHL-305.  These results are also consistent with previous 
studies of IHL-305 in mice (19, 20).  
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 The PK profiles of released CPT-11, SN-38, and SN-38G were prolonged compared 
with results reported for non-liposomal CPT-11. The mean ratio of SN-38 AUC to released 
CPT-11 AUC and APC AUC to released CPT-11 AUC after administration of IHL-305 
ranged from 0.02 to 0.06 and from 0.09 to 0.55, respectively, which are similar to that after 
administration of non-liposomal CPT-11 (30, 31).  After a single dose of IHL-305 at the 
MTD of 160 mg/m
2
, the plasma exposure of released SN-38G was 3.5-fold higher compared 
with a single dose of non-liposomal CPT-11 at the MTD of 150 mg/m
2
, whereas the plasma 
exposure of CPT-11 and SN-38 were similar to that of non-liposomal CPT-11 (30, 31).  This 
data suggest that the PK of the released CPT-11 after administration of IHL-305 is consistent 
with that after administration of non-liposomal CPT-11. 
 The inter-patient variability in the PK disposition of sum total and released CPT-11 
after administration of IHL-305 is lower than that of sum total and released CKD-602 after 
administration of S-CKD602.  At the MTD of IHL-305 (160 mg/m
2
), there was a 2.7-fold 
range in sum total CPT-11 AUC and 4-fold range in released CPT-11 AUC. At the MTD of 
of S-CKD602 (2.1 mg/m
2
), there was a 13-fold range in encapsulated CKD-602 AUC and 
17-fold range in released CKD-602 AUC (16).  The encapsulated CKD-602 AUC was 
similar to the sum total AUC at all doses (16).  Additionally, there is greater PK variability in 
released CPT-11 compared with sum total CPT-11, whereas, there is smaller PK variability 
in released CKD-602 compared with sum total CKD-602.  The difference in the PK between 
IHL-305 and S-CKD602 may be related to the difference in liposomal formulations and 
pegylation between these two agents.  There was also a poor relationship between the dose of 
IHL-305 and the AUC of released CPT-11.  At high doses of IHL-305 the variability of sum 
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total CPT-11 were greater than at lower doses.  The high inter-patient variability in the PK 
disposition of IHL-305 is consistent with other liposomal anticancer agents (5, 26-28).  
The clinical significance of these differences and the factors associated with the PK 
variability need to be evaluated for IHL-305 and other liposomal and nanoparticle anticancer 
agents (4).  IHL-305 exhibits all of the pharmacologic, antitumor, and cytotoxic advantages 
of a long acting, liposomal anticancer agent (1-4, 11, 12).   
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Table 2.1. The Total Form of Sum total CPT-11, Released CPT-11, SN-38, SN-38G, and APC Area Under the Concentration Verses 
Time Curves (AUC) after Administration of IHL-305 at Each Dose 
Dose 
 
(mg/m
2
) 
Number 
of 
Patients 
Sum Total CPT-11 
a,g
  
AUC 
(μg/mLh) 
Released  
CPT-11
g
  
AUC 
(μg/mLh) 
SN-38   
AUClast 
(μg/mLh) 
SN-38G   
AUClast 
(μg/mLh) 
APC   
AUClast 
(μg/mLh) 
3.5 
b
 1 32 
 
0.060 
 
N/A 
e 
 
0.052  
 
0.050  
 
7.0 
b
 3 78  18 
(62 – 97) 
0.21  0.066 
(0.14 – 0.27) 
0.019 
h 
 
0.19 ± 0.18  
(0.032 – 0.38) 
0.083 
f
  
(0.070 – 0.097) 
14.0 
b
 3 198  34 
(168 – 234) 
0.43  0.14 
(0.34 – 0.58) 
N/A 
e 
 
0.21 ± 0.15  
(0.075 – 0.38) 
0.084 
f
  
(0.053 – 0.12) 
28.0 
b
 2 403 
(332 – 474) 
3.69 
(0.98 – 6.40) 
N/A 
e 
 
0.21  
(0.18 – 0.23) 
0.077
 
(0.072 – 0.083) 
33.5 
b
 1 405 
 
0.45 
 
0.060  
 
0.13  
 
0.082  
 
37.0 
b 
3 549  118 
(444 – 677) 
1.74  1.39 
(0.77 – 3.34) 
0.070 
h 
 
0.26 ± 0.065  
(0.21 – 0.33) 
0.10 ± 0.030  
(0.077 – 0.14) 
50.0 
b 
3 624  76 
(542 – 691) 
1.26  0.42 
(1.00 – 1.75) 
0.070 
i 
(0.056 – 0.085) 
0.30 ± 0.14  
(0.21 – 0.46) 
0.28 ± 0.20  
(0.12 – 0.50) 
67.0 
c, d 
6 767 ± 179 
c
  
(567 – 1,039) c 
1,158 ± 235 
d 
(944 – 1,410) d 
2.53 ± 2.79 
c 
(0.77 – 8.13) c 
4.59 ± 1.19 
d 
(3.26 – 5.53) d 
0.078 ± 0.045 
c 
(0.058 – 0.31) c 
0.21 ± 0.095 
d 
(0.12 – 0.31) d 
0.54 ± 0.32 
c 
(0.23 – 1.05) c 
2.79 ± 2.29 
d 
(1.41 – 5.44) d 
0.32 ± 0.13 
c 
(0.20 – 0.55) c 
1.63 ± 0.70 
d 
(1.22 – 2.44) d 
80.0 2 1,698 
(1,165 – 2,231) 
8.69 
(7.83 – 9.54) 
0.16 
(0.080 – 0.24) 
1.67  
(0.24 – 3.09) 
0.79  
(0.21 – 1.37) 
88.0  3 1,388  396 
(932 – 1,644) 
4.04  1.79 
(2.94 – 6.04) 
0.10 ± 0.048 
(0.061 – 0.16) 
1.16 ± 0.21  
(0.94 – 1.35) 
0.97 ± 0.88  
(0.36 – 1.98) 
120.0 4 1,744  738 11.93  9.73 0.17 ± 0.23 3.43 ± 1.97  2.27 ± 0.93  
6
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(936 – 2,675) (4.27 – 25.67) (0.047 – 0.51) (1.67 – 5.38) (1.45 – 3.42) 
160.0 6 2,123  893 
(1,299 – 3,502) 
12.63  7.52 
(6.73 – 27.45) 
0.25 ± 0.22 
(0.053 – 0.66) 
3.90 ± 1.53  
(1.70 – 5.57) 
5.98 ± 7.44  
(1.76 – 20.90) 
210.0
 
2 3,488 
(1,738 – 5,238) 
7.93 
(7.69 – 8.16) 
0.16 
(0.050 – 0.26) 
2.56  
(1.29 – 3.82) 
1.07  
(0.70 – 1.44) 
a 
The sum total (encapsulated + released) CPT-11 AUC was based on measured concentrations in plasma and was not calculated based 
on adding the encapsulated + released concentrations. 
 
b
 At dose < 67 mg/m
2
, all patients had PK samples obtained from 0 to 24 hours after end of infusion. Thus, the sum total CPT-11, 
released CPT-11, SN-38, SN-38G, and APC AUC for these patients is from 0 to 25 h because the percent of the AUC from 0 to 
infinity that was extrapolated was > 15%. 
 
c
 The first three patients at 67 mg/m
2
 had PK samples obtained from 0 to 24 hours after end of infusion and the percent of the AUC 
from 0 to infinity that was extrapolated was > 15%. So the AUCs from 0 to 25 h of sum total CPT-11, released CPT-11, SN-38, SN-
38G, and APC for all the six patients in this dose group were calculated. 
 
d
 The last three patients at 67 mg/m
2
 had PK samples obtained from 0 to 192 hours after end of infusion. Thus, the sum total CPT-11, 
released CPT-11, SN-38, SN-38G, and APC AUC for these patients is from 0 to infinity. 
 
e
 Every patient in each dose level treated at 3.5, 14, and 28 mg/m
2
 had no quantifiable concentrations of SN-38.  
 
f
 One patient in each dose level treated at 7.0 and 14.0 mg/m
2
 had no quantifiable concentrations of SN-38G. 
 
g
 The total (lactone + hydroxyl acid) form of sum total  (encapsulated + released) and released CPT-11 AUCs are presented. 
 
h
 Two patients in each dose level treated at 7.0 and 37.0 mg/m
2
 had no quantifiable concentrations of SN-38. 
 
i
 One patient at 50 mg/m
2
 had 1 quantifiable concentrations of SN-38 and thus an accurate SN-38 AUC could not be calculated for this 
patient. 
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Table 2.2. The Ratio of  Released CPT-11 AUC to Sum Total CPT-11 AUC, SN-38 AUC to Released CPT-11 AUC, SN-38G AUC to 
SN-38 AUC, and APC AUC to Released CPT-11 AUC after Administration of IHL-305 at Each Dose 
Dose 
(mg/m2) 
Number 
of 
Patients 
Ratio Released CPT-11 
AUC  to  
Sum total CPT-11 
AUC 
a,e
 
Ratio SN-38 AUC 
to 
Released CPT-11 
AUC 
b,e
 
Ratio SN-38G AUC 
to 
SN-38 AUC 
b,e
 
Ratio APC AUC 
to 
Released CPT-11 AUC 
b,e
 
3.5 1 0.0019 N/A 
 
N/A
 
 
0.83 
7.0 3 0.0027  0.0007 
(0.0022 – 0.0036) 
0.072  
 
1.65
 
 
0.46 
(0.42 – 0.50) 
14.0 3 0.0023  0.0011 
(0.0015 – 0.0035) 
N/A 
 
N/A
 
 
0.24 
(0.15 – 0.34) 
28.0 2 0.0082 
(0.0030 – 0.014) 
N/A 
 
N/A
 
 
0.048 
(0.011 – 0.085) 
33.5 1 0.0011 0.13  
 
2.13  
 
0.18 
37.0
 
3 0.0029  0.0017 
(0.0017 – 0.0049) 
0.021  
 
3.49
 
 
0.092  0.077 
(0.030– 0.18) 
50.0
 
3 0.0021  0.0010 
(0.0014 – 0.0032) 
0.057  
(0.032 – 0.082) 
4.58
 
(3.74 – 5.42) 
0.25  0.21 
(0.071 – 0.48) 
67.0 
c,d 
6 0.0031 ± 0.0029 
c 
(0.0013 – 0.0087) c 
0.0040 ± 0.0008 
d 
(0.0034 – 0.0049) d 
0.038 ± 0.020 
c 
(0.019 – 0.073) c 
0.049 ± 0.018 
d 
(0.035 – 0.069) d 
8.17 ± 3.60 
c 
(5.00 – 14.12) c 
12.42 ± 4.77 
d 
(8.14 – 17.56) d 
0.19 ± 0.078 
c 
(0.067 – 0.25) c 
0.40 ± 0.16 
d 
(0.22 – 0.54) d 
80.0 2 0.0055 
(0.0043 – 0.0067) 
0.018 
(0.011 – 0.026) 
7.92 
(3.02 – 12.82) 
0.087 
(0.028 – 0.14) 
88.0  3 0.0030  0.0010 
(0.0018 – 0.0037) 
0.027 ± 0.0068  
(0.020 – 0.034) 
13.48 ± 6.91 
(6.05 – 19.73) 
0.32  0.35 
(0.061 – 0.72) 
6
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120.0 4 0.010  0.012 
(0.0016 – 0.027) 
0.018 ± 0.018  
(0.0022 – 0.044) 
38.69 ± 31.86 
(10.45 – 83.93) 
0.25  0.094 
(0.13 – 0.35) 
160.0 6 0.0065  0.0036 
(0.0026 – 0.0124) 
0.023 ± 0.025  
(0.0091 – 0.073) 
23.17 ± 10.56 
(5.37 – 34.46) 
0.55  0.72 
(0.21 – 2.01) 
210.0
 
2 0.0030 
(0.0016 – 0.0044) 
0.022 
(0.0071 – 0.036) 
40.44 
(4.93 – 75.95) 
0.15 
(0.097 – 0.20) 
 
a 
The ratio of released CPT-11 AUC to sum total CPT-11 AUC was calculated as released CPT-11 AUC from 0 to 25 h divided by 
sum total CPT-11 AUC from 0 to 25 h for dose lower than 67 mg/m
2
 and released CPT-11 AUC from 0 to infinity divided by sum 
total CPT-11 AUC from 0 to infinity for dose higher than 67 mg/m
2
. 
 
 
b 
The ratios of SN-38 AUC to released CPT-11 AUC, SN-38G AUC to SN-38 AUC, and APC AUC to released CPT-11 AUC were 
calculated based on AUC from 0 to 25 h for dose lower than 67 mg/m
2
 and from 0 to 193 h for dose higher than 67 mg/m
2
.  
 
c
 The first three patients at 67 mg/m
2
 had PK samples obtained from 0 to 24 hours after end of infusion and the percent of the AUC 
from 0 to infinity that was extrapolated was > 15%. So the ratios of released CPT-11 AUC to sum total CPT-11 AUC, SN-38 AUC to 
released CPT-11 AUC, SN-38G AUC to SN-38 AUC, and APC AUC to released CPT-11 AUC were calculated based on AUC from 0 
to 25 h for all the six patients in this dose group. 
 
d
 The last three patients at 67 mg/m
2
 had PK samples obtained from 0 to 192 hours after end of infusion. Thus, the ratio of SN-38 
AUC to released CPT-11 AUC, SN-38G AUC to SN-38 AUC, and APC AUC to released CPT-11 AUC for these patients were 
calculated based on AUC from 0 to 193 h and from 0 to infinity for the ratio of released CPT-11 AUC to sum total CPT-11 AUC,. 
 
e
 The ratios of released CPT-11 AUC to sum total CPT-11 AUC, SN-38 AUC to released CPT-11 AUC, SN-38G AUC to SN-38 
AUC, and APC AUC to released CPT-11 AUC were calculated for individual patient values and not the mean of the cohort. 
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Table 2.3. The Nadir and Percentage Decrease at Nadir in ANC, Platelets, RBC, and Monocytes on Cycles 1, 2, 3, and 4 
 
 
 
 
 
 
 
 Cycle 1 Cycle 2 Cycle 3 Cycle 4 
Blood 
Cells 
% Decrease 
 
Mean ± SD 
(Range) 
[n = 42] 
Nadir 
(cells x 
10
3/μL) 
Mean ± SD 
(Range) 
[n = 42] 
% Decrease 
 
Mean ± SD 
(Range) 
[n = 32] 
Nadir 
(cells x 
10
3/μL) 
Mean ± SD 
(Range) 
[n = 32] 
% Decrease 
 
Mean ± SD 
(Range) 
[n = 19] 
Nadir 
(cells x 
10
3/μL) 
Mean ± SD 
(Range) 
[n = 19] 
% Decrease 
 
Mean ± SD 
(Range) 
[n = 19] 
Nadir 
(cells x 
10
3/μL) 
Mean ± SD 
(Range) 
[n = 19] 
ANC 28.8 ± 20.3 
(0.0 – 84.8) 
 
3.9 ± 1.7 
(1.3 – 8.0) 
19.4 ± 20.6 
(0.0 – 64.0) 
3.2 ± 1.4 
(0.8 – 7.3) 
27.8 ± 21.8 
(0.0 – 68.2) 
 
3.2 ± 1.6 
(0.8 – 7.2) 
22.4 ± 22.8 
(0.0 – 87.7) 
 
3.6 ± 1.7 
(0.3 – 6.7) 
Platelets 17.3 ± 19.8 
(0.0 – 74.1) 
 
252.6 ± 
97.9 
(88.8 – 
518.0) 
12.7 ± 20.1 
(0.0 – 81.6) 
239.2 ± 
100.2 
(47.6 – 
567.0) 
10.7 ± 9.3 
(0.0 – 27.3) 
 
239.4 ± 80.5 
(115 – 388) 
16.6 ± 22.0 
(0.0 – 82.3) 
 
237.7 ± 99.1 
(35.8 – 
375.0) 
RBC 9.2 ± 6.2 
(0.0 – 25.6) 
 
3.8 ± 0.53 
(2.6 – 4.7) 
6.8 ± 5.6 
(0.0 – 18.6) 
3.7 ± .58 
(2.7 – 4.7) 
5.0 ± 4.6 
(0.0 – 17.7) 
 
4.1 ± .42 
(3.1 – 4.8) 
5.7 ± 4.2 
(0.0 – 12.7) 
 
3.9 ± .47 
(3.0 – 4.8) 
Mono 42.0 ± 23.9 
(0.0 – 80.1) 
 
0.45 ± 0.35 
(0.08 - 1.89) 
38.9 ± 25.8 
(0.0 – 97.9) 
0.36 ± .17 
(0.02 - 0.88) 
36.9 ± 28.6 
(0.0 – 99.1) 
 
0.33 ± .14 
(0.01 - 0.52) 
40.0 ± 21.5 
(4.26 – 
81.6) 
 
0.36 ± .12 
(0.16 - 0.54) 
6
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Figure 2.1a, 2.1b, 2.1c, and 2.1d. Concentrations versus time profiles of sum total CPT-11, 
released CPT-11 and SN-38 in all patients treated with IHL-305 at the maximum tolerated 
69 
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dose (160 mg/m
2
). Figure 2.1a and 2.1c represent the concentration versus time profile from 
0 to 193 hour. Figure 2.1b and 2.1d represent the concentration versus time profile from 0 to 
49 hour.  The sum total (□,___) and released (∆,___ ) CPT-11 concentrations for each patient 
and the average sum total (■, ----) and released (▲,----) CPT-11 concentrations are 
presented.  The SN-38 (◊,___) for each patient and the average SN-38 (♦, ----) concentrations 
are presented.  The average sum total CPT-11, released CPT-11, and SN-38 AUCs were 
2,123, 12.63, and 0.25 μg/mLh, respectively. 
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Figure 2.2A, 2.2B, 2.2C, 2.2D, and 2.2E.  Relationship between dose of IHL-305 and AUC 
of sum total CPT-11, released CPT-11, SN-38, SN-38G, and APC. Figures 2.2A, 2.2B, 2.2C, 
2.2D, and 2E represent the AUC of sum total CPT-11, released CPT-11, SN-38, SN-38G, 
and APC, respectively.  IHL-305 was administered at 3.5, 7, 10.5, 14, 28, 33.5, 37, 50, 67, 
80, 88, 120, 160, and 210 mg/m2.  The patients with DLT are represented by the T. The AUC 
for patients treated at dose of 3.5 to 50 mg/m
2
 was calculated from 0 to 25 h and for patients 
treated at dose of 80 to 210 mg/m
2
 was calculated from 0 to 193 h. The AUC for the first 
three patients treated at dose of 67 mg/m
2
 was calculated from 0 to 25 h and for the last three 
patients treated at dose of 67 mg/m
2
 was calculated from 0 to 193 h. 
 
 
 
  
 
 
CHAPTER 3 
 
 
FACTORS AFFECTING THE PHARMACOKINETICS (PK) AND 
PHARMACODYNAMICS (PD) OF PEGYLATED LIPOSOMAL 
IRINOTECAN (IHL-305) IN PATIENTS WITH ADVANCED 
SOLID TUMORS 
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A. INTRODUCTION 
IHL-305 is a PEGylated liposomal formulation of irinotecan (CPT-11), a 
camptothecin analogue which inhibits topoisomerase I and has been approved for the 
treatment of metastatic colorectal cancer (1-4). The PEGylated liposomal formulation 
consists of phospholipids covalently bound to polyethylene glycol (PEG) only on the outside 
of the lipid bilayer.  CPT-11 is a prodrug that requires activation to the active metabolite, 7-
ethyl-10-hydroxy-camptothecin (SN-38), which is approximately 100- to 1000-fold more 
active than the parent drug. SN-38 is further conjugated to form an inactive glucuronide (SN-
38G) by uridine diphosphate glucuronosyltransferases (UGTs), primarily the UGT1A1 
isoform. Other identified CPT-11 metabolites are 7-ethyl-10-[4-N-(5-aminopentanoic acid)-
1-piperidino]-carbonyloxycamptothecin (APC) and 7-ethyl-10-[4-amino-1-piperidino]-
carbonyloxycamptothecin (NPC) (3, 5).  
The development of PEGylated liposomes, such as PEGylated liposomal doxorubicin 
(Doxil), CKD-602 (S-CKD602), and CPT-11 (IHL-305) was based on the discovery that 
incorporation of PEG-lipids into liposomes yields preparations with prolonged plasma 
exposure and superior tumor delivery compared to conventional liposomes composed of 
natural phospholipids (4, 6, 7).  Doxil® is approved for the treatment of refractory ovarian 
cancer, Kaposi sarcoma, and multiple myeloma (8, 9).  The PEGylated liposomes of Doxil 
and IHL-305 were made using two different methods. The PEGylated liposome of Doxil was 
made by adding the PEG lipid before the process of liposomal formation which results PEG 
tether being projected on both the inside and outside of liposome.  The PEGylated liposome 
of IHL-305 is made by adding the PEG lipids after the process of liposomal formation which 
results in PEG tether only being localized on the outer leaflet (10). Encapsulation of the CPT-
 76 
11 allow for release of the active-lactone form into the tumor over a protracted period of 
time, which is ideal for a cell cycle-specific drug (1-4, 11, 12).   
The pharmacokinetic (PK) disposition of carrier-mediated agents, such as, 
nanoparticles, nanosomes, and conjugated agents, is dependent upon the carrier until the drug 
is released from the carrier.  Unlike traditional anticancer agents which are cleared by the 
liver and kidneys, the clearance of non-PEGylated and PEGylated liposomes is via the 
mononuclear phagocytic system, which has also been called the reticuloendothelial system 
(RES) which include monocytes, macrophages and dendritic cells located primarily in the 
liver and spleen (13).  Uptake by the MPS usually results in sequestering of the encapsulated 
drug in the MPS, where it can be degraded.  In addition, the uptake of the liposomes by the 
MPS may result in acute impairment of the MPS and toxicity.  PEGylated liposomes are 
cleared much slower via MPS compared to non-PEGylated liposomes (6).  Once the drug is 
released from the carrier, the PK disposition of the drug will be the same as after 
administration of the non-carrier form of the drug (4, 13). Thus, the PK of liposomes are 
complex. 
The nomenclature used to describe the PK disposition of carrier-mediated drugs 
includes encapsulated or conjugated (drug within or bound to the carrier), released (the active 
drug released from the carrier), and sum total (encapsulated or conjugated drug plus released 
drug).  The ability to evaluate the various forms (encapsulated and released) of the drug after 
administration of nanosome or nanoparticle formulations is dependent upon specific sample 
processing methods (14).  The drug that remains encapsulated within nanosomes or 
nanoparticles, or linked to a conjugate or polymer is an inactive prodrug, thus the drug must 
be released from the carrier to be active.   
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Nanoparticle agents have higher variability in PK (drug clearance, systemic exposure, 
distribution, etc.) disposition with potentially higher variability in pharmacodynamic (PD) 
(antitumor response and toxicity) disposition as compared with traditional small molecule 
chemotherapy.  However, the factors affecting the PK and pharmacodynamic variability of 
encapsulated and released forms of conventional and PEGylated liposomes remain unclear, 
but most likely include the MPS (1). We have evaluated factors affecting the PK and PD of 
liposomal anticancer agents.  We were the first to report a reduced clearance of the liposomal 
encapsulated forms of Doxil and S-CKD602 in patients ≥ 60 years of age (15, 16).  We have 
also reported that patients with a lean body composition may have a reduced tissue 
distribution and an increased plasma exposure of S-CKD602. In addition, we have reported 
an age related decrease in the function of monocytes which may be associated with a reduced 
clearance of liposomes and reduced cytotoxicity to the monocytes (17, 18).   
 The clinical results of the phase I study and limited PK results were previously 
published (19).  IHL-305 was associated with higher interpatient variability in the PK 
disposition of sum total (encapsulated + released) and released CPT-11 (19).  The objectives 
of this study were to evaluate the factors associated with the inter-patient variability in the 
PK and PD of IHL-305 in patients with advanced solid tumors. 
 
 78 
B. PATIENTS AND METHODS 
Patients 
 Written informed consent, approved by the Institutional Review board of the Sarah 
Cannon Research Institute and Vanderbilt University Medical Center, was obtained from all 
patients prior to study entry. All other eligibility criteria were previously reported. 
  
Dosage and Administration 
IHL-305 is a formulation of CPT-11 encapsulated in long-circulating PEGylated 
liposome.  In IHL-305, the PEGylated liposome bilayer is composed of cholesterol and 
hydrogenated soybean phosphatidylcholine (HSPC), and the surface of liposomes is modified 
with PEG. The mean particle diameter is approximately 100 nm and the ratio of CPT-11 to 
lipid is 1:4. The PEGylated liposomal formulation was generated by Terumo Corporation 
(Tokyo, Japan). IHL-305 was supplied by Yakult Honsha Corporation in sterile 10 mL light-
resistant, single-use glass vials as a translucent white to pale yellow liquid with a nominal 
total CPT-11 concentration of 5 mg/mL.  IHL-305 was diluted 25-fold in 5% dextrose or 
normal saline prior to administration.  Prior to administration of the study drug, patients were 
premedicated with ondansetron (or other 5-HT3 inhibitor should circumstances require) and 
dexamethasone, according to each institution’s standard of care.  
IHL-305 was administered IVx1 over 60 minutes every 4 weeks.  Doses 
administrated (expressed in mg of CPT-11) were 3.5, 7, 10.5, 14, 28, 33.5, 37, 50, 67, 80, 88, 
120, 160, and 210 mg/m
2
. This phase I study followed a standard dose escalation design with 
patients enrolled in cohorts of 3, with the possibility of extending the cohort up to 6 patients 
depending on the number of dose-limiting toxicities (DLT) (18). No intra-patient dose 
escalation was permitted. The MTD was defined based on standard criteria. 
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Blood Counts 
ANC and monocyte counts were obtained at least once per week on cycle 1 of the 
IHL-305 study. Additional counts were obtained as clinically required.  The % decrease in 
ANC and monocytes at nadir was calculated using the standard formula [(Pre value – nadir) / 
Pre-value] x 100.   
 
Sample Collection, Processing and Analytical Studies  
 Plasma samples for PK assessment were obtained from all patients.  On cycle 1, 
blood (5 mL) was collected in tubes containing sodium heparin at prior to administration, at 
end of the infusion (approximately 1 h), and at 1.5 h, 2 h, 3 h, 5 h, 9 h, 13 h, and 25 h after 
the start of the infusion for patients treated at < 67 mg/m
2
 and the first three patients treated 
at 67 mg/m
2
. Additional samples at 49 h, 73 h, 97 h, 169 h (day 7), 192 h (day 8), and 216 h 
(day 9) after the start of the infusion were also collected for patients treated at > 67 mg/m
2
 
and the last three patients treated at 67 mg/m
2
.   
 The blood samples were centrifuged at 3,000 x g for 15 min at 4ºC to separate plasma 
samples. Plasma samples were processed to measure sum total (encapsulated + released) 
CPT-11 and released CPT-11, SN-38, SN-38G, APC, and NPC as previously described (20). 
The sum total CPT-11, released CPT-11, SN-38, SN-38G, APC, and NPC concentrations 
were measured by a high-performance liquid chromatography (HPLC) as previously 
described (20). The total (lactone + hydroxy acid) form of camptothecin was measured for 
sum total CPT-11, released CPT-11, SN-38, SN-38G, and APC samples.  The lower limit of 
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quantitation (LLQ) of the total form sum total CPT-11, released CPT-11, SN-38, SN-38G, 
APC, and NPC were 100, 2, 2, 2, 2, and 2 ng/mL, respectively. 
 
Compartmental Pharmacokinetic Analysis  
 Compartmental PK analysis of sum total CPT-11 after administration of IHL-305 was 
performed using WinNonlin (version 5.0.1; Pharsight Corp., Mountain View, Calif.) (21).  
Different PK model structures were considered to characterize the disposition of IHL-305 in 
plasma.  In the model development, one- and two-compartment models with linear and non-
linear (Michaelis-Menten) clearance were evaluated to describe the plasma disposition of 
IHL-305.  The final model structure used for the PK analysis produced identifiable 
parameters in all patients except one patient. 
 PK model parameters for sum total CPT-11 after administration of IHL-305 included 
the volume of the central compartment (Vc) and intercompartment rate constants, (k12, k21) 
(21).  The elimination rate constant from the central compartment (k10) was used to represent 
linear clearance.  For the non-linear clearance, the maximum rate (velocity, Vmax) and a 
Michaelis constant (Km) were estimated using the standard Michaelis Menten Equation 
described below where X1 represents the amount remaining. 
 
XVK
XV
dt
dX
m 11
1max1



 
 Using standard equations, clearance (CL) and elimination half life (t1/2) were 
calculated using parameter estimates from the models. The area under the IHL-305 plasma 
concentration versus time curve from 0 to infinity (AUC0-∞) were calculated using the log 
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trapezoidal method by simulating the concentration versus time data from each patient using 
patient-specific parameters (21).  The AUC was also normalized by dose (AUC/Dose).   
 The evaluation of the goodness of fit and the estimated parameters was based on the 
Akaike information criterion, the precision of the parameter estimates, the random 
distribution of weighted residuals between measured and predicted concentrations with 
respect to time, and the absence of a significant correlation between independent model 
parameters (<0.95) (21). 
 
Evaluation of the Factors  
 The patient’s age, gender, the ratio of total body weight to ideal body weight 
(TBW/IBW), and % decrease in monocytes at nadir were evaluated as potential factors 
associated with the PK variability of IHL-305.  The ratio of total body weight to ideal body 
weight (TBW/IBW) was calculated using standard equations and was used as measure of 
body composition. These same factors were evaluated as a potential factor associated with 
the PD variability of IHL-305.   
 
Statistical Analysis 
 The relationship between TBW/IBW and AUC/Dose was analyzed using multiple 
linear regressions controlling for age.  The relationship between clearance and the % 
decrease in monocytes was analyzed using simple linear regression. The relationship between 
dose normalized sum total CPT-11 AUC and the % decrease in monocytes was analyzed 
using simple linear regression. The relationship between the % decrease in monocytes and 
age was analyzed using multiple linear regressions controlling for dose.  The % decrease in 
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monocytes and ANC at nadir within a patient were compared using the Wilcoxon signed 
ranked test.  The % decrease in monocytes and ANC at nadir in patients < 60 and ≥ 60 years 
of age were compared using the Two Sample T-test.  The influence of gender on PK values 
was assessed using Two Sample T-test and ANCOVA by incorporating body surface area as 
a covariate. The statistical analysis was performed using SAS software (Cary, NC) (22). 
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C. RESULTS 
Patient Characteristics 
 Patient characteristics were described previously (19).  42 patients were enrolled on 
this study from 14 December 2006 to 15 December 2008 at Sarah Cannon Research Institute 
and Vanderbilt University Medical Center.  The numbers of male and female patients 
evaluated in the phase I study were 13 and 26, respectively.  The mean (median, range) age 
of the patients was 59.3 years (60 years, 41 to 75 years).  PK studies of IHL-305 were 
performed in 39 patients.   
 
Linear and Non-Linear Pharmacokinetic Disposition of IHL-305 
 The variability in the PK disposition of sum total CPT-11 was related to linear and 
non-linear (saturable) clearance of IHL-305 in patients.  The occurrence of linear and non-
linear clearance was associated with the dose of IHL-305.  At doses from 3.5 to 50 mg/m
2
, 
the IHL-305 sum total CPT-11 plasma concentration versus time profiles were best described 
using a model with linear clearance in all patients (n = 14).  At doses from 67 to 210 mg/m
2
, 
the IHL-305 sum total CPT-11 plasma concentration versus time profiles were best described 
using a model with linear (n = 16) and non-linear clearance (n = 8). The dose of IHL-305 was 
significantly higher in patients with linear clearance than patients with nonlinear clearance (P 
=0.01). The dose normalized sum total CPT-11 AUC in patients with linear clearance and 
patients with nonlinear clearance are presented in Table 3.1.   
 
Relationship between Age and Body Composition, and the Pharmacokinetic Disposition 
of IHL-305 
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 Based on our previous studies reporting both age and the ratio of total body weight to 
ideal body weight (TBW/IBW) affecting the PK disposition of S-CKD602, we evaluated the 
relationship between these two factors and the PK disposition of IHL-305.  The relationship 
between TBW/IBW and dose normalized CPT-11 AUC (AUC/Dose) in all the patients is 
presented in Figure 3.1.  Controlling for age, there was an inverse relationship between 
TBW/IBW and AUC/Dose (R
2
 = 0.12) where low TBW/IBW was associated with high 
AUC/Dose in patients < 60 years of age.  The effect of age and TBW/IBW together on ratio 
of released CPT-11 AUC to sum total CPT-11 AUC in all the patients was evaluated using 
bubble chart and presented in Figure 3.2.  Patients whose age and TBW/IBW were greater 
than the median of the study had a 1.7- to 2.6- fold higher ratio of released CPT-11 AUC to 
sum total CPT-11 AUC.  
 
Relationship between % Decrease in Monocytes and the Pharmacokinetic Disposition of 
IHL-305 
 Based on our prior studies, the % decrease in monocytes at nadir on cycle 1 was used 
as a measure of monocytes function. The relationship between the % decrease in monocytes 
and dose normalized CPT-11 AUC in patients with linear clearance and nonlinear clearance 
are presented in Figures 3.3a and Figure 3.3b, respectively.  There was a statistically 
significant linear relationship in patients with linear clearance between % decrease in 
monocytes and AUC/Dose (P = 0.008, R
2
 = 0.49), where high % decrease in monocytes was 
associated with low AUC/Dose.  However, the relationship between the % decrease in 
monocytes and dose normalized CPT-11 AUC in patients with nonlinear clearance was not 
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significant (P = 0.37, R
2
 = 0.20) which may be due to the saturation of interaction between 
IHL-305 and monocytes. 
Neutropenia and Monocytopenia Associated with IHL-305  
 To evaluate differential effects of IHL-305 on neutrophils and monocytes we 
evaluated the % decrease of ANC and monocytes at nadir in the blood of patients 
administered IHL-305 on cycle 1.  The mean ± SD day of ANC and monocyte nadir after 
administration of IHL-305 was 18.7 ± 7.4 days and 11.2 ± 6.1 days, respectively (P = 
0.0006).  The parameters describing the neutropenia and monocytopenia administration of 
IHL-305 are summarized in Table 3.2.  After administration of IHL-305 in all patients, the % 
decrease in ANC and monocytes at nadir were 29 ± 20% and 42 ± 24 %, respectively (P = 
0.19).  After administration of IHL-305 in all patients, the ratio of % decrease in monocytes 
to ANC at nadir within a patient was 1.4 ± 1.0.   
 To evaluate age-related effects on the relationship between neutropenia and 
monocytopenia after administration of IHL-305 we evaluated the % decrease of ANC and 
monocytes in the blood of patients < 60 and ≥ 60 years of age.  Categorizing patients as < 60 
or ≥ 60 years of age was based on our previous studies reporting a reduced clearance of 
PEGylated liposomal anticancer agents in patients ≥ 60 years of age compared with patients 
< 60 years of age (27,28).  The mean ± SD age of patients in groups < 60 and ≥ 60 years of 
age were 51.4 ±  4.8 years and 67.3 ± 5.2 years, respectively (P < 0.001).  The parameters 
describing the neutropenia and monocytopenia administration of IHL-305 in patients < 60 
and ≥ 60 years of age are summarized in Table 3.2.  The % decrease in ANC and monocytes 
in patients < 60 years of age were 30 ± 23 % and 45 ± 30 %, respectively (P = 0.46).  The 
ratio of % decrease in monocytes to ANC within a patient < 60 years of age was 1.7 ± 1.4.  
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The % decrease in ANC and monocytes ≥ 60 years of age were 28 ± 19 % and 40 ± 20 %, 
respectively (P = 0.30).  The ratio of % decrease in monocytes to ANC within a patient ≥ 60 
years of age was 1.2 ± 0.7. 
 
Relationship between Age and the Pharmacodynamics of IHL-305 
 The relationship between age and % decrease in monocytes in all patients with dose ≥ 
50 mg/m
2 
is presented in Figure 3.4.  There was a linear relationship between the % decrease 
in monocytes and age in all patients (R
2
 = 0.32), patients with dose ≤ 88 mg/m2 (R2 = 0.49), 
and in patients with dose ≥ 120 mg/m2 (R2 = 0.43) where younger patients have higher % 
decrease in monocytes. Additionally, the % decrease in monocytes is lower in patients with 
dose ≤ 88 mg/m2 compared to patients with dose ≥ 120 mg/m2. 
 
Relationship between Gender and the Pharmacokinetic Disposition of IHL-305 
 The relationship between the gender and clearance in patients with linear clearance is 
presented in Figure 3.5a.  There was a statistically significant (P < 0.05) difference in 
clearance between female and male patients with linear clearance. The clearance of sum total 
CPT-11 was 1.7-fold lower in female patients compared to male patients. The relationship 
between the gender and clearance in patients with linear clearance was evaluated by 
incorporating BSA as a covariate which is presented in Figure 3.5b.  The clearance of sum 
total CPT-11 was 1.6-fold lower in female patients compared to male patients with linear 
clearance.  There was a statistically significant linear relationship (R
2
 = 0.29) between BSA 
and clearance where high BSA was associated with high clearance.     
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D. DISCUSSION 
 Major advances in the use of liposomes, conjugates, and nanoparticles as vehicles to 
deliver drugs have occurred the past 10 years (4, 6, 7).  Doxil
®
 and albumin stabilized 
nanoparticle formulation of paclitaxel (Abraxane
®
) are now FDA approved (8, 9, 23).  In 
addition, there are greater than 100 liposomal and nanoparticle formulations of anticancer 
agents currently in development (4).  This is the first study to identify age, body composition, 
and monocyte counts as factors associated with the PK variability of a PEGylated-liposomal 
CPT-11.  These results are consistant with our prior studies of Doxil
®
 and S-CKD602 (15-
17). 
 The % decrease in monocytes was significantly correlated with clearance of sum total 
CPT-11 where patients with a higher % decrease in monocytes at nadir have an increased 
clearance of sum total CPT-11.  The relationship between changes in monocytes and the PK 
disposition of IHL-305 suggests that the monocytes engulf liposomal anticancer agents via 
their phagocytic function as part of the MPS which causes the release of drug from the 
liposome and cytotoxicity to the monocytes (24).  Additionally, monocytes are more 
sensitive to IHL-305 as compared with neutrophils in our study. This is consistant with our 
previous study that the increased sensitivity is related to the liposomal formulation and not 
the encapsulated drug (25).  The overall difference in monocyte and neutrophil sensitivity to 
IHL-305 is less than reported for S-CKD602. This may be due to CPT-11 being less potent 
than CKD-602 or due to the different liposomal formulations used in each product. 
 The non-linear clearance of IHL-305 was associated with doses of IHL-305 ≥ 67 
mg/m
2
.  The nonlinear clearance of sum total CPT-11 after administration of IHL-305 and 
other nanoparticle agents may be related to the saturation in the clearance capacity of the 
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MPS. Age and body composition are not associated with the PK variability of patients with 
non-linear clearance which is consistent with our prior studies (26). 
   In patients < 60 years of age with a lean body composition have an increased plasma 
exposure of IHL-305.  The relationship between body composition and plasma exposure of 
IHL-305 in patients is consistent with our prior studies of S-CKD602 which showed that 
patients with a lean body composition have a higher plasma exposure of S-CKD602 (17).   
 The influence of gender on the PK of liposomal agents has been reported.  Pardue et 
al. reported that clearance of liposomal ampicillin was higher in female rats compared to 
male rats (27).  In contrast, we found that clearance of total CPT-11 was lower in female 
patients compared to male patients. We also found that the clearance of TLI and S-CKD602 
was lower in female rats compared to male rats (32). These results indicate that gender is an 
influential factor on the PK disposition of liposomal agents. Gender-related differences in 
monocyte function may account for the differences in clearance of liposomal agents.  The 
influence of gender needs to be investigated further. 
 The influence of age on the PD of PEGylated liposomal agents have been reported by 
our group.  There was an inverse relationship between patients age and % decrease in 
monocytes at nadir with younger patients having a higher % decrease in monocytes.  This is 
consistant with our study of S-CKD602 (PEGylated liposomal CKD-602), indicating that an 
age related decrease in the function of monocytes may account for the reduced uptake and 
clearance of PEGylated liposomes and cytotoxicity to the monocytes (25).  
 IHL-305 exhibits all of the pharmacologic, antitumor, and cytotoxic advantages of a 
long acting, liposomal anticancer agent (4, 28-30).  The high inter-patient variability in the 
PK and PD of sum total IHL-305 was associated with age, body composition, gender, 
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saturable clearance and monocyte function. Our data also suggests that IHL-305 undergoes 
non-linear or saturable clearance at higher doses (28).  The clinical significance of these 
differences and the factors associated with them need to be evaluated for IHL-305 and other 
liposomal and nanoparticle anticancer agents.  Ultimately, the best predictor of the PK and 
PD variability of IHL-305 and other liposomal and nanoparticle agents may be a phenotypic 
probe that measures the clearance capacity of liposomes in individual patients (31).  This 
phenotypic probe can then be used to individualize the dosages of liposomal and nanoparticle 
agents for each patient to achieve a target exposure and thus reduce the PD variability of 
these agents (31). 
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Table 3.1. 
 
Compartmental Pharmacokinetic Parameters of Sum Total CPT-11 after IHL-305 in Patients 
with Linear and Non-Linear Disposition 
 
a
 t½ is the terminal half life 
b 
Estimates are from 2 patients. 
 
   
Linear  
Pharmacokinetic  
Disposition 
 
 
Non-Linear 
Pharmacokinetic  
Disposition 
 
 
Parameters 
 
 
 
 
Units 
 
Age < 60
 
Mean  SD 
(Range) 
n = 15 
 
Age  60 
Mean  SD 
(Range) 
n = 15 
 
All Ages 
Mean ± SD 
(Range) 
n = 8 
 
k10 
  
(h
-1
) 
 
0.031  0.0098 
(0.016 – 0.046) 
 
0.034  0.0077 
(0.019 – 0.047) 
 
 
--- 
t½ 
a
  
 
(h) 24.9 ± 8.1 
(15.0 – 43.7) 
21.3 ± 5.6 
(14.8 – 35.8) 
11.6 ± 3.8 
(7.8 – 17.0) 
 
 Vc1 (L/m
2
) 1.6  0.45 
(0.90 – 2.70) 
1.6  0.55 
(1.14 – 2.86) 
 
1.6  0.36 
(1.08 – 2.12) 
CL (L/h/m
2
) 0.048  0.024 
(0.021 – 0.12) 
0.055  0.027 
(0.023 – 0.12) 
 
 
--- 
k12
 
(h
-1
) --- --- 0.15  0.070 b 
(0.10 – 0.20) 
k21 (h
-1
) --- --- 0.095  0.040 b   
(0.066 – 0.12) 
Km (ng/mL) --- --- 32.8  31.3 
(0.93 – 92.7) 
Vmax (ng/h) --- --- 4.54  3.39 
(1.72 – 11.3) 
Sum Total 
AUC/Dose
e 
(μg/mLh)
/(mg/m
2
) 
12.9  4.9 c,d 
(8.19 – 27.5) 
14.5  4.6  c,d 
(8.29 – 25.1) 
14.8  5.3  d 
(7.79 – 23.6) 
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c 
The sum total CPT-11 AUC normalized by dose in patients with linear disposition was not 
significantly different between patients ≥ 60 years of age and patients < 60 years of age (P > 
0.05). 
 
d 
The sum total CPT-11 AUC normalized by dose was not significantly different between 
patients with non-linear disposition and patients with linear disposition that were ≥ 60 and < 
60 years of age (P > 0.05).   
   
e
 Sum total AUC was calculated from 0 to the last sampling time point. 
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Table 3.2.  
Summary of ANC and Monocytes Parameters  
After Administration of IHL-305 
 
   
IHL-305 
 
  
Units 
 
Monocytes 
 
Mean  SD 
(Range) 
 
ANC 
 
Mean  SD 
(Range) 
Ratio 
Monocytes 
to 
ANC 
Mean  SD 
(Range) 
All Patients     
% Decrease % a 42.0  23.9 
(0.0 – 80.1) 
a 
28.8  20.3 
(0.0 – 84.8) 
1.40  0.98 
(0.067 – 4.28) 
     
Patients < 60 yo     
% Decrease % b, d 44.7  29.9 
(0.0 – 80.1) 
b, e 
29.6  22.6 
(0.0 – 84.8) 
1.65  1.36 
(0.22 – 4.28) 
     
Patients ≥ 60 yo     
% Decrease % c, d 40.2  20.3 
(4.35 – 71.6) 
c, e 
28.1  18.9 
(0.0 – 65.3) 
1.24  0.68 
(0.067 – 2.35) 
a 
P > 0.05     
b 
P > 0.05   
c 
P > 0.05   
d 
P > 0.05     
e 
P > 0.05 
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Figure 3.1. Relationship between the ratio of total body weight to ideal body weight 
(TBW/IBW) and dose normalized IHL-305 sum total AUC (AUC/Dose). AUC/Dose in 
patients < 60 and  60 years of age are represented by the solid triangles and the open 
triangles, respectively.  The best-fit line of the data is represented by the curved solid line (R
2
 
= 0.12). After controlling for age, there was an inverse relationship between TBW/IBW and 
AUC/Dose, with a low TBW/IBW being associated with high AUC/Dose in paitents < 60 
years of age. 
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Figure 3.2. Relationship between two factors, age and the ratio of total body weight to ideal 
body weight (TBW/IBW), and ratio of released CPT-11 AUC to sum total CPT-11 AUC. 
Patients are divided into four groups according to the median value of age and TBW/IBW.  
In Figure 3.2, mean value ± SD of ratio of released CPT-11 AUC to sum total CPT-11 AUC 
were 0.0042 ± 0.0028, 0.0038 ± 0.0038, 0.0066 ± 0.0084, and 0.0025 ± 0.0013 in patients < 
60 years of age and TBW/IBW < 1.16, patients ≥ 60 years of age and TBW/IBW < 1.16, 
patients ≥ 60 years of age and TBW/IBW ≥ 1.16, and patients < 60 years of age and 
TBW/IBW ≥ 1.16, respectively.   
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Figures 3.3. Relationship between % decrease in monocytes and dose normalized CPT-11 
AUC (AUC/Dose).  Figures 3.3a and 3.3b represent the relationship between % decrease in 
monocytes and AUC/Dose in patients with linear clearance and nonlinear clearance, 
respectively.  The relationship between AUC/Dose and % decrease in monocytes was best 
described by a linear relationship in patients with linear clearance (P = 0.008, R
2
 = 0.49).   
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Figure 3.4. The relationship between % decrease in monocytes and age in all patients with 
dose ≥ 50 mg/m2.  For patients with dose ≥ 50 mg/m2 and ≤ 88 mg/m2, individual values are 
represented by the solid circles.  For patients with dose ≥ 120 mg/m2, individual values are 
represented by the open triangles.  There was a linear relationship between the % decrease in 
monocytes and age in all patients (R
2
 = 0.32), patients with dose ≤ 88 mg/m2 (R2 = 0.49), and 
in patients with dose ≥ 120 mg/m2 (R2 = 0.43).  
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Figure 3.5. The clearance of total IHL-305 and dose normalized sum total CPT-11 AUC 
(AUC/Dose) in male and female patients.  The clearance of total IHL-305 for male and 
female patients with linear clearance is presented in Figure 3.5a.  The clearance values of 
individual patients are represented by the open triangles.  The mean and geometric mean of 
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for each group is represented by the open circles and the solid triangles, respectively.  Mean 
value ± SD clearance of total IHL-305 for male and female patients were 0.134 ± 0.063 and 
0.0783 ± 0.030 (L/h), respectively (P = 0.02). The effect of gender on clearance of total IHL-
305 with body surface area (BSA) as a covariate is presented in Figures 3.5b.  The clearance 
of individual female and male patients is represented by the open triangles and solid 
triangles, respectively.  Regression lines for data from female patients and male patients are 
represented by dashed line and solid line, respectively.  There is a significant difference in 
clearance of total IHL-305 (P = 0.02) between male and female patients with linear clearance 
after adjust the effects of BSA. 
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CHAPTER 4 
 
 
POPULATION PHARMACOKINETICS OF PEGYLATED 
LIPOSOMAL CKD-602 (S-CKD602) IN PATIENTS WITH 
ADVANCED MALIGNANCIES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter has been published by the Journal of Clinical Pharmacology and is presented in 
the style of that journal.
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A. INTRODUCTION 
S-CKD602 is a STEALTH
®
 liposomal formulation of CKD-602, a camptothecin 
analogue which inhibits topoisomerase I. 
1-3
  The STEALTH liposomal formulation consists 
of phospholipids covalently bound to methoxypolyethylene glycol (mPEG) on the outside of 
the lipid bilayer.  Non-liposomal CKD-602 administered IV at 0.5 mg/m
2
/day for 5 
consecutive days repeated every 21 days is approved in Korea for the treatment of newly 
diagnosed small cell lung cancer and relapsed ovarian cancer. 
4-7
   
The development of STEALTH liposomes was based on the discovery that 
incorporation of mPEG-lipids into liposomes yields preparations with prolonged plasma 
exposure and superior tumor delivery compared to conventional liposomes composed of 
natural phospholipids.
3, 8, 9
  STEALTH liposomal doxorubicin (Doxil®) is approved for the 
treatment of refractory ovarian cancer, Kaposi sarcoma, and multiple myeloma.
10, 11
  The 
generation of a liposomal formulation of a camptothecin analogue, such as CKD-602, has 
specific advantages such as protecting the lactone form and providing prolonged exposure in 
tumors which is associated with greater antitumor effect of camptothecines.
3, 12-16
 The 
STEALTH® liposomal formulation is expected to have an enhanced therapeutic ratio 
compared to free CKD-602 (non-liposomal), as well as a more convenient schedule of 
administration. 
In mice, the plasma exposure of S-CKD602 at 1 mg/kg i.v. × 1 was ~25-fold greater 
than the plasma exposure of nonliposomal CKD-602 at 30 mg/kg i.v. × 1.
6, 17
 In the plasma 
of mice, ~82% of CKD-602 was encapsulated inside the liposome after administration of S-
CKD602.
17
 The duration of exposure of CKD-602 in the tumor was threefold longer with S-
CKD602 than with nonliposomal CKD-602 in mice bearing human tumor xenografts.
17
 The 
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improved pharmacokinetics of S-CKD602 resulted in greater therapeutic index compared to 
free CKD-602. In human tumor xenograft models, the therapeutic index (TI) of S-CKD602 
was estimated to be approximately 6-fold greater than that of free CKD-602 in ES-2 ovarian 
and approximately 3-fold greater in H82 SCLC tumors.
6
 These results are consistent with the 
antitumor response to camptothecin analogs, which is related to the duration of time for 
which the drug concentration is above a critical threshold.
6, 15-18
 
The pharmacokinetic disposition of carrier-mediated agents, such as, nanoparticles, 
nanosomes, and conjugated agents, is dependent upon the carrier until the drug is released 
from the carrier.  Unlike traditional anticancer agents which are cleared by the liver and 
kidneys, the clearance of non-PEGylated and PEGylated liposomes is via the mononuclear 
phagocytic system, which has also been called the reticuloendothelial system (RES) which 
include monocytes, macrophages and dendritic cells located primarily in the liver and 
spleen.
19
  Uptake by the MPS usually results in sequestering of the encapsulated drug in the 
MPS, where it can be degraded.  In addition, the uptake of the liposomes by the MPS may 
result in acute impairment of the MPS and toxicity.  PEGylated liposomes are cleared much 
slower via MPS compared to non-PEGylated liposomes.
8, 20
  Once the drug is released from 
the carrier, the pharmacokinetic disposition of the drug will be the same as after 
administration of the non-carrier form of the drug.
19, 21
 Thus, the pharmacokinetics of 
liposomes are complex. 
Nanoparticle agents have higher variability in pharmacokinetic (drug clearance, 
systemic exposure, distribution, etc.) disposition with potentially higher variability in 
pharmacodynamic (antitumor response and toxicity) disposition as compared with traditional 
small molecule chemotherapy.  However, the factors affecting the pharmacokinetic and 
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pharmacodynamic variability of encapsulated and released forms of conventional and 
PEGylated liposomes remain unclear, but most likely include the MPS.
12
 We have evaluated 
factors affecting the pharmacokinetics and pharmacodynamics of liposomal anticancer 
agents.  We were the first to report a reduced clearance of the liposomal encapsulated forms 
of Doxil and S-CKD602 in patients ≥ 60 years of age.22, 23  We have also reported that 
patients with a lean body composition may have a reduced tissue distribution and an 
increased plasma exposure of S-CKD602. In addition, we have reported an age related 
decrease in the function of monocytes which may be associated with a reduced clearance of 
liposomes and reduced cytotoxicity to the monocytes.
20, 24, 25
 
 S-CKD602 was associated with high interpatient variability in the pharmacokinetic 
disposition of encapsulated and released CKD-602.
26
  Population pharmacokinetic analysis is 
a useful tool for identification of sources of pharmacokinetic variability and can aid in the 
design of alternative dosing regimens to enhance efficacy and safety.  The objectives of this 
study was to describe the population pharmacokinetics of both encapsulated CKD-602 and 
released CKD-602 after administration of the PEGylated liposomal form of the drug and to 
characterize clinical covariates that influence S-CKD602 pharmacokinetics.  
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B. METHODS 
Patients 
 Patients ≥ 18 years of age with a histologically or cytologically confirmed 
malignancy for which no effective therapy was available were eligible for this study.  
Pertinent  eligibility criteria included a Eastern Cooperative Oncology Group (ECOG) 
performance status of 0 to 2, adequate bone marrow, hepatic, and renal function as evidenced 
by the following: absolute neutrophil count (ANC)  1500/L, platelets  100,000/L, total 
bilirubin  1.5 x upper limit of the institutional normal range (ULN), aspartate 
aminotransferase (AST)  1.5 x the ULN if liver metastases were not present and  4 x the 
ULN if liver metastases were present, and absence of microscopic hematuria (18).  Prior 
treatment with camptothecin analogues other than S-CKD602 or non-liposomal CKD-602 
was permitted.  Written informed consent, approved by the Institutional Review board of the 
University of Pittsburgh Medical Center, was obtained from all patients prior to study entry. 
 
Study Design 
This was a phase I, dose escalation study in patients with advanced solid tumors.
26, 27
  
The study design and clinical results have been reported elsewhere.
26, 27
 This phase I study 
followed a standard dose escalation design with patients enrolled in cohorts of 3 initially, 
with the possibility of extending the cohort up to 6 patients depending on the number of 
dose-limiting toxicities (DLT) (18). No intra-patient dose escalation was permitted. The 
MTD was defined as the dose below the dose at which two out of up to six patients 
experienced a DLT. At the 2.5 mg/m
2
 dose level, two out of three patients experienced a 
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DLT. Because the next lower dose (1.7 mg/m
2
) dose level was associated with minimal 
toxicity, an additional intermediate dose level of 2.1 mg/m
2
 was investigated. 
 
Dosage and Administration 
S-CKD602 is a formulation of CKD-602 encapsulated in long-circulating 
STEALTH

 liposomes.  In S-CKD602, the STEALTH
®
 liposome bilayer is composed of N-
(carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-
phosphoethanolamine (MPEG-DSPE) and 1,2-distearoyl-sn-glycero-phosphocholine (DSPC) 
in a molar ratio of approximately 5:95. The mean particle diameter is approximately 100 nm, 
and CKD-602 encapsulation inside the liposomes exceeds 85%.  S-CKD602 was supplied by 
ALZA Corporation in sterile 10 mL single-use amber vials as a clear to slightly opalescent 
suspension with a nominal total CKD-602 concentration of 0.1 mg/mL.  S-CKD602 was 
diluted 3-fold in 5% dextrose prior to administration.  No pre-medications were administered 
prior to S-CKD602. 
S-CKD602 was administered IV over approximately 1 hour every 3 weeks.  Doses 
administrated, expressed in mg of CKD-602 per m
2
, were 0.10, 0.15, 0.20, 0.25, 0.30, 0.35, 
0.40, 0.45, 0.50, 0.65, 0.85, 1.1, 1.7, 2.1, and 2.5 mg/m
2
. 
 
Sample Collection, Processing, and Analytical Studies 
Plasma samples for pharmacokinetic assessment were obtained from all patients.  On 
cycle 1, blood (7 mL) was collected in EDTA (purple top) tubes prior to administration, at 
end of the infusion (approximately 1 h), and at 3 h , 5 h , 7 h , 24 h , 48 h , 72 h, 96 h, 168 h 
(day 8), and 336 h (day 15) after the start of the infusion.  The blood samples were 
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centrifuged at 1,380 x g for 6 min.  The plasma for the determination of the encapsulated and 
released CKD-602 was immediately placed in regrigerator at 4°C and kept refrigerated until 
separatation by solid-phase separation (SPS).
17, 27
  The encapsulated CKD-602 and released 
CKD-602 was fully eluted and separated by SPS as previously described.
17, 27
 The 
encapsulated and released CKD-602 concentrations were then measured by a specific liquid 
chromatographic tandem mass spectrometric assay (LC-MS/MS) as previously described.
17, 
27
 The total (lactone + hydroxy acid) form of CKD-602 was measured for encapsulated and 
released samples.  The lower limit of quantitation (LLQ) of the total form encapsulated and 
released CKD-602 were 2 and 0.05 ng/mL, respectively.
17, 27
   
 
Population Pharmacokinetic Analysis  
 Encapsulated CKD-602 and released CKD-602 concentration-time data were 
analyzed using the nonlinear mixed effects modeling approach as implemented in NONMEM 
(version 6; University of California, San Francisco, CA).  Both the first order approximation 
method and first order conditional estimation (FOCE) method were used in analyses.  S-
PLUS 8.0 (Version 8.0, Insightful Corporation, Seattle, Washington) was used for graphical 
diagnostics and covariate screen. The population pharmacokinetic model of S-CKD602 was 
developed in two steps: (a) basic (structural) model development and (b) covariate model 
development. 
 Mean population pharmacokinetic variables, interindividual variability, and residual 
error were assessed in the model development. Interindividual variability for each 
pharmacokinetic variable was modeled with an exponential function. Residual error models 
of the additive, proportional, exponential, and combination methods were evaluated for the 
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best structural pharmacokinetic model. Individual pharmacokinetic variables were obtained 
by posterior Bayesian estimation.  
 Model selection for nonhierarchical models (i.e., linear and nonlinear elimination 
models) was guided by goodness-of-fit plots (e.g., observed versus predicted plasma 
concentrations, weighted residuals versus predicted concentrations, and weighted residuals 
versus time), Akaike information criterion (AIC), and precision of parameter estimates. AIC 
was calculated as AIC = OFV + 2 x p, where OFV is the NONMEM objective function value 
and p is the number of pharmacokinetic variables. The model was chosen on the basis of 
smaller values of AIC, better precision of estimates, and superior goodness-of-fit plots. 
 
Model Development 
The structural model of encapsulated CKD-602 and released CKD-602 was built 
sequentially. Firstly, the best model for encapsulated CKD-602 was selected from all the 
possible models. Then based on the best model for encapsulated CKD-602, simultaneous 
modeling of the encapsulated and the released CKD-602 were attempted for data from all 
patients. In this modeling process, one-compartment model, two-compartment model and 
three-compartment model with first-order elimination were tested to fit released plasma 
concentration data.  However, the estimation of pharmacokinetic parameters for released 
drug proved to be unsatisfactory because no successful minimization with successful 
covariance step could be achieved.  Therefore, the mean value of pharmacokinetic 
parameters associated with distribution and elimination of released CKD-602 were 
determined from a CKD-602 pharmacokinetic model after administration of non-liposomal 
CKD-602 and fixed in the final population pharmacokinetic model of encapsulated and 
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released CKD-602.  The inter-individual variability of pharmacokinetic parameters 
associated with distribution and elimination of released CKD-602 were not fixed and allowed 
to be estimated in the final population pharmacokinetic model of encapsulated and released 
CKD-602. The ability to fix the mean value of pharmacokinetic parameters of the released 
drug using the estimated mean value of pharmacokinetic parameters from non-liposomal 
drugs is based on our studies reporting the pharmacokinetic disposition of released drug is 
the same as non-liposomal drugs.
28
   
 
Encapsulated Drug Model  
 The structural model was built to fit encapsulated CKD-602 plasma concentration-
time profiles from all 45 patients. One-compartment model and two-compartment model with 
first-order elimination or nonlinear elimination characterized by Michaelis-Menten kinetics 
described as below were tested to fit encapsulated plasma concentration data. 
The pharmacokinetic model used to characterize the disposition of encapsulated 
CKD-602 in all patients is shown in Figure 4.1A. The differential equation describing the 
pharmacokinetic model of encapsulated CKD-602 is as follows: 
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dAEncap/dt  is the elimination rate, Vmax is the maximum elimination rate or maximum 
velocity, Km is the concentration at which half-maximum elimination rate is achieved, VEncap 
is the volume of distribution, AEncap is the encapsulated CKD-602 amount in plasma, CEncap is 
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the plasma concentration of encapsulated CKD-602, k0 is the infusion rate and k0 is 0 after 
stop of infusion. 
 
CKD-602 Model after Administration of Non-liposomal CKD-602 
 CKD-602 pharmacokinetic data were from a phase I and pharmacokinetic study of 
CKD-602 in patients with advanced solid malignancies.
5
  The study design and clinical 
results have been reported elsewhere.
5
 Sixteen patients received CKD-602 (0.5 to 0.9 
mg/m
2
/day) IV x 1 over thirty-minute daily for 5 consecutive days.  Frequent plasma 
sampling was performed prior to administration and at 0.25 h , 0.5 h , 1 h , 1.5 h, 2 h, 3 h, 4 h 
, 6 h , 8 h, 12 h and 24 h after the start of the infusion for all the patients. The structural 
model was built to fit CKD-602 plasma concentration versus time profiles from all 16 
patients. Two-compartment and three-compartment models with first-order elimination were 
tested to fit CKD-602 pharmacokinetic profiles. 
 
Encapsulated and Released Drug Model 
 Based on the best model for encapsulated CKD-602 and the best model for CKD-602 
after administration of nonliposomal CKD-602, one-compartment model with Michaelis-
Menten kinetics for encapsulated drug and two-compartment model with first-order 
elimination for released drug was used to fit combined data of encapsulated and released 
CKD-602 after administration of S-CKD602. In this model developing, in addition to fixing 
mean value of pharmacokinetic parameters [volume of distribution for central compartment 
(VRel1), volume of distribution for peripheral compartment (VRel2), systemic clearance (CLRel) 
and distribution clearance (CLRel-d)] of released drug, patients were further subdivided as 
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linear and nonlinear patients according to the clearance of encapsulated drug from our 
previous pharmacokinetic analysis.
26
  As most of the CKD-602 remains encapsulated in the 
plasma after administration of S-CKD602 and the plasma concentration of released CKD-
602 is only 1% of encapsulated CKD-602, the amount or concentration of CKD-602 existing 
in the non-encapsulated form in the dosage (infusion bag) is important in order to capture the 
relative high concentration of released CKD-602 at earlier time points.  Thus, estimates of 
the non-encapsulated CKD-602 in the formulation were included in models for encapsulated 
and released CKD-602 after administration of S-CKD602.   
The pharmacokinetic model used to characterize the disposition of encapsulated and 
released CKD-602 in patients with linear clearance of encapsulated CKD-602 is shown in 
Figure 4.1B. The differential equations describing the pharmacokinetic model of 
encapsulated and released CKD-602 are as follows: 
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The CLEncap is the clearance of encapsulated CKD-602, CLEncap-Rel is the clearance of release 
CKD-602 from S-CKD602, and E% is the encapsulation percent of CKD602 in the 
formulation. ARel1 is the released CKD-602 amount in central compartment,  ARel2 is the 
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released CKD-602 amount in peripheral compartment and CRel is the plasma concentration of 
released CKD-602. 
The pharmacokinetic model used to characterize the disposition of encapsulated and 
released CKD-602 in patients with nonlinear clearance of encapsulated CKD-602 is shown in 
Figure 4.1C. The differential equations describing the pharmacokinetic model of 
encapsulated and released CKD-602 are as follows: 
0  (0)A ,  _ %
Encap
Remax,max,
0





 
EncapEncapm
EncaplEncap
EncapEncapm
EncapEncapEncap
AVK
AV
 
AVK
AV
Ek
dt
dA
  
0 (0) A  ,                 
%)1(
Rel1
 
1Re
1Re
Re
1Re
1Re
Re
2Re
2Re
Re1Re Remax,
0







l
l
dl
l
l
l
l
l
dll
A
V
CL
A
V
CL
A
V
CL
AVK
AV
Ek
dt
dA
EncapEncapm
EncaplEncap
 
0 (0) A  ,
Rel2
 
1Re
1Re
Re
2Re
2Re
Re2Re  
l
l
dl
l
l
dll A
V
CL
A
V
CL
dt
dA
 
1Re
1Re
Re
l
l
V
A
C
l

 
The Vmax, Encap is the maximum velocity of encapsulated CKD-602, Vmax, Encap-Rel is the 
maximum velocity of release CKD-602 from S-CKD602, and Km is the concentration at 
which half-maximum elimination rate is achieved. 
 
Covariate Analysis 
 The covariate model building was a stepwise process. A screen for potential 
significant covariates was done using S-PLUS 8.0 (Version 8.0, Insightful Corporation, 
Seattle, Washington).  The potential covariates as listed in Table 4.1 were tested for 
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influence on the structural pharmacokinetic variables that describe the pharmacokinetics of 
encapsulated and released CKD-602. The potential significant covariates selected from 
screen were introduced into the covariate model as linear, exponential, or power function, 
and assessed in the population pharmacokinetic models. A significant covariate was selected 
to be retained in the final model if addition of the covariate resulted in a decrease in OFV 
>3.875 (P < 0.05) during the forward full covariate model building, and removal of the 
covariate resulted in an increase in OFV >10.828 (P < 0.001) during the stepwise backward 
model reduction. In addition, the increase in precision of the variable estimate (% relative SE 
of prediction) and reduction in interindividual variability were used as another indicator of 
the improvement of the goodness of fit.  
 
Model Evaluation 
 Bootstrap analyses were performed to evaluate the stability of the final models and 
estimate the confidence interval (CI) of the parameters using the bootstrap option in the 
software package Perl-speaks-NONMEM (M. Karlsson and A. Hooker, Version 3.1.0, Dec 
2009). One thousand replicate bootstrap data sets were obtained by resampling with the 
replacement from the original data set and fitted with the same model to obtain parameter 
estimates for each replicate. The median and 2.5th and 97.5th values for the population 
parameters were obtained.  
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C. RESULTS 
Patient demographics 
 Forty-five patients were enrolled on this study from September 29, 2003 to October 
17, 2005 at University of Pittsburgh Cancer Institute.  Pharmacokinetic studies of 
encapsulated and released CKD-602 were performed in all 45 patients.  Patient 
characteristics are listed in Table 4.1.  The numbers of male and female patients evaluated in 
the phase I study were 21 and 24, respectively.  The mean (median, range) age of the patients 
was 60.6 years (62 years, 33 to 79 years).  Twenty-six patients had tumor in liver and 
nineteen patients did not have tumor in liver. A total of 292 plasma concentrations of 
encapsulated CKD-602 and 268 plasma concentrations of released CKD-602 were used to 
develop the population pharmacokinetic model.  
 
Population Pharmacokinetic Model of S-CKD602 
Encapsulated Drug Model  
 Both linear and nonlinear pharmacokinetic models were evaluated for encapsulated 
CKD-602. A one-compartment model with Michaelis-Menten kinetics (AIC = 2246) better 
described the data than either nonlinear plus linear (AIC = 2257) or linear kinetics (AIC = 
2313). The distribution of residual variability was best described by a proportional plus 
additive error model.  During the covariate screen, tumor in liver was identified as a 
significant covariate for maximum velocity of encapsulated CKD-602.  The pharmacokinetic 
parameter estimates obtained from the final covariate model and the 95% CI from bootstrap 
analysis are provided in Table 4.2.  The observed bootstrap medians were consistent with the 
population mean estimates in general.  In the final model, the mean (interindividual 
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variability, CV%) values for the distribution volume is 3.46 L (70.9%) and is very close to 
plasma volume in humans. The mean Michaelis-Menten constant (Km) were estimated to be 
992 μg/L. The inclusion of tumor in liver as a covariate in the final model decreased the 
inter-individual variability (IIV) of the maximum velocity (Vmax) of encapsulated CKD-602 
by 29%.  Vmax in patients with tumor in liver and patients without tumor in liver were 
estimated to be 150 (IIV 205%) and 97.4 (IIV 205%) μg/h, respectively (P < 0.001).  Vmax 
showed the most inter-individual variability, with IIV for Vmax was estimated to be 205% 
even after the incorporation of tumor in liver as a covariate. 
 Selected individual pharmacokinetic time profiles of encapsulated CKD-602 in 
patients with and without tumors in their livers are shown in Figure 4.2.  The final 
pharmacokinetic model well characterized the nonlinear pharmacokinetic of encapsulated 
CKD-602.  Goodness-of-fit plots from the final pharmacokinetic model are given in Figure 
4.3.  The plots indicated a reasonable fit of the model to the data.  
 
CKD-602 Model after Administration of Non-liposomal CKD-602 
Two-compartment and three-compartment models with first-order elimination were tested to 
fit CKD-602 pharmacokinetic profiles. A two-compartment model with first-order 
elimination resulted in a similar model fit but better precision of parameter estimates 
compared to a three-compartment model with first-order elimination. The distribution of 
residual variability was best described by a proportional error model.  No significant 
covariates were found. The pharmacokinetic parameter estimates from the final model are 
provided in Table 4.3.  The population mean (IIV, CV%)  values of volume of central 
compartment (Vc), elimination clearance (CL), volume of peripheral compartment (Vp), and 
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distribution clearance (CLd) for non-liposomal CKD-602 were 9.72 L, 7.9 L/ h (IIV 27%) , 
27.7 L (IIV 21.8%), and 5.07 L/h. Goodness-of-fit plots from the final pharmacokinetic 
model are given in Figure 4.4.  The plots indicated a reasonable fit of the model to the data.  
 
Encapsulated and Released Drug Model 
 Combined data of the encapsulated and released CKD-602 were modeled separately 
for patients with linear clearance and nonlinear clearance of encapsulated CKD-602.  
Pharmacokinetic parameters [volume of central compartment (VRel1), volume of peripheral 
compartment (VRel2), systemic clearance (CLRel), and distribution clearance (CLRel-d) ] of 
released CKD-602 were determined from CKD-602 pharmacokinetic model after 
administration of non-liposomal CKD-602 and fixed in the final population pharmacokinetic 
model of encapsulated and released CKD-602.  Results of the final covariate model for 
patients with linear clearance of encapsulated CKD-602 are summarized in Table 4.4.  VEncap 
and CLEncap of encapsulated CKD-602 for patients with linear clearance of encapsulated 
CKD-602 were estimated to be 4.69 L (IIV 53%) and 0.089 L/h (IIV 151%), respectively.  
The population mean of encapsulation of CKD-602 in the formulation was estimated to be 
96%. The inclusion of age decreased IIV in the release of CKD-602 from S-CKD602 by 
33%.  The population mean of release rate of CKD-602 from S-CKD602 in patients < 60 
years old (yo) and patients ≥ 60 yo were 0.130 and 0.048 L/h, respectively (P < 0.001).   
 The results of final model for patients with nonlinear clearance of encapsulated CKD-
602 are summarized in Table 4.5. No covariates were identified for these patients.  VEncap, 
Vmax, Encap and Km of encapsulated CKD-602 were estimated to be 3.36 L (IIV 12.6%), 36.1 
μg/h (IIV 28.8%) and 1450 μg/L, respectively.  The ratio of Vmax, Encap-Rel to Km for the 
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release of CKD-602 from S-CKD602 was 0.063 L/h.  The population mean of encapsulation 
of CKD-602 in the formulation was estimated to be 96%. 
 Selected individual pharmacokinetic time profiles of encapsulated and released CKD-
602 in patients with linear clearance and nonlinear clearance of encapsulated CKD-602 are 
shown in Figure 4.5a and Figure 4.5b, respectively.  In general, the observed data of 
encapsulated and released CKD-602 were well described by the final model.  Goodness-of-fit 
plots from the final pharmacokinetic model in patients with linear clearance and nonlinear 
clearance of encapsulated CKD-602 are given in Figure 4.6a and Figure 4.6b, respectively.  
The model adequately describes the pharmacokinetic profile of encapsulated CKD-602 in 
both groups of patients.  Although the pharmacokinetic data of released CKD-602 were 
variable, the observed and model predicted data agreed relatively well.  Bootstrap CIs for 
pharmacokinetic parameters were not obtained because of the computational intensity of the 
parameter estimation. 
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D. DISCUSSION 
 Major advances in the use of liposomes, conjugates, and nanoparticles as vehicles to 
deliver drugs have occurred the past 10 years.
3, 8, 9
  Doxil
®
 and albumin stabilized 
nanoparticle formulation of paclitaxel (Abraxane
®
) are now FDA approved.
10, 11, 29
  In 
addition, there are greater than 200 liposomal and nanoparticle formulations of anticancer 
agents currently in development.
3
  This is the first study where population pharmacokinetic 
modeling was applied to assess the pharmacokinetics of the encapsulated and released drug 
after administration of a pegylated liposomal formulation of a camptothecin analogue.
30, 31
  
This is also the first study identify tumor in liver as a factor associated with the 
pharmacokinetic variability of liposomal agents.  Evaluation of the pharmacokinetic 
disposition of the liposomal encapsulated verses released drug is of the utmost importance 
because the liposomal encapsulated drug is an inactive prodrug and thus only the released 
drug is active.
3, 17
   
 Pegylated-liposomal CKD-602 displayed nonlinear pharmacokinetics best described 
by a one-compartment structural model.  The volume of distribution for encapsulated CKD-
602 was 3.46 L (70.9%) and is very close to plasma volume in humans.  The limited volume 
of distribution of encapsulated-CKD602 is consistent with other liposomal anticancer agents 
since the size of liposome limited their distribution to the normal tissue.
32
  Saturation of 
clearance has been reported for both Doxil® and S-CKD602 and the nonlinear 
pharmacokinetics of these two drugs have been modeled using Michaelis-Menten kinetics.
26, 
33-35
   
 The interpatient variability in the disposition of S-CKD602 can be explained in part 
by the presence of primary or metastatic tumor(s) located in the liver.  Vmax in patients with 
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tumor(s) in the liver is 1.5-fold higher compared with patients without tumor(s) in the liver. 
This data suggest that patients with tumor in liver may have 35% lower plasma exposure and 
are at risk of having a lower response potential.  Most studies show a decrease in clearance of 
small molecule drugs in patients with tumors in the liver.
36-38
  This is the first study reporting 
an increased clearance of drug in patients with tumor involvement in the liver.  The exact 
mechanism of this phenomenon is unknown.  Recruitment of various populations of 
phagocytic cells (monocytes, macrophages and dendritic cells) of the MPS is involved in the 
immune response against tumor cell deposits in liver.
39, 40
  Since liposomes are mainly 
cleared by MPS and liver is an important functional center of MPS, the increased clearance 
of encapsulated CKD-602 may due to enhanced MPS activity in patients with tumor in liver. 
 In patients with linear clearance of encapsulated CKD-602, patients  ≥ 60 years of age 
have a reduced release rate of CKD-602 from S-CKD602 compared with patients < 60 years.  
This is consistent with our prior studies which showed that a reduced clearance of the 
liposomal encapsulated form of S-CKD-602 in patients ≥ 60 years of age and that the release 
of drug from liposome is related to clearance of liposome.
22, 23
  Aging related decrease in the 
function of monocytes may account for the reduced clearance of liposomal agents.
24, 25
 
Tumor in liver is not significantly associated with the pharmacokinetic variability of patients 
with linear clearance of encapsulated CKD-602.  This may due to the lower number of 
patients in the group of patients with linear clearance of encapsulated CKD-602 (n = 20) 
compared to the patients included in the encapsulated CKD-602 pharmacokinetic analysis (n 
= 39).   Age is not associated with the pharmacokinetic variability of patients with nonlinear 
clearance of encapsulated CKD-602.  The results in patients with non-linear clearance may 
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be associated with the overall low number of patients in this group and the number of 
patients with complete concentration versus time profiles.   
The developed model did not take into account the lactone and carboxylate forms of 
CKD-602 since only total (lactone + hydroxy acid) drug concentrations were available on our 
study. Only the lactone form of CKD-602 has antitumor activity, and they undergo a pH-
dependent equilibrium with carboxylate forms. Thus, the model of encapsulated and released 
CKD-602 can only be used to predict total CKD-602 exposure in the encapsulated and 
released forms. However, the pharmacokinetics of encapsulated CKD-602 is not affected by 
this limitation as the drug that remains encapsulated is all in the lactone form because the pH 
of the core solution is around 5.4. 
 In conclusion, a population pharmacokinetic model was developed for encapsulated 
and released CKD-602 in patients with advanced solid tumors. The release rate of CKD-602 
from S-CKD602 was influenced by age and clearance of encapsulated CKD-602 was 
influenced by presence of tumor in liver.  The development of phenotypic probes of MPS 
function in the liver of patients with and without tumors in the liver is needed to further 
evaluate these effects.  The application of the population pharmacokinetic model in optimal 
dosing of pegylated liposomal agents needs to be further investigated to achieve a target 
exposure for each patient with malignant diseases.   
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Table 4.1. 
 
A summary of Patient Demographics and Covariates Included in the Analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
Characteristics 
 
 
 
 
Number of 
patients 
 
Mean  SD 
 
Median 
(Range) 
Age (years)  60.6  12.2 62 (33.– 79) 
Body Surface Area (m2)  1.91  0.30 1.86 (1.36 – 2.76) 
Body Weight (kg)  78.7  21.4 75.5 (44.0 – 148) 
Body Mass Index 
(kg/m2) 
 27.4  5.60 26.7 (18.8 – 45.7) 
Creatinine Clearance 
(ml/min) 
 98.4  46.6 84.7 (33.2 – 277) 
Height (cm)  169  11.9 170 (142 – 196) 
Ratio of Body Weight to 
Ideal Body Weight 
 1.27  0.28 1.22 (0.83 – 2.13) 
Sex
 
   
    Male 24   
    Female 21   
Primary tumor type    
Colorectal            
Adenocarcinoma  
17   
    Ovarian Cancer 5   
    Sarcoma 5   
Non-Small Cell Lung     
Cancer 
4   
Pancreatic  
Adenocarcinoma  
3   
Hepatocellular  
Carcinoma 
2   
    Prostate Carcinoma 2   
Esophageal, Metastatic  
Breast,  Mesothelioma,  
Renal Cell Carcinoma,  
Thyroid, Appendix,  
Unknown Primary 
1 patient 
for each 
type 
  
Patients with Tumors in 
liver 
26   
Patients without tumors 
in liver 
19   
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Table 4.2. 
 
Population Pharmacokinetic Parameters Obtained from the Final Covariate Model for 
Encapsulated CKD-602 
 
Parameter Definition Population 
Mean RSE
a
 (%) 
Bootstrap 
Median (95% 
CI
f
) 
IIV, CV%
b
  
RSE
a
 (%) 
VEncap (L) Volume of 
distribution 
3.63 (9) 3.78 (3.32-6.00) 72 (48) 
Vmax (μg/h)  
w/ tumor in  
liver
c 
w/o tumor in  
liver
d 
Maximum 
velocity 
 
150 (19) 
 
97.4 (32) 
 
163 (102 - 345) 
 
99.7 (52.3 – 186) 
205 (51) 
Km (μg/L) Michaelis-Menten 
constant 
992 (17) 985 (558-1250) NE
e 
Residual variability 
    Proportional error (variability as 
%) 
14.4 (57) 14.8 (9.4-31.9) NA
g
 
    Additive error (μg/L) 10.9 (65) 10.3 (1.65-28.5)  
 
a
 Relative standard error for estimate. 
b
 Coefficient of variation.  
c
 The estimated maximum velocity for patients with tumor in liver. 
d
 The estimated maximum velocity for patients without tumor in liver.  
e
 Negligible. 
f
 Confidence interval calculated from 910  bootstrap resamplings. 
g
 Not estimated. 
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Table 4.3. 
 
Population Pharmacokinetic Parameters Obtained from the Final Model for CKD-602 after 
Administration of Non-liposomal CKD-602 
 
Parameter Definition Population 
Mean RSE (%) 
Bootstrap 
Median (95% 
CI) 
IIV, CV%  
RSE (%) 
Vc (L) Volume of 
distribution for 
central 
compartment 
9.72 (9) 9.57 (7.62-11.84) NE 
CL (L/h) Systemic 
clearance 
7.90 (13) 7.84 (5.77-10.05) 27.0 (38)
 
Vp (L) Volume of 
distribution for 
peripheral 
compartment 
27.7 (15) 27.8 (20.2-35.2) 21.8 (39) 
CLd (L/h) Distribution 
clearance 
5.07 (17) 5.17 (2.90-7.26) NE
 
Residual variability 
    Proportional error (variability as 
%) 
31.3 (9.5) 40.1 (24.3-54.8) NA 
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Table 4.4. 
 
Population Pharmacokinetic Parameters Obtained From the Final Covariate Model for 
Encapsulated and Released CKD-602 in Patients with Linear Clearance of Encapsulated 
CKD-602  
 
Parameter Definition Population Mean 
RSE (%) 
IIV, CV%  RSE 
(%) 
VEncap (L) Volume of distribution for 
encapsulated 
4.69 (2.2) 53 (26) 
VRel1 (L) Volume of distribution for 
central compartment of 
released 
9.72 (NA
c
) 369 (46) 
VRel2 (L) Volume of distribution for 
peripheral compartment of 
released 
27.7 (NA
c
) 180 (103) 
CLEncap (L/h) Clearance of encapsulated 0.089 (6.5) 151 (27) 
CLEncap-Rel (L/h)  
Age < 60 yo
a
 
Age ≥ 60 yob 
Clearance of release CKD-602 
from S-CKD602 
 
0.130 (17) 
0.048 (14) 
58 (65) 
E%, % Encapsulation percent of 
CKD-602 in the formulation 
96.3 (28) NA
c 
CLRel-d (L/h) Distribution clearance for 
released 
5.07 (NA
c
) 126 (55) 
CLRel (L/h) Systemic clearance for 
released 
7.90 (NA
c
)  NA
c
 
Residual variability 
    Proportional error (variability as %) 19.8 (26)  
Additive error for encapsulated (μg/L) 
Additive error for released (μg/L) 
7.82 (31) 
0.019 (38) 
NA
c
 
 
a
 The clearance of release CKD-602 from S- CKD602 for patients younger than 60 years old. 
b
 The clearance of release CKD-602 from S- CKD602 for patients older than 60 years old.  
c
 Not estimated. 
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Table 4.5. 
 
Population Pharmacokinetic Parameters Obtained From the Final Model for Encapsulated 
and Released CKD-602 in Patients with Nonlinear Clearance of Encapsulated CKD-602 
 
Parameter Definition Population Mean 
RSE (%) 
IIV, CV%  RSE 
(%) 
VEncap (L) Volume of distribution for 
encapsulated 
3.36 (4.6) 12.6 (44) 
VRel1 (L) Volume of distribution for 
central compartment of 
released 
9.72 (NA) 115 (104) 
VRel2 (L) Volume of distribution for 
peripheral compartment of 
released 
27.7 (NA) 130 (89) 
Vmax, Encap (μg/h) Maximum velocity of 
encapsulated 
36.1 (81) 28.8 (32) 
Vmax, Encap-Rel 
(μg/h)  
Maximum velocity of release 
CKD-602 from  S-CKD602 
90.9 (81) 28.8 (32) 
Km (μg/L) Michaelis-Menten constant 1450 (16) NA 
E%, % Encapsulation percent of 
CKD-602 in the formulation 
96.3 (31) NA
 
CLRel-d (L/h) Distribution clearance for 
released 
5.07 (NA) NA 
CLRel (L/h) Systemic clearance for 
released 
7.90 (NA)  89 (59) 
Residual variability 
    Proportional error for encapsulated (variability 
as %) 
11.7 % (43)  
Proportional error for released (variability as %) 
Additive error for released (μg/L) 
26.2 % (29) 
0.632 (69) 
NA
a
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Figure 4.1. The final structural pharmacokinetic model for encapsulated alone (one 
compartment with nonlinear clearance) in all patients (A), encapsulated (one compartment 
with linear clearance) and released CKD-602 (two compartments with linear clearance) in 
patients with linear clearance of encapsulated CKD-602 (B), and encapsulated (one 
compartment with nonlinear clearance) and released CKD-602 (two compartments with 
linear clearance) in patients with nonlinear clearance of encapsulated CKD-602 (C). A 
fraction of dose which was administered in the form of non-liposomal CKD-602 was 
included. E% is encapsulation percent of CKD-602 in the formulation.  VRel1, VRel2, CLRel, 
and CLRel-d in Figure 4.1B and 4.1C were fixed based on non-liposomal CKD-602 
pharmacokinetic data. 
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Figure 4.2. Representative individual plots of observed, population predicted, and individual 
predicted values of plasma concentrations of encapsulated CKD-602.  Figure 4.2A, 4.2B, 
4.2C, and 4.2D represent the concentration versus time profile in patients treated with dose of 
0.30 mg/m
2
, 0.5 mg/m
2
, 1.7 mg/m
2
 and 2.1 mg/m
2
 respectively.  The observed (○), 
population predicted (- - -), and individual predicted (―) values of encapsulated CKD-602 in 
patients without tumor in liver are presented.  The observed (♦), population predicted (- - -), 
and individual predicted (―) values of encapsulated CKD-602 in patients with tumor in 
liver are presented.   
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Figure 4.3. Goodness-of-fit plots for the final model of encapsulated CKD-602.  The dashed 
lines in the upper left and right panels are lines of identity . The solid lines in the lower left 
and right panels represent the line y=0. . 
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Figure 4.4. Goodness-of-fit plots for the final model of CKD-602 after administration of 
non-liposomal CKD-602.  The dashed lines in the upper left and right panels are lines of 
identity. The solid lines in the lower left and right panels represent the line y=0. 
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Figures 4.5a and 4.5b. Representative individual plots of observed (○),  and individual 
predicted (―) values of plasma concentrations of encapsulated and the observed (◊) and 
individual predicted (- - -) values of plasma concentrations of released CKD-602 in patients 
with linear clearance of encapsulated CKD-602 (5a) and in patients with nonlinear clearance 
of encapsulated CKD-602 (5b).  
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Figures 4.6a and 4.6b. Observed versus population model-predicted encapsulated and 
released plasma concentrations for the final models in patients with linear clearance of 
encapsulated CKD-602 (4.6a) and in patients with nonlinear clearance of encapsulated CKD-
602 (4.6b).  The dashed lines are lines of identity. 
  
 
CHAPTER 5 
 
 
POPULATION PHARMACOKINETICS OF PEGYLATED 
LIPOSOMAL CPT-11 (IHL-305) IN PATIENTS WITH ADVANCED 
SOLID TUMORS 
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A. INTRODUCTION 
IHL-305 is a PEGylated liposomal formulation of irinotecan (CPT-11), a 
camptothecin analogue which inhibits topoisomerase I and has been approved for the 
treatment of metastatic colorectal cancer (1-4). The PEGylated liposomal formulation 
consists of phospholipids covalently bound to polyethylene glycol (PEG) only on the outside 
of the lipid bilayer.  CPT-11 is a prodrug that requires activation to the active metabolite, 7-
ethyl-10-hydroxy-camptothecin (SN-38), which is approximately 100- to 1000-fold more 
active than the parent drug. SN-38 is further conjugated to form an inactive glucuronide (SN-
38G) by uridine diphosphate glucuronosyltransferases (UGTs), primarily the UGT1A1 
isoform. Other identified CPT-11 metabolites are 7-ethyl-10-[4-N-(5-aminopentanoic acid)-
1-piperidino]-carbonyloxycamptothecin (APC) and 7-ethyl-10-[4-amino-1-piperidino]-
carbonyloxycamptothecin (NPC) (3, 5).  
The development of PEGylated liposomes, such as PEGylated liposomal doxorubicin 
(Doxil), CKD-602 (S-CKD602), and CPT-11 (IHL-305) was based on the discovery that 
incorporation of PEG-lipids into liposomes yields preparations with prolonged plasma 
exposure and superior tumor delivery compared to conventional liposomes composed of 
natural phospholipids (4, 6, 7).  Doxil® is approved for the treatment of refractory ovarian 
cancer, Kaposi sarcoma, and multiple myeloma (8, 9).  The PEGylated liposomes of Doxil 
and IHL-305 were made using two different methods. The PEGylated liposome of Doxil was 
made by adding the PEG lipid before the process of liposomal formation which results PEG 
tether being projected on both the inside and outside of liposome.  The PEGylated liposome 
of IHL-305 is made by adding the PEG lipids after the process of liposomal formation which 
results in PEG tether only being localized on the outer leaflet (10). Encapsulation of the CPT-
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11 allow for release of the active-lactone form into the tumor over a protracted period of 
time, which is ideal for a cell cycle-specific drug (1-4, 11, 12).  The PEGylated liposomal 
formulation is expected to have an enhanced therapeutic ratio compared to non-liposomal 
CPT-11. 
 Studies of the pharmacokinetics (PK) of IHL-305 compared to CPT-11 in mice, rats, 
and dogs showed a marked increase in the concentrations of CPT-11 and its metabolites in 
the plasma, liver, kidney, spleen, and tumor tissue after administration of IHL-305 as 
compared with non-liposomal CPT-11 administration. The plasma exposure of IHL-305 at 
16.7 mg/kg IV x 1 was approximately 302-fold greater than non-liposomal CPT-11 at the 
same dose in tumor-bearing mice (13). In mice bearing human tumor xenografts, the 
exposures of CPT-11 and SN-38 in tumor were 9.0 and 3.9-fold higher and the mean 
residence time of CPT-11 and SN-38 in plasma was 4.4 and 4.7-fold longer for IHL-305 
compared with non-liposomal CPT-11 (14). In addition, the antitumor response was greater 
for IHL-305 compared with non-liposomal CPT-11 (14).  These results are consistent with 
reports that the antitumor response to camptothecin analogues is enhanced by prolonged 
duration of exposures in tumors  (11, 12, 15-17).   
The PK disposition of carrier-mediated agents, such as, nanoparticles, nanosomes, 
and conjugated agents, is dependent upon the carrier until the drug is released from the 
carrier.  Unlike traditional anticancer agents which are cleared by the liver and kidneys, the 
clearance of non-PEGylated and PEGylated liposomes is via the mononuclear phagocytic 
system (MPS) which include monocytes, macrophages and dendritic cells located primarily 
in the liver and spleen (18).  Uptake by the MPS usually results in sequestering of the 
encapsulated drug in the MPS, where it can be degraded.  In addition, the uptake of the 
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liposomes by the MPS may result in acute impairment of the MPS and toxicity.  PEGylated 
liposomes are cleared much slower via MPS compared to non-PEGylated liposomes (6, 19).  
Once the drug is released from the carrier, the PK disposition of the drug will be the same as 
after administration of the non-carrier form of the drug (4, 18). Thus, the PK of liposomes are 
complex. 
The nomenclature used to describe the PK disposition of carrier-mediated drugs 
includes encapsulated or conjugated (drug within or bound to the carrier), released (the active 
drug released from the carrier), and sum total (encapsulated or conjugated drug plus released 
drug).  The ability to evaluate the various forms (encapsulated and released) of the drug after 
administration of nanosome or nanoparticle formulations is dependent upon specific sample 
processing methods (20).  The drug that remains encapsulated within nanosomes or 
nanoparticles, or linked to a conjugate or polymer is an inactive prodrug, thus the drug must 
be released from the carrier to be active.   
Nanoparticle agents have higher variability in PK (drug clearance, systemic exposure, 
distribution, etc.) disposition with potentially higher variability in pharmacodynamic (PD) 
(antitumor response and toxicity) disposition as compared with traditional small molecule 
chemotherapy.  However, the factors affecting the PK and PD variability of encapsulated and 
released forms of conventional and PEGylated liposomes remain unclear, but most likely 
include the MPS (1). We have evaluated factors affecting the PK and PD of liposomal 
anticancer agents.  We were the first to report a reduced clearance of the liposomal 
encapsulated forms of Doxil and S-CKD602 in patients ≥ 60 years of age (21, 22).  We have 
also reported that patients with a lean body composition may have a reduced tissue 
distribution and an increased plasma exposure of S-CKD602. In addition, we have reported 
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an age related decrease in the function of monocytes which may be associated with a reduced 
clearance of liposomes and reduced cytotoxicity to the monocytes (19, 23, 24).   
 The clinical results of the phase I study and limited PK results were previously 
published (25).  IHL-305 was associated with high interpatient variability in the PK 
disposition of sum total (encapsulated + released) and released CPT-11 (25).  Population PK 
analysis is a useful tool for identification of sources of PK variability and can aid in the 
design of alternative dosing regimens to enhance efficacy and safety.  The objectives of this 
study were to describe the population PK of the encapsulated CPT-11, released CPT-11 and 
the active metabolite SN-38 after administration of the PEGylated liposomal form of the drug 
and to characterize clinical covariates that influence IHL-305 PK.  
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B. METHODS 
Patients 
 Written informed consent, approved by the Institutional Review board of the Sarah 
Cannon Research Institute and Vanderbilt University Medical Center, was obtained from all 
patients prior to study entry. Patients ≥ 18 years of age with a histologically confirmed 
malignant solid tumor for which no effective therapy was available or a conventional therapy 
have failed to treat or a conventional therapy does not exist were eligible for this study.  
Patients must have recovered from all acute adverse effects of prior therapies, excluding 
alopecia.  Pertinent  eligibility criteria included a Eastern Cooperative Oncology Group 
(ECOG) performance status of 0, 1, or 2, adequate bone marrow, hepatic, and renal function 
as evidenced by the following: absolute neutrophil count (ANC)  1500/L, platelets  
100,000/L, total bilirubin within normal institutional limits, aspartate aminotransferase 
(AST)  2.5 x institutional upper limit of normal (ULN) if liver metastases were not present 
and  5.0 x ULN if liver metastases were present, plasma creatinine  1.5 x the institutional 
ULN or creatinine clearance  60 ml/min/1.73 m2 for patients with creatinine levels above 
institutional normal.  Patients must have the ability to understand and the willingness to sign 
a written informed consent document.  Patient were excluded from the study for any of the 
following: prior treatment with CPT-11; chemotherapy or radiotherapy within 4 weeks (6 
weeks for nitrosoureas or mitomycin C); treatment with any other investigational agent 
during study; brain metastases; a history of allergic reactions to compounds of similar 
chemical composition to IHL-305; concurrent serious infections; pregnancy or breastfeeding; 
uncontrolled intercurrent illness including ongoing or active infection, unstable angina 
pectoris or psychiatric illness/social situations; significant cardiac disease including heart 
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failure that meets New York Heart Association (NYHA) class III and IV definitions, history 
of myocardial infarction within one year of study entry, uncontrolled dysrhythmias or poorly 
controlled angina; a history of serious ventricular arrhythmia, QTc ≥ 450 msec for men and 
470 msec for women, or LVEF ≤ 40% by MUGA.  Prior treatment with camptothecin 
analogues other than IHL-305 or CPT-11 was permitted.   
 
Dosage and Administration 
IHL-305 is a formulation of CPT-11 encapsulated in long-circulating PEGylated 
liposome.  In IHL-305, the PEGylated liposome bilayer is composed of cholesterol and 
hydrogenated soybean phosphatidylcholine (HSPC), and the surface of liposomes is modified 
with PEG. The mean particle diameter is approximately 100 nm and the ratio of CPT-11 to 
lipid is 1:4. The PEGylated liposomal formulation was generated by Terumo Corporation 
(Tokyo, Japan). IHL-305 was supplied by Yakult Honsha Corporation in sterile 10 mL light-
resistant, single-use glass vials as a translucent white to pale yellow liquid with a nominal 
total CPT-11 concentration of 5 mg/mL.  IHL-305 was diluted 25-fold in 5% dextrose or 
normal saline prior to administration.  Prior to administration of the study drug, patients were 
premedicated with ondansetron (or other 5-HT3 inhibitor should circumstances require) and 
dexamethasone, according to each institution’s standard of care.  
IHL-305 was administered IV x 1 over 60 minutes every 4 weeks.  Doses 
administrated (expressed in mg of CPT-11) were 3.5, 7, 10.5, 14, 28, 33.5, 37, 50, 67, 80, 88, 
120, 160, and 210 mg/m
2
. This phase I study followed a standard dose escalation design with 
patients enrolled in cohorts of 3, with the possibility of extending the cohort up to 6 patients 
depending on the number of dose-limiting toxicities (DLT) (18). No intra-patient dose 
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escalation was permitted. The maximum tolerated dose (MTD) was defined based on 
standard criteria. 
 
Sample Collection, Processing, and Analytical Studies 
 Plasma samples for PK assessment were obtained from all patients.  On cycle 1, 
blood (5 mL) was collected in tubes containing sodium heparin at prior to administration, at 
end of the infusion (approximately 1 h), and at 1.5 h, 2 h, 3 h, 5 h, 9 h, 13 h, and 25 h after 
the start of the infusion for patients treated at < 67 mg/m
2
 and the first three patients treated 
at 67 mg/m
2
. Additional samples at 49 h, 73 h, 97 h, 169 h (day 7), 192 h (day 8), and 216 h 
(day 9) after the start of the infusion were also collected for the last three patients treated at 
67 mg/m
2
 and patients treated at > 67 mg/m
2
.   
 The blood samples were centrifuged at 3,000 x g for 15 min at 4ºC to separate plasma 
samples. Plasma samples were processed to measure sum total (encapsulated + released) 
CPT-11 and released CPT-11, and SN-38 as previously described (26). The sum total CPT-
11, released CPT-11, and SN-38 concentrations were measured by a high-performance liquid 
chromatography (HPLC) as previously described (26). The total (lactone + hydroxy acid) 
form of camptothecin was measured for sum total CPT-11, released CPT-11, and SN-38 
samples.  The lower limit of quantitation (LLQ) of the total form sum total CPT-11, released 
CPT-11, and SN-38 were 100, 2, and 2 ng/mL, respectively. The encapsulated concentration 
of CPT-11 was calculated as difference between sum total and released CPT-11. 
 
Population PK Analysis  
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 Encapsulated CPT-11, released CPT-11 and SN-38 concentration-time data were 
analyzed using the nonlinear mixed effects modeling approach as implemented in NONMEM 
(version 6; University of California, San Francisco, CA).  The first order conditional 
estimation (FOCE) method were used in analyses.  S-PLUS 8.0 (Version 8.0, Insightful 
Corporation, Seattle, Washington) was used for graphical diagnostics and covariate screen. 
The population PK model of IHL-305 was developed in two steps: (a) basic (structural) 
model development and (b) covariate model development. 
 Mean population PK variables, interindividual variability, and residual error were 
assessed in the model development (27, 28). Interindividual variability for each PK variable 
was modeled with an exponential function. Residual error models of the additive, 
proportional, exponential, and combination methods were evaluated for the best structural 
PK model. Individual PK variables were obtained by posterior Bayesian estimation (27, 28). 
Model selection for nonhierarchical models (i.e., linear and nonlinear elimination models) 
was guided by goodness-of-fit plots (e.g., observed versus predicted plasma concentrations, 
weighted residuals versus predicted concentrations, and weighted residuals versus time), 
Akaike information criterion (AIC), and precision of parameter estimates. AIC was 
calculated as AIC = OFV + 2 x p, where OFV is the NONMEM objective function value and 
p is the number of PK variables. The model was chosen on the basis of smaller values of 
AIC, better precision of estimates, and superior goodness-of-fit plots. 
 
Encapsulated Drug, Released Drug and Active Metabolite Model 
The structural model of encapsulated CPT-11, released CPT-11, and SN-38 was built 
sequentially. Firstly, the best model for encapsulated CPT-11 was selected from all the 
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possible models. Then based on the best model for encapsulated CPT-11, simultaneous 
modeling of the encapsulated and the released CPT-11 were performed for data from all 
patients, in which various compartment models for released drug were tested. Finally, based 
on the best model for encapsulated and released CPT-11, simultaneous modeling of the 
encapsulated CPT-11, released CPT-11 and SN-38 were attempted for data from all patients.   
Encapsulated Drug Model. The structural model was built to fit encapsulated CPT-
11 plasma concentration-time profiles from all 39 patients. One-compartment model and 
two-compartment model with first-order elimination or nonlinear elimination characterized 
by Michaelis-Menten kinetics were tested to fit encapsulated plasma concentration data.  
Released Drug Model. Based on the best model for encapsulated CPT-11, one-
compartment model, two-compartment model and three-compartment model with first-order 
elimination were tested to fit released plasma concentration data in the simultaneous 
modeling of the encapsulated and the released drug. As most of the CPT-11 remains 
encapsulated in the plasma after administration of IHL-305 and the plasma concentration of 
released CPT-11 is only 1% of encapsulated CPT-11, the amount or concentration of CPT-11 
that is non-encapsulated in the dosage (infusion bag) is important to capture relative to the 
high concentrations of released CPT-11 at earlier time points.  Thus, estimates of the non-
encapsulated CPT-11 in the formulation were included in models for encapsulated and 
released CPT-11 after administration of IHL-305. 
Active Metabolite Model. Base on the best model for encapsulated and released 
CPT-11, one-compartment model, two-compartment model and three-compartment model 
with first-order elimination (Eq. A) were tested to fit SN-38 plasma concentration data in the 
simultaneous modeling of the encapsulated CPT-11, released CPT-11 and SN-38.  However, 
 148 
the estimation of PK parameters for the released CPT-11 and SN-38 proved to be 
unsatisfactory because no successful termination with covariance step could be achieved.  
Therefore, in this modeling process, the PK parameters associated with distribution and 
elimination of encapsulated and released CPT-11 were determined from PK model of the 
encapsulated and released CPT-11 and fixed in the population PK model of encapsulated 
CPT-11, released CPT-11, and SN-38.  In addition to fixing PK parameters of encapsulated 
and released CPT-11, two-compartment model with linear clearance was used and the initial 
estimate range of parameter estimates was set according to a published PK model for SN-38 
(29).  
The PK model used to characterize the disposition of encapsulated CPT-11, released 
CPT-11 and SN-38 is shown in Figure 5.1. The differential equations describing the PK 
model of encapsulated CPT-11, released CPT-11 and SN-38 are as follows: 
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dAEncap/dt  is the elimination rate, Vmax, Encap is the maximum velocity of encapsulated CPT-
11, FRel is the fraction of encapsulated CPT-11 released from IHL-305, and Km is the 
concentration at which half-maximum elimination rate is achieved, VEncap is the volume of 
distribution of encapsulated CPT-11, CLRel is the clearance of the released CPT-11, VRel is 
the volume of distribution of released CPT-11, E% is the encapsulation percent of CKD602 
in the formulation, CLSN-38 is the apparent systemic clearance of SN-38, CLSN-38-d is the 
apparent distribution clearance of SN-38, VSN-3-1 is the apparent volume of distribution for 
the central compartment of SN-38, VSN-38-2 is the apparent volume of distribution for the 
peripheral compartment of SN-38. AEncap is encapsulated CPT-11 amount in plasma, CEncap is 
the plasma concentration of encapsulated CPT-11, ARel is released CPT-11 amount in 
plasma, CRel is the plasma concentration of released CPT-11, ASN-38-1 is SN-38 amount in 
plasma, CSN-38 is the plasma concentration of SN-38. k0 is the infusion rate and k0 is 0 after 
stop of infusion. 
 
Covariate Analysis 
 The covariate model building was a stepwise process. A screen for potential 
significant covariates was done using S-PLUS 8.0 (Version 8.0, Insightful Corporation, 
Seattle, Washington).  The potential covariates as listed in Table 5.1 were tested for 
influence on the structural PK variables. The potential significant covariates selected from 
screen were introduced into the covariate model as linear, exponential, or power function, 
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and assessed in the population PK models. A significant covariate was selected to be retained 
in the final model if addition of the covariate resulted in a decrease in OFV >3.875 (P < 0.05) 
during the forward full covariate model building, and removal of the covariate resulted in an 
increase in OFV >10.828 (P < 0.001) during the stepwise backward model reduction (30). In 
addition, the increase in precision of the variable estimate (% relative SE of prediction) and 
reduction in interindividual variability were used as another indicator of the improvement of 
the goodness of fit.  
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C. RESULTS 
Patient demographics 
 Fourty-two patients were enrolled on this study from 14 December 2006 to 15 
December 2008 at Sarah Cannon Research Institute and Vanderbilt University Medical 
Center.  PK studies of encapsulated CPT-11, released CPT-11 and SN-38 were performed in 
39 patients.  Patient characteristics are listed in Table 5.1.  The numbers of male and female 
patients evaluated in the phase I study were 13 and 26, respectively.  The mean (median, 
range) age of the patients was 59.3 years (60 years, 41 to 75 years).  A total of 392 plasma 
concentrations of encapsulated CPT-11, 322 plasma concentrations of released CPT-11 and 
123 plasma concentrations of SN-38 were used to develop the population PK model. The PK 
model used to characterize the disposition of encapsulated CPT-11, released CPT-11, and 
SN-38 is shown in Figure 5.1. 
 
Population PK Model of IHL-305 
Encapsulated and Released Drug Model. The encapsulated and released CPT-11 
were modeled simultaneously for all patients. For encapsulated CPT-11, both linear and 
nonlinear PK models were evaluated. A one-compartment model with Michaelis-Menten 
kinetics (AIC = 1616) better described the data than either nonlinear plus linear (AIC = 1619) 
or linear kinetics (AIC = 1630). For released CPT-11, a one-compartment model with linear 
kinetics (AIC = -913) best described the data than either two-compartment model with linear 
kinetics (AIC = -911) or three-compartment model with linear kinetics (AIC = -877).  The 
distribution of residual variability was best described by a proportional error model.  During 
the covariate screen, gender was identified as a significant covariate for volume of 
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distribution of encapsulated CPT-11 (Vencap) and maximum velocity of encapsulated CPT-11 
(Vmax, encap).  The PK parameter estimates obtained from the final covariate model are 
provided in Table 5.2.  The inclusion of gender as a covariate in the final model decreased 
the inter-individual variability (IIV) of Vencap and  Vmax, encap by 5.7%, and 4.3%, respectively. 
Vencap in female patients and male patients were estimated to be 2.4 L (IIV 22.4%) and 3.6 L 
(IIV 22.4%), respectively (P < 0.001).  The estimated Vencap for both female and male 
patients are very close to plasma volume in humans. Vmax, encap in female and male patients 
was estimated to be 13.2 mg/h (IIV 40.8%) and 19.2 mg/h (IIV 40.8%), respectively (P < 
0.001). The mean Michaelis-Menten constant (Km) were estimated to be 117 mg/L. The 
fraction of encapsulated CPT-11 released from IHL-305 (FRel) was estimated to be 0.7 and 
showed the most inter-individual variability, with IIV for FRel was estimated to be 153%. The 
population mean of encapsulation of CPT-11 in the formulation was estimated to be 94.1%. 
The volume of distribution of released CPT-11 was estimated to be 402 L (IIV 61.3%). The 
clearance of released CPT-11 was estimated to be 19 L/h (IIV 40.4%).  
Active Metabolite Model. The final PK model for encapsulated CPT-11, released 
CPT-11, and SN-38 was built by fixing PK parameters of encapsulated and released CPT-11 
estimated from the final model of encapsulated and released CPT-11. A two-compartment 
model with linear kinetics was used to describe the data of SN-38.  The population mean 
values of SN-38 for apparent volume of central compartment (VSN-38-1), apparent systemic 
clearance (CLSN-38), apparent volume of peripheral compartment (VSN-38-2), and apparent 
distribution clearance (CLSN-38-d) were 108 L (IIV 57.5%), 300.2 L/h (IIV 24.4%), 2433.5 L, 
and 113.4 L/h (IIV 66.3%), respectively. 
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 Goodness-of-fit plots from the final PK model in all patients are given in Figure 5.2.  
The model adequately describes the PK profile of encapsulated CPT-11. Both the population 
predicted (R
2
 = 0.90) and individual predicted (R
2
 = 0.97) PK data of encapsulated CPT-11 
correlated well with the observed data. Although the PK data of released CPT-11 were 
variable, the population predicted (R
2
 = 0.75) PK data of released CPT-11 correlated 
relatively well with the observed data. The individual predicted (R
2
 = 0.94) PK data of 
released CPT-11 correlated well with the observed data. The PK data of SN-38 is reasonably 
but less adequately described by the final model compared to encapsulated and released 
CPT-11. The observed PK data of SN-38 better correlated with the individual predicted PK 
data (R
2
 = 0.77) than population predicted PK data (R
2
 = 0.17). The observed The Selected 
individual PK time profiles of encapsulated CPT-11, released CPT-11, and SN-38 are shown 
in Figure 5.3.  In general, the observed data of encapsulated CPT-11, released CPT-11and 
SN-38 were well described by the final model.   
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D. DISCUSSION 
 Major advances in the use of liposomes, conjugates, and nanoparticles as vehicles to 
deliver drugs have occurred the past 10 years (4, 6, 7).  Doxil
®
 and albumin stabilized 
nanoparticle formulation of paclitaxel (Abraxane
®
) are now FDA approved (8, 9, 31).  In 
addition, there are greater than 200 liposomal and nanoparticle formulations of anticancer 
agents currently in development (4).  This is the first study where population PK modeling 
was applied to assess the PK of the encapsulated drug, released drug, and its active 
metabolite after administration of a pegylated liposomal formulation of a camptothecin 
analogue  (26,27,28).  Evaluation of the PK disposition of the liposomal encapsulated verses 
released drug is of the utmost importance because the liposomal encapsulated drug is an 
inactive prodrug and thus only the released drug is active (1,3).   
The inter-individual variability in the disposition of IHL-305 can be explained in part 
by gender.  Vencap and Vmax, encap in male patients is 1.5-fold higher compared with female 
patients. This data suggest that male patients may have 50% lower exposure and are at risk of 
having a lower response potential.  This gender effect on Vmax, encap of encapsulated drugs is 
consistent with previous observations of gender associated variability in clearance of TLI 
(Optisomal Topotecan), S-CKD602, and Doxil (32, 33). For TLI and S-CKD602, CL was 
1.2-fold (p = 0.14) and 1.4-fold (p = 0.009) lower in female rats compared with male rats, 
respectively (33). Female patients had lower CL of Doxil (p <0.001), IHL-305 (p = 0.068), 
and SCKD-602 (p = 0.67) as compared with male patients overall and also when stratified by 
age (32). The effect of gender on PK of Doxil was also reported in a population PK analysis 
of of Doxil (34). The gender effect on Vencap has not been reported. The greater Vencap in male 
patients may be explained by the greater blood volume in males compared to females (35). 
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The gender effect on Vencap may also due to the correlation between Vencap and Vmax, encap in 
the PK model. Overall, these results suggest that gender may be a significant factor affecting 
the PK disposition of liposomal agents and may play a role in the high PK variability 
reported in patients treated with liposomal anticancer agents.  
Pegylated-liposomal CPT-11 displayed nonlinear PK best described by a one-
compartment structural model. The mean values of volume of distribution for encapsulated 
CPT-11 were 3.22 L for male patients and 2.55 L for female patients, which are very close to 
plasma volume in humans. The limited volume of distribution of encapsulated CPT-11 is 
consistent with other liposomal anticancer agents since the size of liposome limited their 
distribution to the normal tissue (36, 37).  Saturation of clearance has been reported for both 
Doxil® and S-CKD602 and the nonlinear PK of these two drugs have been modeled using 
Michaelis-Menten kinetics (38-41).  
The PK disposition of released CPT-11 was described by a one-compartment model 
with linear clearance.  In contrast, the PK disposition of CPT-11 after administration of 
nonliposomal CPT-11 was described by two-compartment or three-compartment models with 
linear clearance in the PK analysis by others. This suggests the PK disposition of released 
CPT after administration of IHL-305 was primarily dominated by the disposition of the 
liposome carrier.  Published CL values of the total form of non-liposomal CPT-11 are in the 
range of 12 to 24 L/h/m
2
 during short infusions (30 to 90 minutes) (42-44). In our model, CL 
of the total form of released CPT-11 was estimated to be 19 L/h (10.3 L/h/m
2
), which is close 
but slight lower than previously reported values. Similarly, the steady-state volume of 
distribution estimate of 402 L (217 L/m
2
) for released CPT-11 falls within the range of 
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reported steady state volume of distribution (377 to 871 L) for non-liposomal CPT-11 (42, 
45, 46).  
The model prediction for SN-38 was not as accurate as for encapsulated and released 
CPT-11. This may be related to the highly variable and low concentration levels of SN-38. In 
addition, the final model of encapsulated CPT-11, released CPT-11 and SN-38 was built 
sequentially so the model of encapsulated and released CPT-11 drives the model of SN-38. 
Therefore any error caused by model misspecification of the parent drug model will be 
carried over and exaggerated in the model of active metabolite.   
The model that are developed did not take into account the lactone and carboxylate 
forms of CPT-11 since only the total (lactone + hydroxy acid) form of the drug were 
measured in our study. Only the lactone form of CPT-11 has antitumor activity, and they 
undergo a pH-dependent equilibrium with carboxylate forms. Thus, the model of 
encapsulated and released CPT-11 can only be used to predict total CPT-11 exposure in the 
encapsulated and released forms. However, the PK of encapsulated CPT-11 is not affected by 
this limitation as the drug that remains encapsulated is all in the lactone form because the pH 
of the core solution is approximately 5.4. 
In conclusion, a population PK model was developed for encapsulated and released 
CPT-11 in patients with advanced solid tumors. The volume of distribution and clearance of 
encapsulated CPT-11 was influenced by gender.  The effect of gender on PK of IHL-305 
needs to be further evaluated.  This model will not only help to understand the PK of 
PEGylated liposomal drugs but may also be useful in predicting the PK and optimize dosing 
of pegylated liposomal agents to achieve a target exposure for a patient with cancer.   
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Table 5.1. 
 
A summary of Patient Demographics and Covariates Included in the Analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
Characteristics 
 
 
 
 
Number of 
patients 
 
Mean  SD 
 
Median 
(Range) 
Age (years)  60.0  9.4 60 (42– 75) 
Body Surface Area (m2)  1.9  0.3 1.9 (1.4 – 2.4) 
Body Weight (kg)  76.7  20.4 75.3 (47.1 – 124.5) 
Body Mass Index 
(kg/m2) 
 27.0  6.8 26.3 (17.2 – 53.6) 
Height (cm)  169  10.3 168 (152 – 188) 
Ratio of Body Weight to 
Ideal Body Weight 
 1.3  0.4 1.2 (0.8 – 2.7) 
Sex
 
   
    Male 13   
    Female 26   
Primary tumor type    
    Ovarian Cancer 8   
    Breast Cacner 6   
Lung Cancer 6   
Bladder  2   
Head and Neck                          
Squamous 
2   
    Neuroendocrine    
Carcinoma 
2   
Adenoid cystic, Anus, 
Cervical, Colon, Gastric, 
Mediastinal, Metastatic 
breast, Metastatic 
prostate, Metastatic 
carcinoid, Pancreatic, 
Prosta, Right 4
th
 toe, 
Uterine 
1 patient 
for each 
type 
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Table 5.2. 
 
Population PK Parameters Obtained From the Final Model for Encapsulated CPT-11, 
Released CPT-11 and SN-38. 
 
Parameter Definition Population Mean 
RSE
a
 (%) 
IIV, CV%
b
  
RSE
a
 (%) 
VEncap (L) 
Female
c 
Male
d 
Volume of distribution for 
encapsulated 
 
2.4 (3.9) 
3.6 (6.1) 
22.4 (21) 
VRelease (L) Volume of distribution for 
central compartment of released 
402 (32) 61.3 (28) 
Vmax, encap (mg/h) 
Female 
Male 
Maximum velocity of 
encapsulated 
 
13.2 (30) 
19.2 (30) 
40.8 (20) 
FRel Fraction of encapsulated CPT-11 
released from IHL-305 
0.7 (63) 153 (53) 
Km (mg/L) Michaelis-Menten constant 117 (38) NA
e
 
Encapsulation, % Encapsulation percent of CPT-
11 in the formulation 
94.1 (34) NA
e 
CLRel (L/h) Systemic clearance for released 19 (7.1)  40.4 (44) 
VSN-38-1 (L) Apparent volume of distribution 
for central compartment of  
SN-38 
108 (NE) 57.5 (24) 
VSN-38-2 (L) Apparent volume of distribution 
for peripheral compartment of 
SN-38 
2433.5 (NE) NE 
CLSN-38 (L/h) Apparent systemic clearance of 
SN-38 
300.2 (10) 24.4 (25) 
CLSN-38- d (L/h) Apparent distribution clearance 
of SN-38 
113.4 (NE) 66.3 (18) 
Residual variability 
    Proportional error for encapsulated (variability as 
%) 
24.5 % (19)  
Proportional error for released (variability as %) 
Proportional error for SN-38 (variability as %) 
28.1 % (15) 
25.6 % (18) 
NA
e
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a
 Relative standard error (RSE) for estimate. 
b
 Coefficient of variation (CV%).  
c
 The estimated volume of distribution of encapsulated CPT-11 for female patients. 
d
 The estimated volume of distribution of encapsulated CPT-11 for male patients.  
e
 Not estimated. 
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Figure 5.1. The final structural PK model for encapsulated CPT-11, released CPT-11 and 
SN-38. A fraction of dose which was administered in the form of non-liposomal CPT-11 was 
included. E% is encapsulation percent of CPT-11 in the formulation.   
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Figure 5.2. Goodness-of-fit plots for the final model of encapsulated CPT-11, released CPT-
11, and SN-38.  The dashed lines are lines of identity. 
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Figures 5.3. Representative individual plots of observed (○) and individual predicted (―) 
values of plasma concentrations of encapsulated CPT-11, observed (◊) and individual 
predicted (― ―) values of plasma concentrations of released CPT-11, and observed (∆) and 
individual predicted (∙∙∙∙∙∙) values of plasma concentrations of SN-38 in patients. For the 
representative patient receiving dose of 7 mg/m
2
, there is no detectable concentration of SN-
38. 
 
  
 
CHAPTER 6 
 
 
MECHANISM-BASED PHARMACOKINETIC-
PHARMACODYNAMIC MODEL CHARACTERIZING BI-
DIRECTIONAL INTERACTION BETWEEN PEGYLATED 
LIPOSOMAL CKD-602 (S-CKD602) AND MONOCYTES  
IN PATIENTS WITH ADVANCED MALIGNANCIES 
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A. INTRODUCTION 
Liposomes (microparticulate phospholipid vesicles) have been used with growing 
success as pharmaceutical carriers for anticancer agents. Conventional liposomes are quickly 
opsonized by plasma proteins, recognized as foreign bodies, and rapidly removed by the 
mononuclear phagocytic system (MPS) which has also been called the reticuloendothelial 
system (RES) (1, 2).  The development of STEALTH or Polyethylene Glycol (PEG)ylated 
liposomes was based on the discovery that incorporation of mPEG-lipids into liposomes 
yields preparations with prolonged plasma exposure and superior tumor delivery compared to 
conventional liposomes composed of natural phospholipids (3-5).  PEGylated liposomal 
doxorubicin (Doxil®) is approved for the treatment of refractory ovarian cancer, Kaposi 
sarcoma, and multiple myeloma (6, 7).   
S-CKD602 is a PEGylated liposomal formulation of CKD-602, a camptothecin 
analogue which inhibits topoisomerase I (3, 8, 9).  Non-liposomal CKD-602 administered IV 
at 0.5 mg/m
2
/day for 5 consecutive days repeated every 21 days is approved in Korea for the 
treatment of newly diagnosed small cell lung cancer and relapsed ovarian cancer (10-13).  
Encapsulation of the CKD-602 in the acidic core of a PEGylated liposome protect the active-
lactone form of the drug from being converted to the inactive-hydroxy acid form in the blood 
and allow for release of the active-lactone form into the tumor over a protracted period of 
time, which is ideal for a cell cycle-specific drug (3, 14-18).  The PEGylated liposomal 
formulation is expected to have an enhanced therapeutic ratio compared to non-liposomal 
CKD-602, as well as a more convenient schedule of administration. 
The pharmacokinetic (PK) disposition of carrier-mediated agents, such as, 
nanoparticles, nanosomes, and conjugated agents, is dependent upon the carrier until the drug 
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is released from the carrier.  Unlike traditional anticancer agents which are cleared by the 
liver and kidneys, the clearance of non-PEGylated and PEGylated liposomes is via the MPS 
which include monocytes, macrophages and dendritic cells located primarily in the liver and 
spleen (2).  PEGylated liposomes are cleared much slower via MPS compared to non-
PEGylated liposomes (4, 19).  Uptake of the liposomes or nanoparticles by the MPS usually 
results in sequestering of the encapsulated drug in the MPS and the sequestered drug in the 
MPS may cause acute cytotoxicity to the MPS. This toxicity to the MPS in turn decreases 
clearance of the PEGylated liposomal anticancer agents and alters the pharmacodynamics 
(PD) of the agents. Thus, there is a bi-directional interaction between PEGylated liposomal 
anticancer agents and MPS.  Since a major portion of the liposomal encapsulated drug 
molecules are confined primarily to the blood compartment due to their relative large size 
(20), we have reported that there is a significant and clinically relevant interaction between 
liposomal agents and MPS cells in the blood circulation (19). This bi-directional interaction 
between PEGylated liposomal anticancer agents and monocytes is very important in 
determining the PK and PD of PEGylated liposomal anticancer agents and potentially other 
nano and conjugated agents.  
Clinical PK analysis of Doxil suggests a dose-dependent clearance saturation of 
clearance when a broad dose range is examined (21). Non-linear clearance was also observed 
in a phase I PK study of S-CKD602 (22).  In addition, Gabizon and colleagues reported that 
the clearance of sum total (encapsulated + released) doxorubicin decreased by approximately 
25 to 50% from cycle 1 to 3 (19, 23).  We reported that this reduction in clearance of Doxil® 
from cycle 1 to cycle 3 was associated with a reduction in pre-cycle monocyte count (19, 24).  
We have also reported that high % decrease in monocytes was associated with high clearance 
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of IHL-305 (25). These studies suggest that the dose-dependent and cycle-dependent 
clearance of PEGylated liposomal anticancer agents may due to the bi-directional interaction 
between PEGylated liposomal drug and monocytes in blood.  
The PK of PEGylated liposomal anticancer agents and Non-PEGylated liposomal 
anticancer agents in humans have been studied using the population modeling approach (26-
31). Conventional compartment models such as one-compartment and two-compartment 
models were commonly used in these PK studies (26-31).  The dose-dependent clearance of 
PEGylated liposomal anticancer agents was modeled using Michaelis-Menten kinetics (30). 
The bi-directional interaction between PEGylated liposomal drug and monocytes has not 
been incorporated in the PK model of these agents.  
As monocytes of the MPS play an important role in the PK disposition of liposomes, 
the monocytopenia after administration of PEGylated liposomal anticancer agents was 
selected as a PD measure of these agents in this study. Monocytopenia is commonly 
observed after chemotherapy as a result of myelosuppression and early monocytopenia was 
reported to be a predictor of neutropenia (32, 33). The results of our prior study suggest that 
monocytes are more sensitive to S-CKD602 as compared with neutrophils and that the 
increased sensitivity is related to the liposomal formulation and not the encapsulated CKD-
602 (19). Therefore, the monocytopenia after administration of PEGylated liposomal agents 
have a different mechanism from monocytopenia resulted from treatment with conventional 
small molecule chemotherapeutic drugs. Incorporation of the bi-directional interaction 
between PEGylated liposomal formulation and monocytes are important to characterize the 
PK and PD of these agents.  
 171 
Although a few physiologically based PD models of chemotherapy-induced anemia, 
neutropenia, and thrombocytopenia have been developed, PD models of monocytopenia 
especially as related to nanoparticle PK and PD have not been reported (34-38). As 
monocytes are derived from the same granulocyte-macrophage progenitor cells as other 
leukocytes, PD models of leukocytopenia may be applicable to monocytopenia. As we only 
have relatively sparse PD data of monocytopenia, a semiphysiological model proposed by 
Friberg et al. for chemotherapy-related myelosuppression was chosen as a standard model to 
describe monocytopenia after S-CKD602 (34, 35). In this model, the cell maturation 
associated with myelopoiesis is described by multiple transit compartments with the same 
rate constant between each compartment to account for the time delay for onset of response 
(34, 35). In addition, a feedback loop was included to account for rebound of leukocytes 
typically observed in myelosuppression profiles. This model has been widely applied to 
various anticancer agents to describe neutropenia, leukocytopenia, and thrombocytopenia 
because it involves minimum number of parameters (28, 35, 39-42).  
The clinical results of the phase I and PK study of S-CKD602 were previously 
published (43, 44).  PK study of S-CKD602 using conventional compartment model have 
also been published (22). Monocytopenia after chemotherapy are conventionally believed 
due to myelosuppression. However, it is unclear if the monocytopenia is due to direct 
cytotoxicity to monocytes in the blood or cytotoxicity to progenitor cells in bone marrow. 
We believe the bi-directional interaction between PEGylated liposomal anticancer drugs and 
monocytes are more important to characterize the monocytopenia after these agents and PK 
of these agents. The objectives of this study were to develop a mechanism-based population 
PK-PD model to investigate the nature of nonlinear PK of S-CKD602 and to increase our 
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understanding of the bi-directional interaction between PEGylated liposomal anticancer 
agents and monocytes in blood of cancer patients.  
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B. METHODS 
Study Design 
The PK data were obtained from a phase I study of S-CKD602 in patients with 
advanced solid tumors (22, 45). The study design and clinical results have been reported 
elsewhere (22, 45). Forty-five patients (21 males) received S-CKD602 at 0.1 to 2.5 mg/m
2
 IV 
x 1 over approximately 1 hour every 3 weeks.  No pre-medications were administered prior 
to S-CKD602.  Written informed consent, approved by the Institutional Review board of the 
University of Pittsburgh Medical Center, was obtained from all patients prior to study entry. 
All other eligibility criteria were previously reported (22). Serial plasma samples were 
obtained prior to drug administration; at the end of the infusion (lasting ~ 1h); and at 3, 5, 7, 
24, 48, 72, 96, 168 (day 8), and 336 h (day 15) after the start of the infusion. Total (lactone + 
hydroxyl acid) concentrations of encapsulated and released CKD-602 in plasma were 
determined by liquid chromatography-tandem mass spectrometry (46).  The lower limit of 
quantitation (LLQ) of the total form encapsulated and released CKD-602 were 2 and 0.05 
ng/mL, respectively. Samples of peripheral blood were collected before dosing on days 7, 14, 
21, and 28.  
 
Population PK-PD Analysis  
Model Development  
We believe that the bi-directional interaction between PEGylated liposomal 
anticancer agents and monocytes plays the key role in the elimination of PEGylated 
liposomal anticancer agents and monocytopenia observed in our prior studies (19). We 
developed a mechanism-based model based on receptor binding kinetics to describe the bi-
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directional interaction between the concentration versus time profile of encapsulated CKD-
602 and time course of monocytes. We also developed a myelosuppression-based model in 
absence of the bi-directional interaction to compare with the mechanism-based model. For 
each kind of model, a variety of model structures were tested.  The best model was selected 
on the basis of smaller values of AIC, better precision of estimates, and superior goodness-
of-fit plots (47). 
 
Model I. Myelosuppression-based Model 
The PK-PD model of encapsulated CKD-602 and monocytes was built sequentially. 
One compartment model with Michaelis-Menten kinetics best described the PK data of 
encapsulated CKD-602 in our previous analysis. The individual PK parameters of 
encapsulated CKD-602 determined from the best PK model of encapsulated CKD-602 were 
used in the PD model of monocytes. In the PK modeling part, PK parameters (Vencap, Vmax, 
and Km) were estimated for each individual. For the PD modeling of monocytopenia, all of 
the individual values of the PK parameters were fixed for each patient and the predicted 
individual encapsulated CKD-602 concentrations-time profiles were used as input functions 
into this PK-PD model. The PD parameters were simultaneously estimated in the PD 
modeling part. This sequential modeling approach was selected over a simultaneous PK-PD 
estimation to expedite the PD modeling by using the existing individual estimates of PK 
parameters. 
A chemotherapy-induced myelosuppression model developed by Friberg et al. was 
used to describe the monocytopenia after administration of S-CKD602 (Figure 6.1A) (35). 
The model consists of a proliferating compartment (Prol) that represents progenitor cells, 
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three transit compartments of maturing cells (Transit), and a compartment of circulating 
monocytes. A negative feedback mechanism (MONO0/MONO)
γ
 from circulating cells on 
proliferating cells is included to describe the rebound of cells including an overshoot 
compared to the baseline value (MONO0). The drug concentration in plasma of the central 
compartment (Conc) is assumed to reduce the proliferation rate by the function EDrug, which 
was modeled to be an Emax model, [Emax x Conc/(EC50 + Conc)]. The differential equations 
were written as 
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dAEncap/dt  is the elimination rate, Vmax is the maximum elimination rate or maximum 
velocity, Km is the concentration at which half-maximum elimination rate is achieved, VEncap 
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is the volume of distribution, AEncap is encapsulated CKD-602 amount in plasma, CEncap is the 
plasma concentration of encapsulated CKD-602, k0 is the infusion rate and k0 is 0 after stop 
of infusion, ktr is the transit rate constant, Emax is the maximum attainable effect, EC50 is the 
concentration producing 50% of Emax, Mono0 is the baseline monocyte count, γ is the 
feedback constant, ktr is the proliferation rate constant, kmono is the removal rate constant of 
monocyte, Mono is the monocyte count. The drug concentration in the central compartment 
(Conc) is assumed to reduce the proliferation rate by the function EDrug, which was modeled 
using an Emax model. In the transit compartments, it is assumed that the only loss of cells is 
into the next compartment. As the proliferative cells differentiate into more mature cell types, 
the concentration of cells is maintained by cell division. At steady state, dProl/d t = 0, and 
therefore kprol = ktr. To minimize the number of parameters to be estimated, it was assumed in 
the modeling that kmono = ktr. Thus, the structural model parameters to be estimated were 
Mono0, ktr, γ, Emax and EC50.  
 
Model II. Mechanism-based PK-PD Model 
A mechanism based PK-PD model that incorporates the interaction between 
PEGylated liposomal anticancer agents and monocytes was developed for S-CKD602 
(Figure 6.1B). Concentration versus time data of encapsulated CKD-602 in plasma and 
monocyte count in blood were fit simultaneously by this model. Drug is dosed IV into the 
systemic circulation (blood compartment) at a zero-order rate (k0). The distribution of 
PEGylated liposome is described by a one-compartment model and the PEGylated liposome 
is eliminated by interacting with monocyte to form liposome-monocyte complex (kon) which 
represents the phagocytosis of S-CKD602 by the monocyte. PEGylated liposome is also 
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degraded at a first-order rate (kdeg). This represents the elimination of the liposome through 
routes other than uptake by monocytes. The parameters describing the production and loss of 
monocytes are kin and kout. The production rate of monocytes kin is equal to kout multiplied by 
baseline monocyte value. The differential equations were written as 
0  (0)A  ,    
Encapdeg0
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dt
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dAEncap/dt  is the elimination rate, AEncap is encapsulated CKD-602 amount in plasma, CEncap 
is the plasma concentration of encapsulated CKD-602, VEncap is the volume of distribution of 
encapsulated CKD-602, Mono is the monocyte count, kon is the association rate constant, kdeg 
is the degradation rate constant of S-CKD602, kout is the removal rate constant of monocyte, 
k0 is the infusion rate and k0 = 0 after stop of infusion. Since the unit of encapsulated CKD-
602 is μg/L and the unit of monocyte count is 109/L, the factor is a parameter (Factor) used to 
bridge the unit gap.  
 
Data Analysis 
 Encapsulated CKD-602 concentration versus time profile and monocyte count versus 
time data were analyzed using the nonlinear mixed effects modeling approach as 
implemented in NONMEM (version 6; University of California, San Francisco, CA) for the 
mechanistic and myelosuppression based models.  The first order conditional estimation 
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(FOCE) method were used in analyses.  S-PLUS 8.0 (Version 8.0, Insightful Corporation, 
Seattle, Washington) was used for graphical diagnostics.  
 Mean population PK-PD variables, interindividual variability, and residual error were 
assessed in the model development (48, 49). Interindividual variability for each PK-PD 
variable was modeled with an exponential function. Residual error models of the additive, 
proportional, exponential, and combination methods were evaluated for the best structural 
PK-PD model. Individual PK-PD variables were obtained by posterior Bayesian estimation 
(48, 49). Model selection for nonhierarchical models (i.e., linear and nonlinear elimination 
models) was guided by goodness-of-fit plots (e.g., observed versus predicted plasma 
concentrations, weighted residuals versus predicted concentrations, and weighted residuals 
versus time), Akaike information criterion (AIC), and precision of parameter estimates. AIC 
was calculated as AIC = OFV + 2 x p, where OFV is the NONMEM objective function value 
and p is the number of PK-PD variables.  
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C. RESULTS 
Patient demographics 
 Forty-five patients were enrolled on this study from September 29, 2003 to October 
17, 2005 at University of Pittsburgh Cancer Institute, Pittsburgh, PA.  Plasma concentrations 
of encapsulated CKD-602 and monocyte counts were obtained from 45 patients.  Patient 
characteristics are listed in Table 6.1.  The numbers of male and female patients evaluated in 
the phase I study were 21 and 24, respectively.  The mean (median, range) age of the patients 
was 60.6 years (62 years, 33 to 79 years).  A total of 292 plasma concentrations of 
encapsulated CKD-602 and 123 monocyte counts were used to develop the population PK-
PD model. The mean ± SD numbers of concentrations of encapsulated CKD-602 and 
monocyte counts per patient were 6.5 ± 2.3 and 4.9 ± 2.7, respectively. 
 
Model I. Myelosuppression-based Model 
The encapsulated CKD-602 and monocytes were modeled sequentially for all 
patients. The distribution of residual variability was best described by a proportional error 
model.  The PK and PD parameter estimates obtained from the final model are provided in 
Table 6.2.  In the final model, the mean and interindividual variability (IIV, CV%) values for 
the distribution volume of encapsulated CKD-602 (Vencap) was 3.46 L and 78.6%, 
respectively.  The estimated Vencap was very close to plasma volume in humans.  The mean 
Michaelis-Menten constant (Km) was estimated to be 877 μg/L. The maximum velocity 
(Vmax) of encapsulated CKD-602 was estimated to be 95.5 (IIV 234%) μg/h. The mean 
transit compartment rate constant (ktr) was estimated to be 0.0774 h
-1
. The mean maximum 
inhibition effect was estimated to be 0.64. The inhibition constant (EC50) of S-CKD602 was 
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estimated to be 355 (IIV 146%) μg/L. The baseline monocyte value was estimated to be 
0.605 (IIV 35.5%) x10
9
/L. The mean feedback constant was estimated to be 0.0955. 
 Goodness-of-fit plots from the myelosuppression-based PK-PD model in all patients 
are depicted in Figure 6.2.  The model adequately describes the PK profile of encapsulated 
CKD-602.  The observed PK data correlated well with the population predicted (R
2
 = 0.80) 
and individual predicted (R
2
 = 0.98) data by this model. Although the PD data of monocytes 
were variable, the observed and model predicted data agreed relatively well.  The observed 
PD data better correlated with the individual predicted PD data (R
2
 = 0.83) than population 
predicted PD data (R
2
 = 0.43).  The representative individual PK profiles of encapsulated 
CKD-602 and time course of monocytopenia in patients are shown in Figure 6.3.  The 
observed data of encapsulated CKD-602 and monocytes were well described by the 
myelosuppression-based model.   
 
Model II. Mechanism-based PK-PD Model 
The encapsulated CKD-602 and monocytes were modeled simultaneously for all 
patients. The distribution of residual variability was best described by a proportional plus 
additive error model.  The PK-PD parameter estimates obtained from the final model are 
provided in Table 6.3.  The volume of distribution (Vencap) was estimated to be 4.1 L (IIV 
58.9%).  The estimated Vencap is close to the plasma volume in humans. The mean association 
rate constant (kon) was estimated to be 1.9 L∙h
-1
. The degradation rate constant (kdeg) of S-
CKD602 was estimated to be 0.0178 (IIV 50.6%) h
-1
. The baseline monocyte value was 
estimated to be 0.671 (IIV 29.9%) x10
9
/L. The removal rate constant (kout) of monocytes was 
estimated to be 0.00677 (IIV 3.5%) h
-1
.  The adjusting factor was estimated to be 382 μg/109. 
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 Goodness-of-fit plots from the mechanism-based PK-PD model in all patients are 
given in Figure 6.4.  Similar to myelosuppression-based model, the population-predicted and 
individual-predicted encapsulated CKD-602 concentrations were highly correlated with the 
observed values and the observed and model predicted data agreed relatively well.  The 
representative individual PK profiles of encapsulated CKD-602 and time course of 
monocytopenia in patients are shown in Figure 6.5.  The observed data of encapsulated 
CKD-602 concentration and monocytes were well described by the mechanism-based model.   
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D. DISCUSSION 
Major advances in the use of liposomes, conjugates, and nanoparticles as vehicles to 
deliver drugs have occurred the past 10 years (3-5).  Doxil
®
 and albumin stabilized 
nanoparticle formulation of paclitaxel (Abraxane
®
) are now FDA approved (6, 7, 50).  In 
addition, there are greater than 200 liposomal and nanoparticle formulations of anticancer 
agents currently in development (3).  Despite these fast development, one key hurdle 
preventing the wider success of liposome-based therapeutics is the complexity in PK and PD 
of liposomal agents in humans.  Evaluation of the relationship of liposomal drug PK and PD 
and monocytes is of the utmost importance because the nonlinear PK of liposomal drug may 
be explained by the saturation of MPS and the bi-directional interaction between liposomal 
drugs and monocytes. 
We developed a fully integrated mechanism-based population PK/PD model that 
described the relationship between PEGylated liposomal anticancer drug and monocyte in 
cancer patients treated with S-CKD602, a PEGylated liposomal CKD-602.  In this model, an 
irreversible binding of liposomal drug to monocyte was used to account for the bi-directional 
interaction between PEGylated liposomal anticancer drug and monocyte. This model 
adequately described the observed clinical data, as illustrated in Figs. 4, 5 and Table 6.3. To 
our knowledge, this is the first mechanism-based model that includes the bi-directional 
interaction between PEGylated liposomal anticancer drug and monocytes for PEGylated 
liposomal anticancer drug in cancer patients. 
In the mechanism-based model, the mean value of volume of distribution for 
encapsulated CKD-602 (Vencap) was 4.1 L and is close to plasma volume in humans.  The 
estimated volume of distribution is consistent with our prior PK study of S-CKD602, in 
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which Vencap for patients with nonlinear clearance of encapsulated CKD-602 was estimated to 
be 2.1 ± 0.7 L/m
2
 (22).  In addition, the limited volume of distribution of encapsulated CKD-
602 is consistent with other liposomal anticancer agents as the size of liposome limited their 
distribution to the normal tissue (20, 51).  The half life of monocytes was estimated to be 102 
hours, which is close but longer than the reported half life of monocytes in healthy human 
(mean 72 hours, range 36 – 104 hours) (52, 53). This discrepancy might be explained by the 
limited number of PD data and lack of information about removal rate constant in the data. In 
this model, S-CKD602 was eliminated via uptake by monocytes (as represented by 
kon•AEncap•Mono) and linear degradation (as represented by kdeg•AEncap). The association rate 
constant for uptake by monocytes (1.9 L∙h-1) is much greater than the estimated degradation 
rate constant of S-CKD602 (0.0178 h
-1
).  This suggests the importance of the uptake of 
liposomal drugs by monocyte in blood in determining the elimination of S-CKD602 from the 
central compartment.  
The adjusting factor was introduced to the mechanism-based model to bridge the unit 
gap between amount of PEGylated liposomal drug and monocyte count. In our study, we 
have the monocyte absolute count data in unit of number of cells per liter and encapsulated 
CKD-602 amount in microgram.  As the liposome interacts with monocyte via the receptor 
on the cell surface and the monocyte count is not equal to the concentration of receptors, it is 
not appropriate to convert the monocyte count data using molar unit. Therefore, we need this 
adjusting factor to address this issue in the model. We performed modeling on the data with 
encapsulated CKD-602 amount in microgram and in moles separately.  The results from 
these two different data sets did not show much difference.   
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The degradation of liposome through route other than uptake by monocytes as 
represented by kdeg was important in the mechanism-based model. We tested the model with 
and without kdeg and deletion of kdeg from the final mechanism-based model resulted in an 
increase in AIC of 86. It is known that the primary accumulation sites of liposomes are liver 
and spleen and liposomes may be cleared by other phagocytes on sites (eg. Kupffer cells) 
(54, 55).  Therefore, the contribution of other routes is also very important to PK of S-
CKD602. 
In the myelosuppression-based model, the estimated mean values of volume of 
distribution for encapsulated CKD-602 (3.46 L) is close to the estimates from mechanism-
based model and consistent with other liposomal anticancer.  The half-life of monocytes 
calculated as 0.693/ktr was estimated to be 9.0 hours, which is much shorter than the half-life 
of monocytes estimated from the mechanism-based model and the reported value from 
literature. This may be due to direct cytotoxicity of liposomes on monocytes in blood. This 
may also be explained by the different structures between these two models. The 
myelosuppression-based model incorporated three transit compartments and the rate constant 
between each compartment was same and equal to the removal rate constant of monocytes 
from blood circulation. Thus, the offset of the toxic effect on monocyte was counted by three 
transit compartments in the myelosuppression-based model, whereas, it was counted by one 
step in the mechanism-based model.  
The decrease in monocyte following PEGylated liposomal anticancer agents can be 
explained by the bi-directional interaction between PEGylated liposomal anticancer agents 
and monocytes or chemotherapy induced monocytopenia as described in our mechanism-
based model and myelosuppression model. We developed a mechanism-based PK-PD model 
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based on the bi-directional interaction between PEGylated liposomal anticancer agents and 
monocytes. Meanwhile, to account for chemotherapy induced myelosuppression, we used a 
myelosuppression-based PK-PD model which has been frequently used to describe 
neutropenia or leukocytopenia after chemotherapy. Although monocytes and neutrophils 
have different morphology and functions, both of them are phagocytes and they are derived 
from the same progenitor cells following similar procedure. To test our hypothesis, we 
compared the model fit of the mechanism-based and the myelosuppression-based PK-PD 
model.   
The population prediction of PK data obtained from mechanism-based model had a 
higher correlation with the observed PK data compared to that from myelosuppression-based 
model. This may suggest that incorporation of bi-directional interaction between PEGylated 
liposomal anticancer agents and monocytes in the model helped to explain the interindividual 
variability in the PK of S-CKD602. Although the individual prediction of PK data from 
mechanism-based model was more accurate than that from myelosuppression-based model, 
the population prediction of PK data from mechanism-based model was lower than the 
observed PK data at higher concentration level. This may suggest that the degradation of S-
CKD602 through other routes was saturated at high concentration levels. Overall, both of 
these two models adequately described the PK data. 
Both of the mechanism-based and myelosuppression-based PK-PD models described 
the observed PD data of monocytopenia relatively well. This suggests that both the 
chemotherapy induced myelosuppression and the bi-directional interaction between 
PEGylated liposomal anticancer agents and monocytes are important to describe the PD 
profile of monocytes after administration of S-CKD602. However, these two models 
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predicted two different time courses of monocyte count change after administration of S-
CKD602. The myelosuppression-based model predicted a day of nadir around the observed 
day of nadir whereas the mechanism-based model predicted an earlier day of nadir compared 
to the observed. As no monocyte count was collected at the earlier time after administration 
of S-CKD602, the exact monocyte profile at earlier time points needs to be determined in 
future studies. PD profile of monocytes reached nadir at 2 days after administration of 
liposomal alendonate in rats (56). The half-life of monocytes in rats is about 2 days, which is 
similar to the reported half-life of monocytes in human (52, 53). The PD profile of 
monocytopenia after administration of liposomal alendonate suggested that the day of 
monocyte nadir after administration of S-CKD602 may be earlier than the observed value 
(8.6 ± 3.3 days). Thus, cytotoxic effects in blood and in bone marrow explain the decrease in 
monocytes after administration of PEGylated liposomal anticancer agents. 
The individual predicted value of monocyte counts from myelosuppression-based 
model showed higher correlation with observed monocyte counts compared to mechanism-
based model. The mechanism-based model overestimated monocyte count at lower monocyte 
count and underestimated monocyte count at higher monocyte count compared to 
myelosuppression-based model. This may be explained by the absence of feedback loop in 
the mechanism-based model. We tested the myelosuppression-based model without the 
feedback loop which produced a more serious overestimation monocyte count at lower 
monocyte count and underestimation of monocyte count at higher monocyte count than 
mechanism-based model (data not shown). The feedback loop was incorporated in 
myelosuppression-based model to describe leukocytopenia and neutropenia because it is 
known that the proliferation rate of progenitor cells can be affected by endogenous growth 
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factors and cytokines and that circulating neutrophil counts and the growth factor G-CSF 
levels are inversely related (35, 57, 58). No feedback mechanism has been reported for 
monocytes. The better PD fit of myelosuppression-based model suggest that feedback loop 
may be applicable for monocytes. However, the addition of feedback loop to the developed 
mechanism-based model did not improve the PD fits.  
In conclusion, a mechanism-based PK-PD model was developed for encapsulated 
CKD-602 and monocyte counts in patients with advanced solid tumors.  Comparison of this 
model and the myelosuppression-based model helped to explain PK and PD of PEGylated 
liposomal anticancer agents. The developed mechanism-based PK-PD model may be useful 
in predicting the PK and optimize dosing of pegylated liposomal agents to achieve a target 
exposure for each patient with malignant diseases.  This model could also be used to describe 
the bi-directional interaction between PK and monocytes for other nanoparticle and 
conjugated anticancer agents as a method to profile and classify these agents. 
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Table 6.1. 
 
A summary of Patient Demographics 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
Characteristics 
 
 
 
 
Number of 
patients 
 
Mean  SD 
 
Median 
(Range) 
Age (years)  60.6  12.2 62 (33.– 79) 
Body Surface Area (m2)  1.91  0.30 1.86 (1.36 – 2.76) 
Body Weight (kg)  78.7  21.4 75.5 (44.0 – 148) 
Body Mass Index 
(kg/m2) 
 27.4  5.60 26.7 (18.8 – 45.7) 
Creatinine Clearance 
(ml/min) 
 98.4  46.6 84.7 (33.2 – 277) 
Height (cm)  169  11.9 170 (142 – 196) 
Ratio of Body Weight to 
Ideal Body Weight 
 1.27  0.28 1.22 (0.83 – 2.13) 
Sex
 
   
    Male 24   
    Female 21   
Primary tumor type    
Colorectal            
Adenocarcinoma  
17   
    Ovarian Cancer 5   
    Sarcoma 5   
Non-Small Cell Lung     
Cancer 
4   
Pancreatic  
Adenocarcinoma  
3   
Hepatocellular  
Carcinoma 
2   
    Prostate Carcinoma 2   
Esophageal, Metastatic  
Breast,  Mesothelioma,  
Renal Cell Carcinoma,  
Thyroid, Appendix,  
Unknown Primary 
1 patient 
for each 
type 
  
Patients with Tumors in 
liver 
26   
Patients without tumors 
in liver 
19   
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Table 6.2. 
 
Population PK-PD Parameters Obtained From the Myelosuppression-Based Model for 
Encapsulated CKD-602 and Monocytes. 
 
Parameter Definition Population Mean 
RSE
a
 (%) 
IIV, CV%
b
  
RSE
a
 (%) 
VEncap (L) Volume of distribution for 
encapsulated CKD-602 
3.46 (7.8) 70.9 (43) 
Vmax (μg/h) Maximum velocity of 
encapsulated CKD-602 
95.5 (31) 234 (34) 
km (μg/L) Michaelis-Menten constant 877 (21) NE (NA) 
Mono0 (10
9
/L)  Baseline monocyte count 0.605 (14) 35.5 (43) 
ktr (1/h) Transit rate constant 0.0774 (7.7) NE (NA) 
Emax Maximum inhibition 0.64 (31) NE (NA) 
EC50 (μg/L)  Inhibition constant 355 (60) 146 (80) 
γ Feedback constant 0.0955 (12) NE (NA) 
Residual variability 
Proportional error (variability as %) 
Encapsulated CKD-602 
Monocytes 
 
13.3 % (52) 
37.3% (36) 
 
NA
c
 
NA
c
 
Additive error 
Encapsulated CKD-602 (μg/L) 
Monocytes (10
9
/L) 
 
8.66 (54) 
NE (NA) 
 
NA
c 
NA
c
 
 
a
 Relative standard error for estimate. 
b
 Coefficient of variation.  
c Not estimated. 
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Table 6.3. 
 
Population PK-PD Parameters Obtained From the Mechanism-Based Model for 
Encapsulated CKD-602 and Monocytes. 
 
Parameter Definition Population Mean 
RSE
a
 (%) 
IIV, CV%
b
  
RSE
a
 (%) 
VEncap (L) Volume of distribution for 
encapsulated CKD-602 
4.10 (11) 58.9 (35) 
kon (L/h) Association rate constant 1.9 (47) 16.9 (75) 
kdeg (1/h) Degradation rate constant of S-
CKD602 
0.0178 (28) 50.6 (42) 
Mono0 (10
9
/L)  Baseline monocyte count 0.671 (7.7) 29.9 (45) 
kout (1/h) Removal rate constant of 
monocyte 
0.00677 (18) 3.5 (195) 
Factor (μg/109) Adjusting factor 382 (34) 99.3 (89) 
Residual variability 
Proportional error (variability as %) 
Encapsulated CKD-602 
Monocytes 
 
19.3 % (45) 
10.2 % (48) 
 
NA
c
 
NA
c
 
Additive error 
Encapsulated CKD-602 (μg/L) 
Monocytes (10
9
/L) 
 
9.02 (42) 
0.0471 (30) 
 
NA
c 
NA
c
 
 
a
 Relative standard error for estimate. 
b
 Coefficient of variation.  
c Not estimated. 
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Figure 6.1. The myelosuppression-based PK-PD model for (A) and the mechanism-based 
PK-PD model (B) for encapsulated CKD-602 and monocytes. 
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Figure 6.2. Goodness-of-fit plots for the myelosuppression-based model of encapsulated 
CKD-602 and monocytes.  The solid lines are lines of identity. 
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Figure 6.3. Representative individual plots of observed (○) and individual predicted (―) 
values from myelosuppression-based model for the plasma concentrations of encapsulated 
CKD-602 and monocyte count in all patients.  
 
 199 
 
Figure 6.4. Goodness-of-fit plots for the mechanism-based model of encapsulated CKD-602 
and monocytes.  The solid lines are lines of identity. 
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Figure 6.5. Representative individual plots of observed (○) and individual predicted (―) 
values from mechanism-based model for the plasma concentrations of encapsulated CKD-
602 and monocyte counts in all patients. 
  
 
CHAPTER 7 
 
 
MECHANISM-BASED PHARMACOKINETIC-
PHARMACODYNAMIC MODEL CHARACTERIZING BI-
DIRECTIONAL INTERACTION BETWEEN PEGYLATED 
LIPOSOMAL CPT-11 (IHL-305) AND MONOCYTES IN 
PATIENTS WITH ADVANCED MALIGNANCIES 
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A. INTRODUCTION 
Liposomes (microparticulate phospholipid vesicles) have been used with growing 
success as pharmaceutical carriers for anticancer agents. Conventional liposomes are quickly 
opsonized by plasma proteins, recognized as foreign bodies, and rapidly removed by the 
mononuclear phagocytic system (MPS) which has also been called the reticuloendothelial 
system (RES) (1, 2).  The development of STEALTH or Polyethylene Glycol (PEG)ylated 
liposomes was based on the discovery that incorporation of mPEG-lipids into liposomes 
yields preparations with prolonged plasma exposure and superior tumor delivery compared to 
conventional liposomes composed of natural phospholipids (3-5).  PEGylated liposomal 
doxorubicin (Doxil®) is approved for the treatment of refractory ovarian cancer, Kaposi 
sarcoma, and multiple myeloma (6, 7).   
IHL-305 is a PEGylated liposomal formulation of irinotecan (CPT-11), a 
camptothecin analogue which inhibits topoisomerase I and has been approved for the 
treatment of metastatic colorectal cancer (3, 8-10). The PEGylated liposomal formulation 
consists of phospholipids covalently bound to polyethylene glycol (PEG) only on the outside 
of the lipid bilayer.  CPT-11 is a prodrug that requires activation to the active metabolite, 7-
ethyl-10-hydroxy-camptothecin (SN-38), which is approximately 100- to 1000-fold more 
active than the parent drug. SN-38 is further conjugated to form an inactive glucuronide (SN-
38G) by uridine diphosphate glucuronosyltransferases (UGTs), primarily the UGT1A1 
isoform. Other identified CPT-11 metabolites are 7-ethyl-10-[4-N-(5-aminopentanoic acid)-
1-piperidino]-carbonyloxycamptothecin (APC) and 7-ethyl-10-[4-amino-1-piperidino]-
carbonyloxycamptothecin (NPC) (10, 11).  
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The PEGylated liposomes of Doxil and IHL-305 were made using two different 
methods. The PEGylated liposome of Doxil was made by adding the PEG lipid before the 
process of liposomal formation which results PEG tether being projected on both the inside 
and outside of liposome.  The PEGylated liposome of IHL-305 is made by adding the PEG 
lipids after the process of liposomal formation which results in PEG tether only being 
localized on the outer leaflet (12). Encapsulation of the CPT-11 allow for release of the 
active-lactone form into the tumor over a protracted period of time, which is ideal for a cell 
cycle-specific drug (3, 8-10, 13, 14).   
The pharmacokinetic (PK) disposition of carrier-mediated agents, such as, 
nanoparticles, nanosomes, and conjugated agents, is dependent upon the carrier until the drug 
is released from the carrier.  Unlike traditional anticancer agents which are cleared by the 
liver and kidneys, the clearance of non-PEGylated and PEGylated liposomes is via MPS 
which include monocytes, macrophages and dendritic cells located primarily in the liver and 
spleen (2).  PEGylated liposomes are cleared much slower via MPS compared to non-
PEGylated liposomes (4, 15).  Uptake of the liposomes or nanoparticles by the MPS usually 
results in sequestering of the encapsulated drug in the MPS and the sequestered drug in the 
MPS may cause acute cytotoxicity to the MPS. This toxicity to the MPS in turn decreases 
clearance of the PEGylated liposomal anticancer agents and alters the PK and 
pharmacodynamics (PD) of PEGylated liposomal anticancer agents. Thus, there is a bi-
directional interaction between PEGylated liposomal anticancer agents and MPS.  Since a 
major portion of the liposomal encapsulated drug molecules are confined primarily to the 
blood compartment due to their relative large size (16), we have reported that there is a 
significant and clinically relevant interaction between liposomal agents and MPS cells in the 
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blood circulation (15). This bi-directional interaction between PEGylated liposomal 
anticancer agents and monocytes is very important in determining the PK and PD of 
PEGylated liposomal anticancer agents and potentially other nano and conjugated agents.  
Clinical PK analysis of Doxil suggests a dose-dependent clearance saturation of 
clearance when a broad dose range is examined (17). Non-linear clearance was also observed 
in a phase I PK study of S-CKD602 (18).  In addition, Gabizon and colleagues reported that 
the clearance of sum total (encapsulated + released) doxorubicin decreased by approximately 
25 to 50% from cycle 1 to 3 (15, 19).  We reported that this reduction in clearance of Doxil® 
from cycle 1 to cycle 3 was associated with a reduction in pre-cycle monocyte count  (20).  
We have also reported that high % decrease in monocytes was associated with high clearance 
of IHL-305 (21). These studies suggest that the dose-dependent and cycle-dependent 
clearance of PEGylated liposomal anticancer agents may due to the bi-directional interaction 
between PEGylated liposomal drug and monocytes in blood.  
The PK of PEGylated liposomal anticancer agents and Non-PEGylated liposomal 
anticancer agents in humans have been studied using the population modeling approach (22-
27). Conventional compartment models such as one-compartment and two-compartment 
models were commonly used in these PK studies (22-27).  The dose-dependent clearance of 
PEGylated liposomal anticancer agents was modeled using Michaelis-Menten kinetics (26). 
Mechanistic models based on physiology and pharmacology generally are more reliable for 
prediction of PK and PD than empirical models. Mechanistic PD models have been reported 
for neutropenia (28, 29). However, to date, mechanism-based models have not been 
developed for the PK and PD of PEGylated liposomal anticancer agents.    
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As monocytes of the MPS play an important role in the PK disposition of liposomes, 
the monocytopenia after administration of PEGylated liposomal anticancer agents was 
selected as a PD measure of these agents in this study. Monocytopenia is commonly 
observed after chemotherapy as a result of myelosuppression and early monocytopenia was 
reported to be a predictor of neutropenia (30, 31). The results of our prior study suggest that 
monocytes are more sensitive to S-CKD602 as compared with neutrophils and that the 
increased sensitivity is related to the liposomal formulation and not the encapsulated CKD-
602 (15). Therefore, the monocytopenia after administration of PEGylated liposomal agents 
have a different mechanism from monocytopenia resulted from treatment with conventional 
small molecule chemotherapeutic drugs. Incorporation of the bi-directional interaction 
between PEGylated liposomal formulation and monocytes are important to characterize the 
PK and PD of these agents.  
Although a few physiologically based PD models of chemotherapy-induced anemia, 
neutropenia, and thrombocytopenia have been developed, PD models of monocytopenia 
especially as related to nanoparticle PK and PD have not been reported (28, 32-35). As 
monocytes are derived from the same granulocyte-macrophage progenitor cells as other 
leukocytes, PD models of leukocytopenia may be applicable to monocytopenia. As we only 
have relatively sparse PD data of monocytopenia, a semiphysiological model proposed by 
Friberg et al. for chemotherapy-related myelosuppression was chosen as a standard model to 
describe monocytopenia after IHL-305 (28, 32). In this model, the cell maturation associated 
with myelopoiesis is described by multiple transit compartments with the same rate constant 
between each compartment to account for the time delay for onset of response (28, 32). In 
addition, a feedback loop was included to account for rebound of leukocytes typically 
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observed in myelosuppression profiles. This model has been widely applied to various 
anticancer agents to describe neutropenia, leukocytopenia, and thrombocytopenia because it 
involves minimum number of parameters (24, 28, 36-39).  
The clinical results of the phase I study and limited PK results were previously 
published (40).  The PK variability of IHL-305 is associated with linear and non-linear 
clearance (21). Monocytopenia after chemotherapy are conventionally believed due to 
myelosuppression. However, it is unclear if the monocytopenia is due to direct cytotoxicity 
to monocytes in the blood or cytotoxicity to progenitor cells in bone marrow. We believe the 
bi-directional interaction between PEGylated liposomal anticancer drugs and monocytes are 
more important to characterize the monocytopenia after these agents and PK of these agents. 
The objectives of this study were to develop a mechanism-based population PK-PD model to 
investigate the nature of nonlinear PK of IHL-305 and to increase our understanding of the 
bi-directional interaction between PEGylated liposomal anticancer agents and monocytes in 
blood of cancer patients. 
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B. METHODS 
Study Design 
The PK data were obtained from a phase I study of IHL-305 in patients with 
advanced solid tumors (40).  The study design and clinical results have been reported 
elsewhere (40). Thirty-nine patients (13 males) received IHL-305 at 3.5 to 210 mg/m
2
 IV x 1 
over approximately 1 hour every 4 weeks.  Prior to administration of the study drug, patients 
were premedicated with ondansetron (or other 5-HT3 inhibitor should circumstances require) 
and dexamethasone, according to each institution’s standard of care. Written informed 
consent, approved by the Institutional Review board of the Sarah Cannon Research Institute 
and Vanderbilt University Medical Center, was obtained from all patients prior to study 
entry. Serial plasma samples were obtained at the following times: prior to administration, at 
end of the infusion (approximately 1 h), and at 1.5 h , 2 h , 3 h , 5 h , 9 h , 13 h, and 25 h after 
the start of the infusion for patients treated at < 67 mg/m
2
 and the first three patients treated 
at 67 mg/m
2
. Additional samples at 49 h, 73 h, 97 h, 169 h (day 7), 192 h (day 8), and 216 h 
(day 9) after the start of the infusion were also collected for the last three patients treated at 
67 mg/m
2
 and patients treated at > 67 mg/m
2
. Total (lactone + hydroxyl acid) concentrations 
of sum total CPT-11, released CPT-11 and SN-38 in plasma were determined by a high-
performance liquid chromatography (HPLC) as previously described (41).  The lower limit 
of quantitation (LLQ) of the total form sum total CPT-11, released CPT-11 and SN-38 were 
100, 2 and 2 ng/mL, respectively.  Encapsulated CPT-11 was calculated by substracting the 
released CPT-11 concentration from sum total CPT-11 concentration at each time point. 
Complete blood counts were obtained weekly and as medically indicated.   
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Model Development  
We believe that the bi-directional interaction between PEGylated liposomal 
anticancer agents and monocytes plays the key role in the elimination of PEGylated 
liposomal anticancer agents and monocytopenia observed in our prior studies (15). We 
developed a mechanism-based model based on receptor binding kinetics to describe the bi-
directional interaction between the concentration versus time profile of encapsulated CPT-11 
and time course of monocytes. We also developed a myelosuppression-based model in 
absence of the bi-directional interaction to compare with the mechanism-based model. For 
each kind of model, a variety of model structures were tested.  The best model was selected 
on the basis of smaller values of AIC, better precision of estimates, and superior goodness-
of-fit plots (42). 
 
Model I. Myelosuppression-based Model 
The PK-PD model of encapsulated CPT-11 and monocytes was built sequentially. 
One compartment model with Michaelis-Menten kinetics best described the PK data of 
encapsulated CPT-11 in our previous analysis. The individual PK parameters of encapsulated 
CPT-11 determined from the best PK model of encapsulated CPT-11 were used in the PD 
model of monocytes. In the PK modeling part, PK parameters (Vencap, Vmax, and Km) were 
estimated for each individual. For the PD modeling of monocytopenia, all of the individual 
values of the PK parameters were fixed for each patient and the predicted individual 
encapsulated CPT-11 concentrations-time profiles were used as input functions into this PK-
PD model. The PD parameters were simultaneously estimated in the PD modeling part. This 
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sequential modeling approach was selected over a simultaneous PK-PD estimation to 
expedite the PD modeling by using the existing individual estimates of PK parameters. 
A chemotherapy-induced myelosuppression model developed by Friberg et al. was 
used to describe the monocytopenia after administration of IHL-305 (Figure 7.1A) (28). The 
model consists of a proliferating compartment (Prol) that represents progenitor cells, three 
transit compartments of maturing cells (Transit), and a compartment of circulating 
monocytes. A negative feedback mechanism (MONO0/MONO)
γ
 from circulating cells on 
proliferating cells is included to describe the rebound of cells including an overshoot 
compared to the baseline value (MONO0). The drug concentration in the central 
compartment (Conc) is assumed to reduce the proliferation rate by the function EDrug, which 
was modeled to be an Emax model, [Emax x Conc/(EC50 + Conc)]. The differential equations 
were written as 
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dAEncap/dt  is the elimination rate, Vmax is the maximum elimination rate or maximum 
velocity, Km is the concentration at which half-maximum elimination rate is achieved, VEncap 
is the volume of distribution, AEncap is the encapsulated CPT-11 amount in plasma, CEncap is 
the plasma concentration of encapsulated CPT-11, k0 is the infusion rate and k0 is 0 after stop 
of infusion, ktr is the transit rate constant, Emax is the maximum attainable effect, EC50 is the 
concentration producing 50% of Emax, Mono0 is the baseline monocyte count, γ is the 
feedback constant, ktr is the proliferation rate constant, kmono is the removal rate constant of 
monocyte, Mono is the monocyte count. The drug concentration in the central compartment 
(Conc) is assumed to reduce the proliferation rate by the function EDrug, which was modeled 
using an Emax model. In the transit compartments, it is assumed that the only loss of cells is 
into the next compartment. As the proliferative cells differentiate into more mature cell types, 
the concentration of cells is maintained by cell division. At steady state, dProl/d t = 0, and 
therefore kprol = ktr. To minimize the number of parameters to be estimated, it was assumed in 
the modeling that kmono = ktr. Thus, the structural model parameters to be estimated were 
Mono0, ktr, γ, Emax and EC50.  
 
Model II. Mechanism-based PK-PD Model 
A mechanism based PK-PD model that incorporates the interaction between 
PEGylated liposomal anticancer agents and monocytes was developed for IHL-305 (Figure 
7.1B). Concentration versus time data of encapsulated CPT-11 in plasma and monocyte 
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count in blood were fit simultaneously by this model. Drug is dosed IV into the systemic 
circulation (blood compartment) at a zero-order rate (k0). The distribution of PEGylated 
liposome is described by a one-compartment model and the PEGylated liposome is 
eliminated by interacting with monocyte to form liposome-monocyte complex (kon) which 
represents the phagocytosis of IHL-305 by the monocyte. PEGylated liposome is also 
degraded at a first-order rate (kdeg). This represents the elimination of the liposome through 
routes other than uptake by monocytes. The parameters describing the production and loss of 
monocytes are kin and kout. The production rate of monocytes kin is equal to kout multiplied by 
baseline monocyte value. The differential equations were written as 
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dAEncap/dt  is the elimination rate, AEncap is encapsulated CPT-11 amount in plasma, CEncap is 
the plasma concentration of encapsulated CPT-11, VEncap is the volume of distribution of 
encapsulated CPT-11, Mono is the monocyte count, kon is the association rate constant, kdeg is 
the degradation rate constant of IHL-305, kout is the removal rate constant of monocyte, k0 is 
the infusion rate and k0 is 0 after stop of infusion. Since the unit of encapsulated CPT-11 is 
mg/L and the unit of monocyte count is 10
9
/L, factor is a parameter used to bridge the unit 
gap.  
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Data Analysis 
 Encapsulated CPT-11 concentration versus time profile and monocyte count versus 
time data were analyzed using the nonlinear mixed effects modeling approach as 
implemented in NONMEM (version 6; University of California, San Francisco, CA) for the 
mechanistic and myelosuppression based models.  The first order conditional estimation 
(FOCE) method were used in analyses.  S-PLUS 8.0 (Version 8.0, Insightful Corporation, 
Seattle, Washington) was used for graphical diagnostics.  
 Mean population PK-PD variables, interindividual variability, and residual error were 
assessed in the model development (43, 44). Interindividual variability for each PK-PD 
variable was modeled with an exponential function. Residual error models of the additive, 
proportional, exponential, and combination methods were evaluated for the best structural 
PK-PD model. Individual PK-PD variables were obtained by posterior Bayesian estimation 
(43, 44). Model selection for nonhierarchical models (i.e., linear and nonlinear elimination 
models) was guided by goodness-of-fit plots (e.g., observed versus predicted plasma 
concentrations, weighted residuals versus predicted concentrations, and weighted residuals 
versus time), Akaike information criterion (AIC), and precision of parameter estimates. AIC 
was calculated as AIC = OFV + 2 x p, where OFV is the NONMEM objective function value 
and p is the number of PK-PD variables.  
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C. RESULTS 
Patient demographics 
 Forty-two patients were enrolled on this study from 14 December 2006 to 15 
December 2008 at Sarah Cannon Research Institute and Vanderbilt University Medical 
Center, Nashville, TN.  Plasma concentrations of encapsulated CPT-11 and monocyte counts 
were obtained from 39 patients.  Patient characteristics are listed in Table 7.1.  The numbers 
of male and female patients evaluated in the phase I study were 13 and 26, respectively.  The 
mean (median, range) age of the patients was 59.3 years (60 years, 41 to 75 years).  A total of 
392 plasma concentrations of encapsulated CPT-11 and 95 monocytes count were used to 
develop the population PK model. The mean ± SD numbers of concentrations of 
encapsulated CPT-11 and monocyte counts per patient were 10.1 ± 1.5 and 4.5 ± 1.6, 
respectively. 
 
Model I. Myelosuppression-based Model 
The encapsulated CPT-11 and monocytes were modeled sequentially for all patients. 
The distribution of residual variability was best described by a proportional plus additive 
error model.  The PK and PD parameter estimates obtained from the final model are provided 
in Table 7.2.  In the final model, the mean and interindividual variability (IIV, CV%) values 
for the distribution volume of encapsulated CPT-11 (Vencap) was 2.93 L and 27.9%, 
respectively.  The estimated Vencap was very close to the plasma volume in humans.  The 
mean Michaelis-Menten constant (Km) was estimated to be 103 mg/L. The maximum 
velocity (Vmax) of encapsulated CPT-11 was estimated to be 14.2 (IIV 41.8%) mg/h. The 
mean transit compartment rate constant (ktr) was estimated to be 0.0628 h
-1
. The mean 
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maximum inhibition effect was estimated to be 0.95. The inhibition constant (EC50) of IHL-
305 was estimated to be 21.3 (IIV 54%) mg/L. The baseline monocyte value was estimated 
to be 0.564 (IIV 34.9%) x10
9
/L. The mean feedback constant was estimated to be 0.319. 
 Goodness-of-fit plots from the myelosuppression-based PK-PD model in all patients 
are depicted in Figure 7.2.  The model adequately describes the PK profile of encapsulated 
CPT-11.  The observed PK data correlated well with the population predicted (R
2
 = 0.76) and 
individual predicted (R
2
 = 0.93) data by this model. Although the PD data of monocytes were 
variable, the observed and model predicted data agreed relatively well.  The observed PD 
data better correlated with the individual predicted PD data (R
2
 = 0.86) than population 
predicted PD data (R
2
 = 0.07).  The representative individual PK profiles of encapsulated 
CPT-11 and time course of monocytopenia in patients are shown in Figure 7.3.  The 
observed data of encapsulated CPT-11 and monocytes were well described by the 
myelosuppression-based model.   
 
Model II. Mechanism-based PK-PD Model 
The encapsulated CPT-11 and monocytes were modeled simultaneously for all 
patients. The distribution of residual variability was best described by a proportional plus 
additive error model.  The PK-PD parameter estimates obtained from the final model are 
provided in Table 7.3.  The volume of distribution (Vencap) was estimated to be 2.86 L (IIV 
27.4%).  The estimated Vencap was close to the plasma volume in humans. The mean 
association rate constant (kon) was estimated to be 0.00001 L∙h
-1
. The degradation rate 
constant (kdeg) of IHL-305 was estimated to be 0.0389 (IIV 23%) h
-1
. The baseline monocyte 
value was estimated to be 0.619 (IIV 33.8%) x10
9
/L. The removal rate constant (kout) of 
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monocytes was estimated to be 0.00487 (IIV 54.6%) h
-1
.  The adjusting factor was estimated 
to be 0.0358 mg∙L/109. 
 Goodness-of-fit plots from the mechanism-based PK-PD model in all patients are 
depicted in Figure 7.4.  The mechanism-based model adequately describes the PK profile of 
encapsulated CPT-11. The observed PK data correlated well with the population predicted 
(R
2
 = 0.77) and individual predicted (R
2
 = 0.94) data by this model. Although the PD data of 
monocytes were variable, the observed and model predicted data agreed relatively well.  The 
observed PD data better correlated with the individual predicted PD data (R
2
 = 0.86) than 
population predicted PD data (R
2
 = 0.07).  The representative individual PK profiles of 
encapsulated CPT-11 and time course of monocytopenia are shown in Figure 7.5.  The 
observed data of encapsulated CPT-11 and monocytes were well described by the 
mechanism-based model.   
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D. DISCUSSION 
Major advances in the use of liposomes, conjugates, and nanoparticles as vehicles to 
deliver drugs have occurred the past 10 years (3-5).  Doxil
®
 and albumin stabilized 
nanoparticle formulation of paclitaxel (Abraxane
®
) are now FDA approved (6, 7, 45).  In 
addition, there are greater than 200 liposomal and nanoparticle formulations of anticancer 
agents currently in development (3).  Despite these fast developments, one key hurdle 
preventing the wider success of liposome-based therapeutics is the complexity in PK and PD 
of liposomal agents in humans.  Evaluation of the relationship of liposomal drug PK and PD 
and monocytes is of the utmost importance because the nonlinear PK of liposomal drug may 
be explained by the saturation of MPS and the bi-directional interaction between liposomal 
drugs and monocytes. 
We developed a fully integrated mechanism-based population PK/PD model that 
described the relationship between PEGylated liposomal anticancer drug and monocyte in 
cancer patients treated with IHL-305, a PEGylated liposomal CPT-11.  In this model, an 
irreversible binding of liposomal drug to monocyte was used to account for the bi-directional 
interaction between PEGylated liposomal anticancer drug and monocyte. This model 
adequately described the observed clinical data, as illustrated in Figs. 4, 5 and Table 7.3. To 
our knowledge, this is the first mechanism-based model that includes the bi-directional 
interaction between PEGylated liposomal anticancer drug and monocytes for PEGylated 
liposomal anticancer drug in cancer patients. 
In the mechanism-based model, the mean value of volume of distribution for 
encapsulated CPT-11 was 2.86 L and is close to plasma volume in humans.  The estimated 
volume of distribution is consistent with our prior population PK study of S-CKD602, in 
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which the volume of distribution of encapsulated CKD-602 was estimated to be 3.63 L (46).  
In addition, the limited volume of distribution of encapsulated CPT-11 is consistent with 
other liposomal anticancer agents since the size of liposome limited their distribution to the 
normal tissue (16, 47).  The half life of monocytes was estimated to be 142 hours. The 
reported half life of monocytes in healthy human (mean 72 hours, range 36 – 104 hours) (48, 
49). This discrepancy might be explained by the limited number of PD data and lack of 
information about removal rate constant in the data.  In this model, IHL-305 was eliminated 
via uptake by monocytes (as represented by kon•AEncap•Mono) and linear degradation as 
represented by (kdeg•AEncap). The association rate constant (kon = 0.00001 L∙h
-1
) is much 
lower than the estimated degradation rate constant of IHL-305 (kdeg = 0.0389 h
-1
).  This data 
suggested that the irreversible binding of monocytes and IHL-305 contribute less than linear 
degradation to the elimination of IHL-305. The toxicity of the sequestered CPT-11 to 
monocytes may be less than other liposomal anticancer agents such as S-CKD-602 as CPT-
11 is a prodrug. In this case, the contribution of IHL-305 to the decrease of monocytes may 
be modest. In addition, the binding of IHL-305 and monocytes may be more reversible than 
irreversible for monocytes. However, due to the limited data points, we were unable to fit the 
data using a reversible binding kinetics.  
The adjusting factor was introduced to the mechanism-based model to bridge the unit 
gap between amount of PEGylated liposomal drug and monocyte count. In our study, we 
have the monocyte absolute count data in unit of number of cells per liter and encapsulated 
CPT-11 amount in microgram.  As liposome interacts with monocyte via the receptor on the 
cell surface, and the monocyte count is not equal to the concentration of receptors, it is not 
appropriate to convert the monocyte count data using molar unit. Therefore, we need this 
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adjusting factor to address this issue in the model. We performed modeling on the data with 
encapsulated CPT-11 amount in microgram and in molar separately. And the results from 
these two different data sets did not show much difference.   
The degradation of liposome through route other than uptake by monocytes as 
represented by kdeg was important in the mechanism-based model. We tested the model with 
and without kdeg and deletion of kdeg from the final mechanism-based model resulted in an 
increase in AIC of 34. It is known that the primary accumulation sites of liposomes are liver 
and spleen and liposomes may be cleared by other phagocytes on sites (eg. Kupffer cells) 
(50, 51). Therefore, the contribution of other routes is also very important to PK of IHL-305. 
In the myelosuppression-based model, the estimated mean values of volume of 
distribution for encapsulated CPT-11 (2.93 L) is close to the estimates from mechanism-
based model and consistent with other liposomal anticancer.  The half-life of monocytes 
calculated as 0.693/ktr was estimated to be 11.0 hours, which is much shorter than the half-
life of monocytes estimated from the mechanism-based model and the reported value from 
literature. This may be due to direct cytotoxicity of liposomes on monocytes in blood. This 
may also be explained by the different structures between these two models. The 
myelosuppression-based model incorporated three transit compartments and the rate constant 
between each compartment was same and equal to the removal rate constant of monocytes 
from blood circulation. Thus, the offset of the toxic effect on monocyte was counted by three 
transit compartments in the myelosuppression-based model, whereas, it was counted by one 
step in the mechanism-based model.  
The correlations between the population and individual predicted and observed PK 
data is slightly better in mechanism-based model compared to myelosuppression-based 
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model. This may suggest that incorporation of bi-directional interaction between PEGylated 
liposomal anticancer agents and monocytes in the model helped to explain the interindividual 
variability in the PK of S-CKD602. In addition, this is consistent with our findings in 
developing mechanism-based model for S-CKD602. 
Both of the mechanism-based and myelosuppression-based PK-PD models described 
the change of monocyte counts over the dosing period relatively well. This suggested that 
both the chemotherapy induced myelosuppression and the bi-directional interaction between 
PEGylated liposomal anticancer agents and monocytes are important to describe the PD 
profile of monocytes after administration of IHL-305. Although the correlation between 
model predicted and observed PD data of these two models were comparable, the prediction 
of PD data from myelosuppression-based model was more accurate than that from 
mechanism-based model. The mechanism-based model overestimated monocyte count at 
lower monocyte count and underestimated monocyte count at higher monocyte count 
compared to myelosuppression-based model. This may be explained by the absence of 
feedback loop in the mechanism-based model. The feedback loop was incorporated in 
myelosuppression-based model to describe leukocytopenia and neutropenia because it is 
known that the proliferation rate of progenitor cells can be affected by endogenous growth 
factors and cytokines and that circulating neutrophil counts and the growth factor G-CSF 
levels are inversely related (28, 52, 53). No feedback mechanism has been reported for 
monocytes. The better PD fit of myelosuppression-based model suggest that feedback loop 
may be applicable for monocytes. However, the addition of feedback loop to the developed 
mechanism-based model did not improve the PD fits.  
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Although the myelosuppression-based model described the PD data relatively well, 
the individual prediction of monocyte counts from this model showed a fluctuating curve of 
monocyte change. This fluctuation of monocyte counts after administration of IHL-305 is 
related to the feedback constant. The fluctuation of monocyte can be reduced by fixing the 
feedback constant at low value. Deletion of this feedback constant from the 
myelosuppression model can delete the fluctuation of monocyte counts but also produces a 
worse model.  
The mechanism-based and myelosuppression-based models predicted two different 
time courses of monocyte count change after administration of IHL-305. The 
myelosuppression-based model predicted a day of nadir around the observed day of nadir 
whereas the mechanism-based model predicted an earlier day of nadir compared to the 
observed. As no monocyte count was collected at the earlier time after administration of 
IHL-305, the exact monocyte profile at earlier time points needs to be determined in future 
studies. PD profile of monocytes reached nadir at 2 days after administration of liposomal 
alendonate in rats (54). The half-life of monocytes in rats is about 2 days, which is similar to 
the reported half-life of monocytes in human (48, 49). The PD profile of monocytopenia after 
administration of liposomal alendonate suggested that the day of monocyte nadir after 
administration of IHL-305 may be earlier than the observed value (11.2 ± 6.1 days). Thus, 
cytotoxic effects in blood and in bone marrow explain the decrease in monocytes after 
administration of PEGylated liposomal anticancer agents. 
In conclusion, a mechanism-based PK-PD model was developed for encapsulated 
CPT-11 and monocyte counts in patients with advanced solid tumors.  Comparison of this 
model and the myelosuppression-based model helped to explain PK and PD of PEGylated 
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liposomal anticancer agents. The developed mechanism-based PK-PD model may be useful 
in predicting the PK and optimize dosing of pegylated liposomal agents to achieve a target 
exposure for a patient with malignant diseases. This model could also be used to describe the 
bi-directional interaction between PK and monocytes for other nanoparticle and conjugated 
anticancer agents as a method to profile and classify these agents.  
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Table 7.1. 
 
A summary of Patient Demographics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
Characteristics 
 
 
 
 
Number of 
patients 
 
Mean  SD 
 
Median 
(Range) 
Age (years)  60.0  9.4 60 (42– 75) 
Body Surface Area (m2)  1.88  0.28 1.85 (1.41 – 2.39) 
Body Weight (kg)  76.7  20.4 75.3 (47.1 – 124.5) 
Body Mass Index 
(kg/m2) 
 27.0  6.8 26.3 (17.2 – 53.6) 
Height (cm)  169  10.3 168 (152 – 188) 
Ratio of Body Weight to 
Ideal Body Weight 
 1.26  0.36 1.16 (0.81 – 2.74) 
Sex
 
   
    Male 13   
    Female 26   
Primary tumor type    
    Ovarian Cancer 8   
    Breast Cancer 6   
Lung Cancer 6   
Bladder  2   
Head and Neck                          
Squamous 
2   
    Neuroendocrine    
Carcinoma 
2   
Adenoid cystic, Anus, 
Cervical, Colon, Gastric, 
Mediastinal, Metastatic 
breast, Metastatic 
prostate, Metastatic 
carcinoid, Pancreatic, 
Prosta, Right 4
th
 toe, 
Uterine 
1 patient 
for each 
type 
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Table 7.2. 
 
Population PK-PD Parameters Obtained From the Myelosuppression-based Model for 
Encapsulated CPT-11 and Monocytes. 
 
Parameter Definition Population Mean 
RSE
a
 (%) 
IIV, CV%
b
  
RSE
a
 (%) 
VEncap (L) Volume of distribution for 
encapsulated CPT-11 
2.93 (5.0) 27.9 (25) 
Vmax (mg/h) Maximum velocity of 
encapsulated CPT-11 
14.2 (38) 41.8 (20) 
km (mg/L) Michaelis-Menten constant 103 (48) NE (NA) 
Baseline (10
9
/L)  Baseline monocyte count 0.564 (7.4) 34.9 (64) 
ktr (1/h) Transit rate constant 0.0628 (1.5) NE (NA) 
Emax Maximum inhibition 0.95 (7.6) NE (NA) 
EC50 (mg/L)  Inhibition constant 21.3 (1) 54 (220) 
γ Feedback constant 0.319 (3.7) NE (NA) 
Residual variability 
Proportional error (variability as %) 
Encapsulated CPT-11 
Monocytes 
 
22.2 % (23) 
21.4% (5.5) 
 
NA
c
 
NA
c
 
Additive error 
Encapsulated CPT-11 (mg/L) 
Monocytes (10
9
/L) 
 
0.199 (177) 
0.00322 (52) 
 
NA
c 
NA
c
 
 
a
 Relative standard error for estimate. 
b
 Coefficient of variation.  
c Not estimated. 
 229 
Table 7.3. 
 
Population PK-PD Parameters Obtained From the Mechanism-based Model for Encapsulated 
CPT-11 and Monocytes. 
 
Parameter Definition Population Mean 
RSE
a
 (%) 
IIV, CV%
b
  
RSE
a
 (%) 
VEncap (L) Volume of distribution for 
encapsulated CPT-11 
2.86 (4.5) 27.4 (24) 
kon (L/h) Association rate constant 0.00001 (30) NE (NA) 
kdeg (1/h) Degradation rate constant of 
IHL-305 
0.0389 (5.1) 23.0 (36) 
Baseline (10
9
/L)  Baseline monocyte count 0.619 (7.2) 33.8 (59) 
kout (1/h) Removal rate constant of 
monocyte 
0.00487 (27) 54.6 (91) 
Factor (μg∙L/109) Adjusting factor 0.0358 (5.7) NE (NA) 
Residual variability 
Proportional error (variability as %) 
Encapsulated CPT-11 
Monocytes 
 
22.1 % (26) 
22.4% (155) 
 
NA
c
 
NA
c
 
Additive error 
Encapsulated CPT-11 (mg/L) 
Monocytes (10
9
/L) 
 
0.484 (51) 
0.00352 (110) 
 
NA
c 
NA
c
 
 
a
 Relative standard error for estimate. 
b
 Coefficient of variation.  
c Not estimated. 
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Figure 7.1. The myelosuppression-based PK-PD model for (A) and the mechanism-based 
PK-PD model (B) for encapsulated CPT-11 and monocytes. 
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Figure 7.2. Goodness-of-fit plots for the myelosuppression-based model of encapsulated 
CPT-11 and monocytes.  The dashed lines are lines of identity. 
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Figures 7.3. Representative individual plots of observed (○) and individual predicted (―) 
values from myelosuppression-based model for the plasma concentrations of encapsulated 
CPT-11 and monocyte count in all patients.  
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Figure 7.4. Goodness-of-fit plots for the mechanism-based model of encapsulated CPT-11 
and monocytes.  The dashed lines are lines of identity. 
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Figures 7.5. Representative individual plots of observed (○) and individual predicted (―) 
values from mechanism-based model for the plasma concentrations of encapsulated CPT-11 
and monocyte counts in all patients. 
  
 
CHAPTER 8 
 
 
MECHANISM-BASED PHARMACOKINETIC-
PHARMACODYNAMIC MODEL CHARACTERIZING BI-
DIRECTIONAL INTERACTION BETWEEN LIPOSOME 
MEMBRANE LIPIDS AND MONOCYTES IN PATIENTS WITH 
ADVANCED MALIGNANCIES 
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A. INTRODUCTION 
Liposomes (microparticulate phospholipid vesicles) have been used with growing 
success as pharmaceutical carriers for anticancer agents. Conventional liposomes are quickly 
opsonized by plasma proteins, recognized as foreign bodies, and rapidly removed by the 
mononuclear phagocytic system (MPS) which has also been called the reticuloendothelial 
system (RES) (1, 2).  The development of STEALTH or Polyethylene Glycol (PEG)ylated 
liposomes was based on the discovery that incorporation of mPEG-lipids into liposomes 
yields preparations with prolonged plasma exposure and superior tumor delivery compared to 
conventional liposomes composed of natural phospholipids (3-5).   
The PEGylated liposomal anticancer agents have demonstrated a superior antitumor 
activity and reduced toxicity compared to conventional liposomal and nonliposomal drugs in 
both preclinical studies and clinical studies. PEGylated liposomal doxorubicin (Doxil®) is 
approved for the treatment of refractory ovarian cancer, Kaposi sarcoma, and multiple 
myeloma (6, 7).  However, nonlinear and highly variable pharmacokinetic (PK) property of 
the PEGylated liposomal anticancer agents was observed in clinic studies. Saturation of 
clearance was reported for both Doxil® and S-CKD602 and cycle dependent PK was 
reported for Doxil® (8-11). In addition, high interpatient variability in the PK of PEGylated 
liposomal CKD-602 (S-CKD602) and other liposomal agents has been reported (12). There 
was a 100-fold range at lower dose and a 10-fold to 20-fold range at higher dose in 
encapsulated CKD-602 AUC (12).  
The complicated PK of PEGylated liposomal anticancer agents was believed to be 
related to the PK of liposomal carrier. The PK disposition of carrier-mediated agents, such 
as, nanoparticles, nanosomes, and conjugated agents, is dependent upon the carrier until the 
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drug is released from the carrier.  Unlike traditional anticancer agents which are cleared by 
the liver and kidneys, the clearance of non-PEGylated and PEGylated liposomes is via the 
MPS which include monocytes, macrophages and dendritic cells located primarily in the 
liver and spleen (2).  PEGylated liposomes are cleared much slower via MPS compared to 
non-PEGylated liposomes (4, 13).  Uptake of the liposomes or nanoparticles by the MPS 
usually results in sequestering of the liposome membrane lipids and encapsulated drug in the 
MPS and the sequestered drug and/or the liposome membrane lipids in the MPS may cause 
acute cytotoxicity to the MPS. This toxicity to the MPS in turn decreases clearance of the 
PEGylated liposomal anticancer agents and alters the pharmacodynamics (PD) of the agents. 
Thus, there is a bi-directional interaction between PEGylated liposomal anticancer agents and 
MPS.  Since a major portion of the liposomal encapsulated drug molecules are confined 
primarily to the blood compartment due to their relative large size, we have reported that 
there is a significant and clinically relevant interaction between liposomal agents and MPS 
cells in the blood circulation (13, 14). This bi-directional interaction between PEGylated 
liposomal anticancer agents and monocytes is very important in determining the PK and PD 
of PEGylated liposomal anticancer agents and potentially other nano and conjugated agents.  
We have developed a mechanism-based population PK-PD model that included the 
bi-directional interaction between PEGylated liposomal anticancer agents and monocytes for 
PEGylated liposomal CKD602 (S-CKD602) and PEGylated liposomal CPT-11 (IHL-305). 
As the liposome membrane lipids may also contribute to the toxicity of PEGylated liposomal 
anticancer agents to monocytes, we developed a population PK-PD model for the liposome 
membrane lipids based on the previously developed mechanism-based PK-PD model. The 
liposome PK and PD data were obtained by pooling the PK and PD data of S-CKD602 and 
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IHL-305. In this pooled data set, the lipid concentrations were calculated using the 
encapsulated drug concentration according to the drug-to-lipid ratio of S-CKD602 and IHL-
305. The pooled data allow a more accurate estimation of the PK and PD parameters due to 
the larger data sets.  
The PEGylated liposomes of S-CKD602 and IHL-305 were made using two different 
methods. The PEGylated liposome of S-CKD602 was made by adding the PEG lipid before 
the process of liposomal formation which results in PEG tether being projected on both the 
inside and outside of liposome.  The PEGylated liposome of IHL-305 is made by adding the 
PEG lipids after the process of liposomal formation which results in PEG tether being only 
localized on the outer leaflet (15).  
The objectives of this study were to evaluate the relationship of PEGylated liposome 
membrane lipids PK and PD and monocytes and to increase our understanding of the bi-
directional interaction between PEGylated liposomal anticancer agents and monocytes in 
blood of cancer patients. 
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B. METHODS 
Study Design 
The PK and PD data of this study was pooled from two separate phase I studies of S-
CKD602 and IHL-305. The concentrations of liposome membrane lipids were calculated 
according to the drug-to-lipid ratio of S-CKD602 and IHL-305. The drug-to-lipid ratios of S-
CKD602 and IHL-305 were 1:8.9, and 1:4, respectively.  
The PK and PD data of S-CKD602 were obtained from a phase I study of S-CKD602 
in patients with advanced solid tumors (8, 12). The study design and clinical results have 
been reported elsewhere (8, 12). Forty-five patients (21 males) received S-CKD602 at 0.1 to 
2.5 mg/m
2
 IV x 1 over approximately 1 hour every 3 weeks.  No pre-medications were 
administered prior to S-CKD602.  Written informed consent, approved by the Institutional 
Review board of the University of Pittsburgh Medical Center, was obtained from all patients 
prior to study entry. All other eligibility criteria were previously reported (8). Serial plasma 
samples were obtained prior to drug administration; at the end of the infusion (lasting ~ 1h); 
and at 3, 5, 7, 24, 48, 72, 96, 168 (day 8), and 336 h (day 15) after the start of the infusion. 
Total (lactone + hydroxyl acid) concentrations of encapsulated CKD-602 in plasma were 
determined by liquid chromatography-tandem mass spectrometry (16).  The lower limit of 
quantitation (LLQ) of the total form encapsulated CKD-602 was 2 ng/mL. Samples of 
peripheral blood were collected before dosing on days 7, 14, 21, and 28.  
The PK and PD data of IHL-305 were obtained from a phase I study of IHL-305 in 
patients with advanced solid tumors (17).  The study design and clinical results have been 
reported elsewhere (17). Thirty-nine patients (13 males) received IHL-305 at 3.5 to 210 
mg/m
2
 IV x 1 over approximately 1 hour every 4 weeks.  Prior to administration of the study 
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drug, patients were premedicated with ondansetron (or other 5-HT3 inhibitor should 
circumstances require) and dexamethasone, according to each institution’s standard of care. 
Written informed consent, approved by the Institutional Review board of the Sarah Cannon 
Research Institute and Vanderbilt University Medical Center, was obtained from all patients 
prior to study entry. Serial plasma samples were obtained at the following times: prior to 
administration, at end of the infusion (approximately 1 h), and at 1.5 h , 2 h , 3 h , 5 h , 9 h , 
13 h, and 25 h after the start of the infusion for patients treated at < 67 mg/m
2
 and the first 
three patients treated at 67 mg/m
2
. Additional samples at 49 h, 73 h, 97 h, 169 h (day 7), 192 
h (day 8), and 216 h (day 9) after the start of the infusion were also collected for patients 
treated at > 67 mg/m
2
 and the last three patients treated at 67 mg/m
2
. Total (lactone + 
hydroxyl acid) concentrations of sum total CPT-11, released CPT-11 in plasma were 
determined by a specific liquid chromatographic tandem mass spectrometry assay (LC-
MS/MS) as previously described (18).  Encapsulated CPT-11 was calculated by substracting 
the released CPT-11 concentration from sum total CPT-11 concentration at each time point. 
The lower limit of quantitation (LLQ) of the total form sum total CPT-11 and released CPT-
11 were 100 and 2 ng/mL, respectively.  Complete blood counts were obtained weekly and as 
medically indicated.   
 
Population PK-PD Analysis  
We believe that the bi-directional interaction between PEGylated liposomal 
anticancer agents and monocytes plays the key role in the elimination of PEGylated 
liposomal anticancer agents and monocytopenia observed in our prior studies (13). In this 
study, we used the previously developed mechanism model that incorporated the bi-
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directional interaction to describe the pooled PK and PD data of S-CKD602 and IHL-305. 
The pooled PK and PD data were analyzed using the nonlinear mixed effects modeling 
approach as implemented in NONMEM (version 6; University of California, San Francisco, 
CA) for the mechanism-based model.  The first order conditional estimation (FOCE) method 
were used in analyses.  S-PLUS 8.0 (Version 8.0, Insightful Corporation, Seattle, 
Washington) was used for graphical diagnostics.  
Mean population PK-PD variables, interindividual variability (IIV), and residual error 
were assessed in the model development (19, 20). IIV for each PK-PD variable was modeled 
with an exponential function. Residual error models of the additive, proportional, 
exponential, and combination methods were evaluated for the best structural PK-PD model. 
Individual PK-PD variables were obtained by posterior Bayesian estimation (19, 20). 
As the PK data were pooled plasma concentrations of liposome membrane lipids from 
two different PEGylated liposomal drugs, the drug type as potential covariates were tested 
for their influence on the drug-related parameters (V, kon, kdeg, Factor). The system-related 
parameters (Mono0, kout) were assumed to be independent of drug. General patient 
characteristics were not evaluated in this study. The covariate model building was a stepwise 
process. A screen for drug type as covariates on drug-related parameters was done using S-
PLUS 8.0 (Version 8.0, Insightful Corporation, Seattle, Washington). The potential 
significant covariates selected from screen were introduced into the covariate model and 
assessed in the population PK models. A significant covariate was selected to be retained in 
the final model if addition of the covariate resulted in a decrease in OFV >3.875 (P < 0.05) 
during the forward full covariate model building, and removal of the covariate resulted in an 
increase in OFV >10.828 (P < 0.001) during the stepwise backward model reduction (21). In 
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addition, the increase in precision of the variable estimate (% relative SE of prediction) and 
reduction in inter-individual (IIV) were used as another indicator of the improvement of the 
goodness of fit.  
 
Mechanism-based PK-PD Model 
A mechanism based PK-PD model that incorporates the interaction between 
PEGylated liposomal anticancer agents and monocytes has been previously developed for S-
CKD602 and IHL-305 (Figure 8.1). Concentration versus time data of liposome membrane 
lipids in plasma and monocyte count in blood were fit simultaneously by this model. Drug is 
dosed IV into the systemic circulation (blood compartment) at a zero-order rate (k0). The 
distribution of PEGylated liposome membrane lipids is described by a one-compartment 
model and the PEGylated liposome membrane lipids is eliminated by interacting with 
monocyte to form liposome-monocyte complex (kon) which represents the phagocytosis of 
PEGylated liposome by the monocyte. The liposome-monocyte complex may then be 
degraded. This represents the degradation or catabolism of the liposome within the 
monocyte. PEGylated liposome membrane lipids is also degraded at a first-order rate (kdeg). 
The parameters describing the production and loss of monocytes are kin and kout. The 
production rate of monocytes kin is calculated as kout multiplied by baseline monocyte value. 
The differential equations were written as 
0  (0)A  ,    
lipidsdeg0

lipidslipidson
lipids AkMonoAkk
dt
dA
 
00
  Mono(0)  ,   / MonoFactorMonoAkMonokkMono
dt
dMono
lipidsonoutout

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lipids
lipids
lipids
V
A
C 
 
dAlipids/dt  is the elimination rate, Alipids is liposome membrane lipids amount in plasma, Clipids 
is the plasma concentration of liposome membrane lipids, Vlipids is the volume of distribution 
of liposome membrane lipids, Mono is the monocyte count, k0 is the infusion rate and k0 = 0 
after stop of infusion. Since the unit of liposome membrane lipids is mg/L and the unit of 
monocyte count is 10
9
/L, the factor is a parameter used to bridge the unit gap.  
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C. RESULTS 
Patient demographics 
 The summary of patients demographic data have been listed in Chapter 4 and Chapter 
5.  
 
Mechanism-based PK-PD Model 
The liposome membrane lipids and monocytes were modeled simultaneously for all 
patients. The distribution of residual variability was best described by a proportional plus 
additive error model.  The PK-PD parameter estimates obtained from the final model are 
provided in Table 8.1.  During the covariate screen, drug type was identified as a significant 
covariate for the association rate constant (kon) and the adjusting factor.  The kon for liposome 
membrane lipids of S-CKD602 and for IHL-305 were estimated to be 0.175 (IIV 283%) L∙h-
1
and 0.0001 (IIV 283%) L∙h-1, respectively. The inclusion of drug type as a covariate in the 
final model decreased the IIV of the kon by 50%.  The adjusting factors for liposome 
membrane lipids of S-CKD602 and for IHL-305 were estimated to be 8.14 (IIV 56%) μg/109 
and 0.393 (IIV 56%) μg/109, respectively. The inclusion of drug type as a covariate in the 
final model decreased the IIV of the adjusting factor by 66%.  The volume of distribution 
(Vlipids) was estimated to be 3.35 L (IIV 34.1%).  The estimated Vlipids is close to the plasma 
volume in humans. The degradation rate constant (kdeg) was estimated to be 0.0326 (IIV 
48.1%) h
-1
. The baseline monocyte value was estimated to be 0.60 (IIV 35.6%) x10
9
/L. The 
degradation rate constant (kout) of monocytes was estimated to be 0.00774 (IIV 46.9%) h
-1
.  
 Goodness-of-fit plots from the mechanism-based PK-PD model in all patients are 
given in Figure 8.2. The model adequately describes the PK profile of liposome membrane 
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lipids.  Both the population predicted (R
2
 = 0.82) and individual predicted (R
2
 = 0.95) PK 
profile correlated well with the observed PK profile. Although the PD data of monocytes 
were variable, the observed and model predicted data agreed relatively well.  The observed 
PD data better correlated with the individual predicted PD data (R
2
 = 0.79) than population 
predicted PD data (R
2
 = 0.22). The representative individual PK time profiles of liposome 
membrane lipids and monocytes in patients after administration of S-CKD602 and IHL-305, 
respectively, are shown in Figure 8.3A and 8.3B.  The observed data of liposome membrane 
lipids concentration and monocytes were well described by the mechanism-based model.   
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D. DISCUSSION 
The bi-directional interaction between PEGylated liposomal anticancer agents and 
monocytes plays the key role in the elimination of PEGylated liposomal anticancer agents 
and monocytopenia observed in our prior studies (13). The bi-directional interaction between 
PEGylated liposomal anticancer agents and monocytes have been evaluated via a 
mechanism-based PK-PD model assuming the encapsulated drug is toxic to the monocyte. In 
this study, the bi-directional interaction between PEGylated liposome membrane lipids and 
monocytes was evaluated to test if PEGylated liposome membrane lipids alone can explain 
the toxicity of these agents to monocyte. 
The inter-individual variability in the PK and PD of liposome membrane lipids can be 
explained in part by the encapsulated drug. The elimination of PEGylated liposome 
membrane lipids via uptake by monocyte is reflected by the association rate constant (kon). 
The kon of S-CKD602 is 1750-fold higher compared with IHL-305. In addition, kon of S-
CKD602 is 5.4-fold higher than kdeg, whereas, kon of IHL-305 is 326-fold lower than kdeg. 
This data suggest that the bi-directional interaction between PEGylated liposomes and 
monocytes may be more important to the elimination of S-CKD602 compared with IHL-305. 
The cytotoxicity effect of PEGylated liposomal anticancer agents on monocytes is reflected 
by the ratio of kon to the adjusting factor. The ratio of kon to the adjusting factor of S-CKD602 
(0.021) is 84-fold higher compared with IHL-305 (0.00025). This data is consistent with 
previous observations of higher ratio of % decrease of monocytes to neutrophils in S-
CKD602 compared to IHL-305. These results may be due to CPT-11 being less potent than 
CKD-602 or due to the different liposomal formulations used in each product. 
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The model predicted PD profiles of S-CKD602 and IHL-305 were different. The 
nadir of monocytes after S-CKD602 last longer compared to IHL-305. The doses and 
concentration levels of liposome membrane lipids in IHL-305 were much higher compared to 
that of S-CKD602. These results suggest that liposome membrane lipids or liposomal carrier 
of S-CKD602 are more toxic than that of IHL-305. However, this difference may also be 
related to the encapsulated drugs in these two PEGylated liposomal drugs as CKD-602 is 
more potent than CPT-11. Therefore, liposome membrane lipids in PEGylated liposomal 
anticancer agents alone may not account for all the toxicity of these agents to monocytes.  
In the mechanism-based model, the mean value of volume of distribution for 
liposome membrane lipids was 3.35 L, which is close to plasma volume in humans.  The 
volume of distribution for liposome membrane lipids reflected the distribution of PEGylated 
liposomes in human and the estimated volume of distribution is consistent with our prior 
population PK study of S-CKD602 and IHL-305 (22). In addition, the limited volume of 
distribution of liposome membrane lipids is consistent with other liposomal anticancer agents 
since the size of liposomes limits their distribution to the normal tissue (14, 23).  The 
estimated half life of monocytes (89 hours) is within the range of the reported half life of 
monocytes in healthy human (mean 72 hours, range 36 – 104 hours) (24, 25).  
In conclusion, a mechanism-based PK-PD model was developed for a pooled 
liposome membrane lipids and monocyte data of S-CKD602 and IHL-305 in patients with 
advanced solid tumors.  S-CKD602 and IHL-305 were found to have different interactions 
with monocyte. The mechanism-based PK-PD model that was developed can be used to 
assess factors influencing the PK and PD of PEGylated liposomal drugs. 
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Table 8.1. 
 
Population PK-PD Parameters Obtained From the Mechanism-Based Model for Liposome 
Membrane Lipids and Monocytes. 
 
Parameter Definition Population Mean 
RSE
a
 (%) 
IIV, CV%
b
  
RSE
a
 (%) 
Vlipids (L) Volume of distribution for 
liposome membrane lipids 
3.35 (11) 34.1 (25) 
kon (L/h) 
      S-CKD602 
      IHL-305 
Association rate constant  
0.175 (47) 
0.0001 (53) 
 
283 (NA) 
kdeg (1/h) Degradation rate constant of 
PEGylated liposome 
0.0326 (35) 48.1 (45) 
Mono0 (10
9
/L)  Baseline monocyte count 0.60 (7.1) 35.6 (40) 
kout (1/h) Degradation rate constant of 
monocyte 
0.00774 (15) 46.9 (110) 
Factor (μg/109) 
      S-CKD602 
      IHL-305 
Adjusting factor  
8.14 (55) 
0.393 (67) 
 
56 (94) 
Residual variability 
Proportional error (variability as %) 
Liposome membrane lipids 
Monocytes 
 
24.0 % (54) 
2.0 % (85) 
 
NA
c
 
NA
c
 
Additive error 
Liposome membrane lipids (mg/L) 
Monocytes (10
9
/L) 
 
0.0538 (43) 
0.0157 (52) 
 
NA
c 
NA
c
 
 
a
 Relative standard error for estimate. 
b
 Coefficient of variation.  
c Not estimated. 
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Figure 8.1. The mechanism-based PK-PD model for liposome membrane lipids and 
monocytes. 
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Figure 8.2. Goodness-of-fit plots for the mechanism-based model of liposome membrane 
lipids and monocytes. The solid lines are lines of identity. 
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Figure 8.3. Representative individual plots of observed (○) and individual predicted (―) 
values from mechanism-based model for the plasma concentrations of liposome membrane 
lipids and monocyte counts in all patients after administration of S-CKD602 (A) and IHL-
305 (B). 
  
  
  
 
CHAPTER 9 
 
 
CONCLUSION 
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General PK Properties of Pegylated Liposomal Anticancer Agents 
Targeted therapies are a major focus of cancer research today (1). With recent 
advances of technology, liposomal-based drug delivery system is designed to address drug 
PK and PD properties such as circulation half-lives, permeability, biodistribution and 
targeting specificity. PEGylated liposomal doxorubicin (Doxil®) is a successful application 
of this system. PEGylated liposomal anticancer agents have their unique PK and PD 
properties related to the liposomal carrier. Evaluation of the PK disposition of the liposomal 
encapsulated verses released drug is of the utmost importance because the liposomal 
encapsulated drug is an inactive prodrug and thus only the released drug is active (2, 3).   
Pegylated liposomal anticancer agents have a distinct PK profile characterized by a 
prolonged circulation time and a reduced volume of distribution. IHL-305 is a PEGylated 
liposomal formulation of irinotecan (CPT-11). The prolonged plasma exposure of released 
CPT-11 over 1 week after administration of IHL-305 is consistent with PEGylated liposomes 
and provides extended exposure compared with non-liposomal CPT-11 (2-5). The PK profile 
of released CPT-11 and its active metabolite SN-38 paralleled with the PK profile of 
sumtotal CPT-11. This observation is consistent with our previous observation of paralled 
PK profiles of released and encapsulated CKD-602 in plasma in a phase I PK study of S-
CKD602 (6). These observations suggest that the release of agents from PEGylated 
liposomal anticancer agents can be the rate determining step for removal of released agent 
and the metabolites from the system.  
The PK disposition of IHL-305 is consistent with the PEGylated concept (2, 7-10). 
The volume of distribution of encapsulated CPT-11 estimated from the population PK 
analysis for female and male patients were 2.4 L and 3.6 L, respectively. The volume of 
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distribution of encapsulated CKD-602 estimated from the population PK analysis was 3.63 L. 
Compared to non-liposomal CPT-11 (377 to 871 L) and CKD-602 (range of Vss, 31 to 87 L), 
the distribution of encapsulated CPT-11 and CKD-602 were significantly reduced (11-14). 
The limited volume of distribution of encapsulated CPT-11 and CKD-602 is consistent with 
other liposomal anticancer agents and is based on their limited distribution to the normal 
tissue (15).   
 Besides prolonged exposure and reduced volume of distribution, we found that the 
variability of IHL-305 PK was associated with non-linear clearance of IHL-305.  Saturation 
of clearance has been reported for both Doxil® and S-CKD602 and the nonlinear PKs of 
these two drugs have been modeled using Michaelis-Menten kinetics (6, 16-18). The 
nonlinear clearance of sum total CPT-11 after administration of IHL-305 and other 
nanoparticle agents may be related to the saturation in the clearance capacity of the 
RES/MPS.  
As only the released drug is active, the PK disposition of the liposomal encapsulated 
verses released drug was evaluated for IHL-305 through noncompartmental and 
compartmental PK analysis (2, 3).  The release drug concentrations and AUC are much lower 
compared with the sum total or encapsulated drug for both S-CKD602 and IHL-305. The 
ratio of released CPT-11 AUC to sum total CPT-11 AUC ranged from 0.001 to 0.01.  This 
data suggests that most of the CPT-11 remains encapsulated in the plasma after 
administration of IHL-305.  These results are also consistent with previous studies of IHL-
305 in mice (19, 20). The mean ratio of SN-38 AUC to released CPT-11 AUC and APC 
AUC to released CPT-11 AUC after administration of IHL-305 ranged from 0.02 to 0.06 and 
from 0.09 to 0.55, respectively. This values are similar to that after administration of non-
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liposomal CPT-11 (21, 22).  After a single dose of IHL-305 at the MTD of 160 mg/m
2
, the 
plasma exposure of CPT-11 and SN-38 were similar to that of non-liposomal CPT-11 at the 
MTD of 150 mg/m
2
(21, 22).  This data suggest that the PK of the released CPT-11 after 
administration of IHL-305 is consistent with that after administration of non-liposomal CPT-
11. In chapter 5, the volume of distribution and clearance of released CPT-11 estimated from 
population PK analysis were also comparable to that of non-liposomal CPT-11. All these 
data suggest that once the drug is released from the carrier, the PK disposition of the drug 
will be the same as after administration of the non-carrier form of the drug. 
 The inter-patient variability in the PK disposition of sum total and released CPT-11 
after administration of IHL-305 is lower than that of sum total and released CKD-602 after 
administration of S-CKD602.  At the MTD of IHL-305 (160 mg/m
2
), there was a 2.7-fold 
range in sum total CPT-11 AUC and 4-fold range in released CPT-11 AUC. At the MTD of 
of S-CKD602 (2.1 mg/m
2
), there was a 13-fold range in encapsulated CKD-602 AUC and 
17-fold range in released CKD-602 AUC (23).  The encapsulated CKD-602 AUC was 
similar to the sum total AUC at all doses (23).  Additionally, there is greater PK variability in 
released CPT-11 compared with sum total CPT-11, whereas, there is smaller PK variability 
in released CKD-602 compared with sum total CKD-602.  The difference in the PK between 
IHL-305 and S-CKD602 may be related to the difference in liposomal formulations and 
pegylation between these two agents.  There was also a poor relationship between the dose of 
IHL-305 and the AUC of released CPT-11.  A poor relationship between the dose of S-
CKD602 and the AUC of released CKD-602 has also been reported (23). Overall, the high 
inter-patient variability in the PK disposition of IHL-305 and S-CKD602 is consistent with 
other liposomal anticancer agents (5, 26-28).  
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Patient Factors Affecting the PK and PD of PEGylated Liposomal Anticancer Agents 
 Patient factors associated with the high inter-patient PK variability of S-CKD602 
were evaluated in this study using population-based PK modeling approach. Age, body 
composition, saturable clearance, and prior PLD therapy were previously identified as 
important factors on the PK disposition of S-CKD602 using individual-based PK modeling 
approach (6). In the population PK analysis of S-CKD602, we found that the clearance of 
encapsulated CKD-602 was influenced by presence of tumor in liver. Vmax in patients with 
tumor(s) in the liver is 1.5-fold higher compared with patients without tumor(s) in the liver. 
Most studies show a decrease in clearance of small molecule drugs in patients with tumors in 
the liver (24-26).  This is the first study reporting an increased clearance of drug in patients 
with tumor involvement in the liver.  The exact mechanism of this phenomenon is unknown.  
However, recruitment of various populations of phagocytic cells (monocytes, macrophages 
and dendritic cells) of the MPS is involved in the immune response against tumor cell 
deposits in liver (27, 28).  Since liposomes are mainly cleared by MPS and liver is an 
important functional site of MPS, the increased clearance of encapsulated CKD-602 may due 
to enhanced MPS activity in patients with tumor in the liver. 
Age was also identified as a significant covariate on the release rate of CKD-602 
from S-CKD602.  In patients with linear clearance of encapsulated CKD-602, patients  ≥ 60 
years of age have a reduced release rate of CKD-602 from S-CKD602 compared with 
patients < 60 years.  This is consistent with our prior studies which showed that a reduced 
clearance of the liposomal encapsulated form of S-CKD-602 in patients ≥ 60 years of age 
and that the release of drug from liposome is related to clearance of liposome.(29, 30)  Aging 
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related decrease in the function of monocytes may account for the reduced clearance of 
liposomal agents (9, 31).  
Patient factors associated with inter-patient PK variability of IHL-305 were evaluated 
in this study using individual-based and population-based PK modeling approach.  In the 
individual-based PK modeling approach, the relationship between patient demographic data 
and the PK parameters estimated for each individual patient were analyzed. In the 
population-based PK modeling approach, patient factors were evaluated by covariate 
analysis. For IHL-305, we found that clearance of total and encapsulated CPT-11 was lower 
in female patients compared to male patients using both model-independent (1.7-fold lower) 
and model-dependent (1.5-fold lower) approach. This gender effect on PK of encapsulated 
drugs is consistent with previous observations of gender associated variability in clearance of 
TLI (Optisomal Topotecan), S-CKD602, and Doxil (32, 33) in rats and patients. For TLI and 
S-CKD602, CL was 1.2-fold (p = 0.14) and 1.4-fold (p = 0.009) lower in female rats 
compared with male rats, respectively (33). Female patients had lower CL of Doxil (p 
<0.001), IHL-305 (p = 0.068), and S-CKD602 (p = 0.67) as compared with male patients 
overall and also when stratified by age (32). The effect of gender on PK of Doxil was also 
reported in a population PK analysis of of Doxil (34). Gender-related differences in 
monocyte function may account for the differences in clearance of liposomal agents.  In the 
population PK analysis of IHL-305, Vencap in male patients was found to be 1.5-fold higher 
compared with female patients. The gender effect on Vencap has not been reported. The 
greater Vencap in male patients may be explained by the greater blood volume in males 
compared to females (35). The gender effect on Vencap may also due to the correlation 
between Vencap and Vmax, encap in the PK model. These results indicate that gender is an 
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influential factor on the PK disposition of liposomal agents. The influence of gender needs to 
be investigated further. 
Body composition was also associated with PK of IHL-305.  Patients < 60 years of 
age with a lean body composition have an increased plasma exposure of IHL-305.  The 
relationship between body composition and plasma exposure of IHL-305 in patients is 
consistent with our prior studies of S-CKD602 which showed that patients with a lean body 
composition have a higher plasma exposure of S-CKD602 (9).  
Patient factors associated with inter-patient PD variability of IHL-305 were evaluated 
in this study using individual-based PK modeling approach.  The % decrease in monocytes at 
nadir and the % decrease in neutrophils at nadir was used as PD measures of IHL-305. There 
was an inverse relationship between patients age and % decrease in monocytes after IHL-305 
with younger patients having a higher % decrease in monocytes.  This is consistant with our 
study of S-CKD602, indicating that an age related decrease in the function of monocytes may 
account for the reduced uptake and clearance of PEGylated liposomes and cytotoxicity to the 
monocytes (36). Additionally, monocytes are more sensitive to IHL-305 as compared with 
neutrophils in our study. This is consistant with our previous study that the increased 
sensitivity is related to the liposomal formulation and not the encapsulated drug (36).  The 
overall difference in monocyte and neutrophil sensitivity to IHL-305 is less than reported for 
S-CKD602. This may be associated with CPT-11 being less potent than CKD-602 or due to 
the different liposomal formulations used in each product. 
Besides the factors affecting PK and PD of IHL-305, we also found the % decrease in 
monocytes as a PD measure was significantly correlated with clearance of sum total CPT-11 
where patients with a higher % decrease in monocytes at nadir have an increased clearance of 
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sum total CPT-11.  The relationship between changes in monocytes and the PK disposition of 
IHL-305 suggests that the monocytes engulf liposomal anticancer agents via their phagocytic 
function as part of the MPS which causes the release of drug from the liposome and 
cytotoxicity to the monocytes (37).  Therefore, evaluation of the relationship of liposomal 
drug PK and PD and monocytes is of the utmost importance because the nonlinear PK of 
liposomal drug may be explained by the saturation of MPS and the bi-directional interaction 
between liposomal drugs and monocytes. 
 
Mechanism-based PK-PD Model 
We developed a fully integrated mechanism-based population PK/PD model that 
described the relationship between PEGylated liposomal anticancer drug and monocytes in 
patients with advanced solid tumor treated with S-CKD602 or IHL-305.  In this model, an 
irreversible binding of liposomal drug to monocyte was used to account for the bi-directional 
interaction between PEGylated liposomal anticancer drug and monocyte. This model 
adequately described the observed clinical data of S-CKD602 and IHL-305, as illustrated in 
Figs. 6.4, 6.5, 7.4, 7.5, Tables 6.3, and 7.3. To our knowledge, this is the first mechanism-
based model that includes the bi-directional interaction between PEGylated liposomal 
anticancer drug and monocytes for PEGylated liposomal anticancer drug in cancer patients. 
This model was also applied to describe the relationship between liposome membrane lipids 
and monocytes in combined patient data from S-CKD602 and IHL-305.  
Monocytopenia after chemotherapy is conventionally believed to be due to 
myelosuppression in bone marrow. However, it is unclear if the monocytopenia after 
PEGylated liposomal anticancer agents is due to direct cytotoxicity to monocytes in the 
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blood or cytotoxicity to progenitor cells in bone marrow. We believe the bi-directional 
interaction between PEGylated liposomal anticancer drugs and monocytes are important to 
characterize the monocytopenia and PK of these agents. Therefore, besides the mechanism-
based PK-PD model, we also used a myelosuppression-based PK-PD model which has been 
frequently used to describe neutropenia or leukocytopenia after chemotherapy to describe the 
monocytopenia after S-CKD602 and IHL-305. Comparison of the mechanism-based model 
and the myelosuppression-based model were used to test our hypothesis. 
The common PK-PD parameters between the mechanism-based model and 
myelosuppression-based model were volume of distribution of encapsulated drug, monocyte 
baseline value, and removal rate constant for monocyte. The mean values of volume of 
distribution for encapsulated CKD-602 (4.1 L) and CPT-11 (2.86 L) estimated from the 
mechanism-based model and encapsulated CKD-602 (3.46 L) and CPT-11 (2.93 L) estimated 
from the myelosuppression-based model are consistent with results from conventional PK 
compartmental models. These values are also close to plasma volume in humans. The half 
life of monocytes estimated from the mechanism-based model using S-CKD602 (102 hours) 
and IHL-305 (142 hours) PK-PD data is longer than the half life of monocytes estimated 
from the myelosuppression-based model using S-CKD602 (9 hours) and IHL-305 (11 hours) 
PK-PD data. Furthermore, the half-life of monocyte estimated from the mechanism-based 
model was more close to the reported half life of monocytes in healthy human (mean 72 
hours, range 36 – 104 hours) compared to the myelosuppression-based model (38, 39). This 
may be explained by the different structures used in the two models. The myelosuppression-
based model incorporated three transit compartments and the rate constant between each 
compartment was same and equal to the removal rate constant of monocytes from blood 
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circulation. Thus, the offset of the toxic effect on monocyte was counted by three transit 
compartments in the myelosuppression-based model, whereas, it was counted by one step in 
the mechanism-based model. The monocyte baseline values estimated from the mechanism-
based model of S-CKD602 (Mono0 = 0.671 x 10
9
/L) and IHL-305 (Mono0 = 0.619 x 10
9
/L) 
and the myelosuppression-based model of S-CKD602 (Mono0 = 0.605 x 10
9
/L) and IHL-305 
(Mono0 = 0.564 x 10
9
/L) were approximately same as the observed median of monocyte 
baseline value of S-CKD602 (Mono0 = 0.645 x 10
9
/L) and IHL-305 (Mono0 = 0.620 x 
10
9
/L). 
In the mechanism-based model, encapsulated drug was eliminated via uptake by 
monocytes (as represented by kon•AEncap•Mono) and linear degradation (as represented by 
kdeg•AEncap). For S-CKD602, the association rate constant for uptake by monocytes (kon = 1.9 
L∙h-1) is much greater than the estimated degradation rate constant of S-CKD602 (kdeg = 
0.0178 h
-1
).  For IHL-305, the association rate constant (kon = 0.00001 L∙h
-1
) is much lower 
than the estimated degradation rate constant of IHL-305 (kdeg = 0.0389 h
-1
).  This data 
suggested that the irreversible interaction between S-CKD602 and monocyte contribute more 
than the linear degradation to the elimination of S-CKD602, whereas, the irreversible binding 
of monocytes and IHL-305 contribute less than linear degradation to the elimination of IHL-
305. This may be due to CPT-11 being less potent than CKD-602 and the toxicity of 
sequestered CPT-11 to monocytes may be less than other anticancer agents encapsulated in 
liposome such as CKD-602. In this case, the contribution of IHL-305 to the decrease of 
monocytes may be modest. In addition, the interaction between IHL-305 and monocytes may 
be likely reversible than irreversible for monocytes.  Due to the limited data points, we were 
not able to fit the data using a reversible binding kinetics model. However, the bi-directional 
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interaction between PEGylated liposomal anticancer agents and monocytes plays a more 
important role in the PK and PD of S-CKD602. 
In the mechanism-based model, the degradation of liposome through route other than 
uptake by monocytes (as represented by kdeg) was important in the mechanism-based model 
for S-CKD602 and IHL-305 data. We tested the model with and without kdeg and deletion of 
kdeg from the final mechanism-based model of S-CKD602 and IHL-305 resulted in an 
increase in AIC of 86 and 34, respectively. It is known that the primary accumulation sites of 
liposomes are liver and spleen.  Therefore, liposomes may also be cleared by phagocytes in 
liver and spleen (40, 41).  Therefore, the contribution of other routes is also very important to 
PK of S-CKD602. 
The model predictions of PK data were comparable between the mechanism-based 
and myelosuppression-based model for both S-CKD602 and IHL-305. The observed PK data 
correlated better with the predicted data from the mechanism-based model than that from the 
myelosuppression-based model. This may suggest that incorporation of bi-directional 
interaction between PEGylated liposomal anticancer agents and monocytes in the model 
helped to explain the interindividual variability in the PK of S-CKD602 and IHL-305. 
The mechanism-based and myelosuppression-based PK-PD models both described 
the observed PD data of monocytopenia relatively well. However, these two models 
predicted two different time courses of monocyte count change after administration of S-
CKD602. The myelosuppression-based model predicted a day of nadir around the observed 
day of nadir whereas the mechanism-based model predicted an earlier nadir compared to the 
observed nadir. As no monocyte count was collected at the earlier time after administration 
of S-CKD602, the exact monocyte profile at earlier time points needs to be determined in 
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future studies. PD profile of monocytes reached nadir at 2 days after administration of 
liposomal alendonate in rats (42). The half-life of monocytes in rats is about 2 days, which is 
similar to the reported half-life of monocytes in human (38, 39). The PD profile of 
monocytopenia after administration of liposomal alendonate suggested that the day of 
monocyte nadir after administration of S-CKD602 may be earlier than the observed value 
(8.6 ± 3.3 days). Thus, cytotoxic effects in blood and in bone marrow may explain the 
decrease in monocytes after administration of PEGylated liposomal anticancer agents. 
For S-CKD602, the individual predicted value of monocyte counts from 
myelosuppression-based model showed higher correlation with observed monocyte counts 
compared to mechanism-based model. For both S-CKD602 and IHL-305, the mechanism-
based model overestimated monocyte count at lower monocyte count and underestimated 
monocyte count at higher monocyte count compared to myelosuppression-based model. This 
may be explained by the absence of feedback loop in the mechanism-based model. We tested 
the myelosuppression-based model without the feedback loop which produced a more serious 
overestimation monocyte count at lower monocyte count and underestimation of monocyte 
count at higher monocyte count than mechanism-based model (data not shown). The 
feedback loop was incorporated in myelosuppression-based model to describe 
leukocytopenia and neutropenia because it is known that the proliferation rate of progenitor 
cells can be affected by endogenous growth factors and cytokines and that circulating 
neutrophil counts and the growth factor G-CSF levels are inversely related (43-45). No 
feedback mechanism has been reported for monocytes. The better PD fit of 
myelosuppression-based model suggest that feedback loop may be applicable for monocytes. 
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However, the addition of feedback loop to the developed mechanism-based model did not 
improve the PD fits.  
We also developed a mechanism-based population PK-PD model for PEGylated 
liposome membrane lipids based on the mechanism-based model for S-CKD602 and IHL-
305. In this model we evaluated the bi-directional interaction between PEGylated liposome 
membrane lipids and monocytes. A pooled liposome membrane lipids and monocyte data of 
S-CKD602 and IHL-305 were used in this model development. We found that the inter-
individual variability in the PK and PD of liposome membrane lipids can be explained in part 
by the encapsulated drug. The results suggested that S-CKD602 and IHL-305 have different 
interactions with monocytes. In addition, the bi-directional interaction between PEGylated 
liposomes and monocytes may be more important to the elimination of PEGylated liposome 
and decrease of monocyte after administration of S-CKD602. This may be due to CPT-11 
being less potent than CKD-602 or due to the different liposomal formulations used in each 
product. Therefore, lipids in PEGylated liposomal anticancer agents alone may not account 
for all the toxicity of these agents to monocytes.  
In summary, the PK of S-CKD602 and IHL-305 were evaluated by 
noncompartmental, individual-based and population-based compartmental PK analysis. The 
patients factors identified through these analyses may also help to explain inter-patient 
variability of other nanoparticle and conjugated anticancer agents. The descriptive population 
PK model of encapsulated drug and released drug for S-CKD602 and IHL-305 may be used 
as the base to develop a population PK model for other PEGylated liposomal anticancer 
agents. Comparison of this model and the myelosuppression-based model helped to explain 
PK and PD of PEGylated liposomal anticancer agents. The developed mechanism-based PK-
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PD model may be useful in predicting the PK and PD and optimize dosing of pegylated 
liposomal agents to achieve a target exposure for each patient with malignant diseases. The 
mechanism-based model developed for S-CKD602 and IHL-305 could also be used to 
describe the bi-directional interaction between PK and monocytes for other nanoparticle and 
conjugated anticancer agents as a method to profile and classify these agents.  
Future Direction 
We found that age, body composition, gender, monocyte function, and tumor in liver 
were patient factors affecting the PK and PD of S-CKD602 and/or IHL-305. Among these 
factors, monocyte function and tumor in liver was the first time being identified as factors 
affecting PK of liposomal drugs. The clinical importance of these factors especially 
monocyte function and tumor in liver needs to be further investigated for S-CKD602, IHL-
305 and other liposomal and nanoparticle anticancer agents.   
Considering the potential myelosuppression effect of released anticancer drug, further 
developments to the mechanism-based model include incorporating the myelosuppression 
effect from released CKD-602. In addition, the PK and PD of PEGylated liposomal 
anticancer drugs are associated with high interpatient variability, including covariate effects 
in the mechanism-based model will increase the predicting potential in clinical situations and 
help to optimize treatment for individuals.  
As this is the first model that incorporated the bi-direcitonal interaction between 
PEGylated liposomal anticancer drugs and monocyte, validation of the model structure with 
additional data will be desired so this model can be used for simulation of clinical trials. An 
external model evaluation will be necessary to show that this model allows reasonable 
extrapolation beyond the data used to develop the model. PK/PD data from a study of a novel 
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biweekly dosage regimen of IHL-305 (referred to as study 2) will be used as validation 
dataset.  
Considering the nonlinear and high variability in the PK and PD of PEGylated 
liposomal anticancer agents, simulation based on a validated PK-PD model can predict 
PK/PD profiles of PEGylated liposomal anticancer agents under various dosage regimens 
and would be very useful in guiding the search for the optimal dose and regimen.  We are 
specifically interested in comparing the differences between shorter, more intense schedules 
and longer, more fractionated schedules, administered the same dose intensity and how these 
issues change the PK and PD of liposomal agents. 
 
 270 
REFERENCE 
1. Wang J, Sui M, Fan W. Nanoparticles for tumor targeted therapies and their 
pharmacokinetics. Curr Drug Metab; 11:129-41. 
2. Zamboni WC. Liposomal, nanoparticle, and conjugated formulations of anticancer 
agents. Clin Cancer Res 2005; 11:8230-4. 
3. Zamboni WC. Concept and clinical evaluation of carrier-mediated anticancer agents. 
Oncologist 2008; 13:248-60. 
4. Innocenti F, Kroetz DL, Schuetz E, et al. Comprehensive pharmacogenetic analysis 
of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 2009; 27:2604-14. 
5. Slatter JG, Schaaf LJ, Sams JP, et al. Pharmacokinetics, metabolism, and excretion of 
irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. Drug 
Metab Dispos 2000; 28:423-33. 
6. Zamboni WC, Strychor S, Maruca L, et al. Pharmacokinetic study of pegylated 
liposomal CKD-602 (S-CKD602) in patients with advanced malignancies. Clin Pharmacol 
Ther 2009; 86:519-26. 
7. Papahadjopoulos D, Allen TM, Gabizon A, et al. Sterically stabilized liposomes: 
improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U 
S A 1991; 88:11460-4. 
8. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the 
EPR effect in macromolecular therapeutics: a review. J Control Release 2000; 65:271-84. 
9. Zamboni WC, Strychor S, Maruca L, et al. Pharmacokinetic Study of Pegylated 
Liposomal CKD-602 (S-CKD602) in Patients With Advanced Malignancies. Clin Pharmacol 
Ther 2009. 
10. Zamboni WC, Strychor S, Joseph E, et al. Plasma, tumor, and tissue disposition of 
STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing 
A375 human melanoma xenografts. Clin Cancer Res 2007; 13:7217-23. 
11. Poujol S, Bressolle F, Duffour J, et al. Pharmacokinetics and pharmacodynamics of 
irinotecan and its metabolites from plasma and saliva data in patients with metastatic 
digestive cancer receiving Folfiri regimen. Cancer Chemother Pharmacol 2006; 58:292-305. 
12. Chabot GG, Abigerges D, Catimel G, et al. Population pharmacokinetics and 
pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. 
Ann Oncol 1995; 6:141-51. 
13. de Jonge MJ, Verweij J, de Bruijn P, et al. Pharmacokinetic, metabolic, and 
pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin. J Clin Oncol 
2000; 18:195-203. 
 271 
14. Lee DH, Kim SW, Bae KS, et al. A phase I and pharmacologic study of belotecan in 
combination with cisplatin in patients with previously untreated extensive-stage disease small 
cell lung cancer. Clin Cancer Res 2007; 13:6182-6. 
15. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 2004; 
303:1818-22. 
16. Gabizon A, Isacson R, Rosengarten O, Tzemach D, Shmeeda H, Sapir R. An open-
label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated 
liposomal doxorubicin. Cancer Chemother Pharmacol 2008; 61:695-702. 
17. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal 
Doxorubicin: review of animal and human studies. Clin Pharmacokinet 2003; 42:419-36. 
18. Gabizon A, Tzemach D, Mak L, Bronstein M, Horowitz AT. Dose dependency of 
pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in 
murine models. J Drug Target 2002; 10:539-48. 
19. Takagi A, Matsuzaki T, Furuta T, al e. Antitumor activity of IHL-305, a novel 
pegylated liposome containing irinotecan, in human xenograft models.  the 2007 American 
Association for Cancer Research–National Cancer Institute–European Organization for 
Research and Treatment of Cancer AACR-NCI-EORTC Conference; 2007 November 2007; 
San Francisco, CA; 2007. 
20. Kurita A, Furuta T, Kaneda N, al. e. Pharmacokinetics of irinotecan and its 
metabolites after iv administration of IHL-305, a novel pegylated liposome containing 
irinotecan, to tumor-bearing mice.  the 2007 American Association for Cancer Research–
National Cancer Institute–European Organization for Research and Treatment of Cancer 
AACR-NCI-EORTC Conference; 2007 November 2007; San Francisco, CA; 2007. 
21. Rothenberg ML, Kuhn JG, Burris HA, 3rd, et al. Phase I and pharmacokinetic trial of 
weekly CPT-11. J Clin Oncol 1993; 11:2194-204. 
22. Rothenberg ML, Kuhn JG, Schaaf LJ, et al. Phase I dose-finding and pharmacokinetic 
trial of irinotecan (CPT-11) administered every two weeks. Ann Oncol 2001; 12:1631-41. 
23. Zamboni WC, Ramalingam S, Friedland DM, et al. Phase I and pharmacokinetic 
study of pegylated liposomal CKD-602 in patients with advanced malignancies. Clin Cancer 
Res 2009; 15:1466-72. 
24. Robieux I, Sorio R, Borsatti E, et al. Pharmacokinetics of vinorelbine in patients with 
liver metastases. Clin Pharmacol Ther 1996; 59:32-40. 
25. Twelves CJ, O'Reilly SM, Coleman RE, Richards MA, Rubens RD. Weekly 
epirubicin for breast cancer with liver metastases and abnormal liver biochemistry. Br J 
Cancer 1989; 60:938-41. 
 272 
26. Wilson WH, Berg SL, Bryant G, et al. Paclitaxel in doxorubicin-refractory or 
mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol 
1994; 12:1621-9. 
27. Heuff G, van der Ende MB, Boutkan H, et al. Macrophage populations in different 
stages of induced hepatic metastases in rats: an immunohistochemical analysis. Scand J 
Immunol 1993; 38:10-6. 
28. Gulubova M, Manolova I, Cirovski G, Sivrev D. Recruitment of dendritic cells in 
human liver with metastases. Clin Exp Metastasis 2008; 25:777-85. 
29. Zamboni WC, Maruca LJ, Strychor S, et al. Age and body composition related-effects 
on the pharmacokinetic disposition of STEALH liposomal CKD-602 (S-CKD602) in patients 
with advanced solid tumors. 2007; 2007. 
30. Sidone BJ, Edwards RP, Zamboni BA, Strychor S, Maruca LJ, Zamboni WC. 
Evaluation of body surface area (BSA) based dosing, age, and body composition as factors 
affecting the pharmacokinetic (PK) variability of STEALTH liposomal doxorubicin (Doxil).  
AACR-NCI-EORTC; 2007; 2007. 
31. De Martinis M, Modesti M, Ginaldi L. Phenotypic and functional changes of 
circulating monocytes and polymorphonuclear leucocytes from elderly persons. Immunol 
Cell Biol 2004; 82:415-20. 
32. La-Beck NM, Wu H, Infante JR, et al. The evaluation of gender on the 
pharmacokinetics (PK) of pegylated liposomal anticancer agents.  ASCO Annual Meeting; 
2010; 2010. p. e13003. 
33. Song G, Wu H, La-Beck N, Zamboni BA, Strychor S, Zamboni WC. Effect of 
Gender on Pharmacokinetic Disposition of Pegylated Liposomal CKD-602 (S-CKD602) and 
Optisomal Topotecan (TLI) in Rats.  AACR 2009. 
34. Zomorodi K, Gupta S. Population Pharmacokinetic Analysis of DOXIL in Adult  
Patients.  AAPS; 1999; 1999. 
35. Lee LN. Volume of Blood in A Human; 1998. 
36. Zamboni WC, Maruca LJ, Strychor S, et al. Bi-Directional Pharmacodynamic 
Interaction between STEALTH Liposomal CKD-602 (S-CKD602) and Monocytes in 
Patients with Refractory Solid Tumors. Clin Cancer Res; Submitted. 
37. Zamboni WC, Eiseman JE, Strychor S, et al. Relationship between the plasma and 
tumor disposition of STEALTH liposomal CKD-602 and macrophages/dendritic cells 
(MDC) in mice bearing human tumor xenografts.  AACR; 2006; 2006. p. 5449. 
38. Jain NC. Essentials of Veterinary Hematology. 1 ed: Williams & Wilkins, Media, PA 
19063; 1993. 
 273 
39. Whitelaw DM. Observations on human monocyte kinetics after pulse labeling. Cell 
Tissue Kinet 1972; 5:311-7. 
40. Koning GA, Morselt HW, Kamps JA, Scherphof GL. Uptake and intracellular 
processing of PEG-liposomes and PEG-immunoliposomes by kupffer cells in vitro 1 *. J 
Liposome Res 2001; 11:195-209. 
41. Van Rooijen N, Sanders A. Kupffer cell depletion by liposome-delivered drugs: 
comparative activity of intracellular clodronate, propamidine, and ethylenediaminetetraacetic 
acid. Hepatology 1996; 23:1239-43. 
42. Haber E, Afergan E, Epstein H, et al. Route of administration-dependent anti-
inflammatory effect of liposomal alendronate. J Control Release. 
43. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Model of 
chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin 
Oncol 2002; 20:4713-21. 
44. Takatani H, Soda H, Fukuda M, et al. Levels of recombinant human granulocyte 
colony-stimulating factor in serum are inversely correlated with circulating neutrophil 
counts. Antimicrob Agents Chemother 1996; 40:988-91. 
45. Hoffbrand AV, Lewis SM, Tuddenham E. Postgraduate Haematology. 4 ed: Oxford, 
United Kingdom, Butterworth-Heinemann; 1999. 
 
 
